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1. 
PROTEOMIC IDENTIFICATION OF 
ANTIBODES 
This application claims the benefit of U.S. Provisional 
Patent Application No. 61/563,380, filed Nov. 23, 2011, the 
entirety of which is incorporated herein by reference. 
This invention was made with government Support under 
5U54AI057156-07 awarded by The National Institutes of 
Health; and HR0011-10-14-0.052 awarded by the Defense 
Advanced Research Projects Agency. The government has 
certain rights in the invention. 
The present invention was made as a result of activities 
undertaken within the scope of a joint research agreement that 
was in effect at the time the present invention was made. The 
parties to said joint research agreement are Board of Regents 
of the University of Texas System and Clayton Foundation for 
Research and its affiliated entity Research Development 
Foundation. 
This application is related to U.S. patent application Ser. 
No. 13/109,467, filed May 17, 2011, the entirety of which is 
incorporated herein by reference. 
INCORPORATION OF SEQUENCE LISTING 
The sequence listing that is contained in the file named 
“UTSBP1004 US ST25.txt”, which is 78 KB (as measured in 
Microsoft Windows(R) and was created on Nov. 23, 2012, is 
filed herewith by electronic submission and is incorporated 
by reference herein. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the field of anti 
body analysis and generation, Such as antibody discovery 
from immunized animals. More particularly, it concerns 
novel methods and compositions for identification and/or 
production of desired antibodies or antigen-binding frag 
mentS. 
2. Description of Related Art 
Over the last 12 years, the development of cancer thera 
peutic antibodies, such as Herceptin (Trastuzumab, anti 
Her2), Rituxan (Rituximab, anti-CD20), Eribitux/Vectibix 
(Cetuximab/Panitumumab, anti-EGFR), Avastin (anti 
VEGF), and others, have saved many tens of thousands of 
lives world-wide. Antibody therapeutics offer distinct advan 
tages relative to Small molecule drugs, namely: (i) better 
understood mechanisms of action; (ii) higher specificity and 
fewer-off target effects; (iii) predictable safety and toxico 
logical profiles. Currently, there are more than 200 antibody 
therapeutics in clinical trials in the U.S., many of them for 
Cancer treatment. 
The discovery of monoclonal antibodies is an immensely 
important aspect in therapeutic antibody development. Addi 
tionally, monoclonal antibodies are widely used for numer 
ous diagnostic and analytical purposes. Since the develop 
ment of the hybridoma technology by Kohler and Milstein 35 
years ago (Kohler and Milstein, 1975), a variety of methods 
for the generation of MAbs have been developed. Such meth 
ods include B-cell immortalization by genetic reprogram 
ming via Epstein-Barr virus (Traggiai et al., 2004) or retro 
virus-mediated gene transfer (Kwakkenbos et al., 2010), 
cloning of V genes by single-cell PCR (Wrammert et al., 
2008; Meijer et al., 2008), and methods for in vitro discovery 
via the display and screening of recombinant antibody librar 
ies (Clackson et al., 1991; Feldhaus et al., 2003; Harvey et al., 
2004; Schaffitzel et al., 1999; Hosse et al., 2006; Mazor et al., 














Both in vitro and in vivo methods for antibody discovery are 
critically dependent on high-throughput screening to deter 
mine antigen specificity. Recently, B-cell analysis has been 
expedited by microengraving techniques that utilize soft 
lithography for the high-throughput identification of antigen 
specific B cells; however, this is at the cost of considerable 
technical complexity due to the need for antibody V gene 
amplification and cell expansion (Jin et al., 2009; Love et al., 
2006). 
Similarly, the success of in vitro antibody discovery tech 
niques is dependent on screening parameters including the 
nature of the display platform, antigen concentration, binding 
avidity during enrichment, multiple rounds of screening (e.g., 
panning or sorting), and importantly, on the design and diver 
sity of synthetic antibody libraries (Hoogenboom, 2005; 
Cobaugh et al., 2008: Persson et al., 2006). 
Current use of display technologies coupled with library 
screening systems, such as a phage display where antibodies 
are isolated by panning, has a number of significant problems. 
In particular, Some antibodies produced by a library may 
cause the death of the organism expressing them and there 
fore they simply cannot be detected. There is a particular 
problem when one is searching for antibodies specific to an 
antigen from a pathogen that might be homologous to one 
produced by the host expression system (e.g., E. coli) 
because, in that instance, important antibodies cannot be 
expressed. The use of E. coli to express libraries of human 
antibodies also Suffers from the problem of codon usage. 
Codons used by humans for specific amino acids are fre 
quently not the optimum ones for the same amino acid in E. 
coli or other host systems. This means that an important 
antibody might not be expressed (or at least not in Sufficient 
quantities) since the codons in its sequence are highly ineffi 
cient in E. coli, resulting in the E. coli being unable to read 
through and express it in full. Codon optimization of antibody 
libraries is obviously not an option since the libraries would 
first have to be sequenced, which defeats the main advantages 
of using libraries. 
There is a pressing need to identify biologically relevant 
antibodies that exhibit a beneficial effect in controlling dis 
eases. Mammals mount antibody (humoral) immune 
responses against infectious agents, toxins, or cancer cells. 
Diseased individuals produce circulating antibodies that rec 
ognize the disease agent, and in many cases (e.g., in patients 
that recover from an infection or in cancer patients in remis 
sion) these antibodies play a key role in recovery and therapy. 
Currently there are no methods available to identify the cir 
culating antibodies in blood and to produce the antibodies 
that are specific to the disease agent and have a therapeutic 
effect. 
On the other hand, the isolation of monoclonal antibodies 
from different animal species is of great value for the devel 
opment of therapeutics and diagnostics. A major limitation of 
the existing methods for isolation of monoclonal antibodies is 
that their application is limited to a very small number of 
species. Different animals have evolved distinct ways of 
diversifying their antibody repertoire and thus can produce 
antibodies that recognize distinct epitopes on an antigen or 
display very high affinity for a particular antigen, compared to 
mice and humans. For example, it is well known in the art that 
antibodies from rabbits generally display much higher affin 
ity than those produced from mice. 
Current production of monoclonal antibodies from a par 
ticular species using hybridoma technology necessitates that 
B cells are immortalized by fusion to a myeloma from that 
species. Such myeloma cell lines are difficult and time con 
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Suming to develop and therefore exist only formice, primates, 
rabbits, and sheep. Alternatively, researchers have attempted 
to generate interspecies hybridomas, by fusing a mouse 
myeloma cell line with B cells from an animal for which 
autologous myeloma cell lines are not available. However, 
interspecies hybrids are generated with very low efficiency 
and are unstable, ceasing to produce monoclonal antibodies 
after a few passages. Thus, at present the production of mono 
clonal antibodies from the vast majority of animals that have 
an adaptive immunoglobulin System is a major challenge. 
Moreover, even for species for which stable B-cell fusions 
can be generated (rabbits, mice, sheep, and primates) the 
isolation of monoclonal antibodies using hybridoma technol 
ogy is a lengthy process requiring 2-6 months after animal 
sacrifice. 
Alternatively monoclonal antibodies can be isolated in 
vitro from large libraries of the variable (V) chains of the 
immunoglobulin repertoire from an immunized animal and 
then screening by a variety of display methods, such as phage 
display, yeast display, or bacterial display. Once again the 
utility of these methods is limited to the few species for which 
extensive information on their immunoglobulin repertoire is 
available, namely mice, primates, and rabbits. This is because 
the cloning of the immunoglobulin repertoire requires the 
availability of sets of oligonucleotide primers capable of 
amplifying the majority, preferably all, of the immunoglobu 
lin variable regions that are generated in that animal via 
Somatic recombination mechanisms. This in turn requires 
extensive information on the sequences of immunoglobulins 
expressed in a particular species and it is not available for the 
vast majority of animals that have an antibody-encoding, 
humoral immune system. Additionally, it is not known 
whether the antibodies isolated by combinatorial library 
screening correspond to those that have been expanded by the 
immune system and produced in large amounts in animals. 
All of these techniques are somewhat complex, inconve 
nient, and time consuming. Therefore, there remains a need to 
develop a more efficient and accurate method for identifying 
antigen-specific antibodies or monoclonal antibodies directly 
from a patient or any animal. 
SUMMARY OF THE INVENTION 
Aspects of the present invention overcome a major defi 
ciency in the art by providing novel methods for determining 
antibody sequences in a biological sample, Such as serum. 
Accordingly, in a first embodiment there is provided a method 
for determining antibody V, or V, sequences in a subject 
comprising (a) obtaining nucleic acid, and the corresponding 
amino acid, sequence information of V or V, gene reper 
toires of a subject; (b) obtaining mass spectra of peptides 
derived from antibodies of the subject; and (c) using the 
sequence information and the mass spectra to determine the 
amino acid sequence of the V of V of one or more antibod 
ies in the Subject, wherein step (a) or (b) comprises obtaining 
a sample from the Subject. 
In certain aspects, obtaining mass spectra of peptides 
derived from antibodies comprises obtaining mass spectra of 
peptides that have been modified with two different cysteine 
modifying agents. In some aspects, the mass difference 
between peptides modified with the two different cysteine 
modifying agents is determined and correlated spectra exhib 
iting the expected differential mass shift but identified as 
different peptide sequences are labeled as misidentified pep 
tides and can be removed or not used to determine an antibody 













according to the embodiments include, but are not limited to, 
iodoacetamide and iodoethanol (e.g., with a mass difference 
of ~13 Da (12.995 Da)). 
In further aspects, using sequence information and mass 
spectra to determine the amino acid sequence of a V or V. 
comprises determining the average mass deviation (AMD) 
for the peptides and retaining sequence with an AMD less 
thana threshold value. For example, AMD can be determined 
by comparing the average observed masses of peptides 
obtained by mass spectrometry to the expected masses based 
on the amino acid sequence to thereby determine the average 
difference between obtained and expected peptide masses. 
For example, the threshold value can be 3.0 ppm or less, such 
as 3.0 ppm, 2.5 ppm, 2.0 ppm, 1.5 ppm, 1.0 ppm, or 0.5 ppm 
and only peptides with an AMD below this threshold are used 
to determine a V or V, sequence. 
Thus, in a further embodiment, a method is provided for 
determining antibody V or V, Sequences in a subject (e.g., 
sequences in circulation) comprising (a) obtaining nucleic 
acid, and the corresponding amino acid, sequence informa 
tion of V, or V, gene repertoires of a subject; (b) obtaining 
mass spectra of peptides derived from antibodies of the sub 
ject; (c) screening the mass spectra to remove misidentified 
peptides by determining the average mass deviation (AMD) 
for the peptides and retaining sequence with an AMD less 
than a threshold value; and (d) using the sequence informa 
tion and the Screened mass spectra to determine the amino 
acid sequence of the V or V, of one or more antibodies in the 
Subject, wherein step (a) or (b) comprises obtaining a sample 
from the Subject. As described above, in some aspects, the 
threshold value can be 3.0 ppm or less, such as 3.0 ppm, 2.5 
ppm, 2.0 ppm, 1.5 ppm, 1.0 ppm, or 0.5 ppm. 
In a further embodiment a method if provided of identify 
ing a repertoire of different antibodies specific to an antigen in 
a biological fluid of a Subject comprisinga) obtaining nucleic 
acid, and the corresponding amino acid, sequence informa 
tion of the V and natively paired V, gene repertoires encoded 
by a plurality of B cells in a Subject; b) obtaining mass spectra 
of peptides derived from antibody V or V, chains of the 
Subject; and c) using the sequence information and the mass 
spectra to determine the amino acid sequence of the V and 
V, of antibodies in the biological fluid of the subject, wherein 
step a) or b) comprises obtaining a sample from the Subject. 
For example, in some aspects, step b) comprises obtaining 
mass spectra of peptides derived from antibody V, V, or V. 
and V chains of the Subject. 
In a still a further embodiment a method is provided for of 
identifying a repertoire of different V, and/or V, chains from 
antibodies specific to an antigen in a biological fluid of a 
Subject comprising: a) obtaining nucleic acid, and the corre 
sponding amino acid, sequence information of the V and/or 
V, gene repertoires encoded by a plurality of B cells in a 
subject; b) identifying the clonotype for each of the V and/or 
V, genes; c) obtaining mass spectra of peptides derived from 
V and/or V chains of antibodies of the Subject; and d) using 
the sequence information and the mass spectra to determine 
the amino acid sequence of the V of one or more antibodies 
in the biological fluid of the subject, wherein step a) or c) 
comprises obtaining a sample from the Subject. Thus, in cer 
tain aspects, a method of the embodiments is defined as a 
method of identifying a repertoire of different antibodies in a 
Subject. In certain aspects, a method comprises identifying 5. 
10, 15, 20, 25, 50, 100 or more clonotypes, such as between 
about 5 and 250 antibody clonotypes. 
As used herein an antibody “clonotype” refers to antibod 
ies that are derived from the same B-cell lineage and have the 
same V and J germ line sequences. Such antibodies bind to 
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Substantially the same epitope of an antigen. Antibodies from 
the same clonotype will comprise highly homologous but not 
identical variable chain sequences. In certain aspects, anti 
body chains of the same clonotype are identified by compar 
ing CDR3 sequences (in particular VHCDR3 sequences). For 
example, for antibody chains having a CDR3 of 1-5 amino 
acids, antibody chains of the same clonotype have identical 
CDR3 sequences. Forantibody chains with a CDR3 sequence 
of 6-10amino acids, antibodies of the same clonotype have no 
more than a single mismatch in the CDR3 sequence. For 
antibody chains with a CDR3 sequence of over 10 amino 
acids, antibodies of the same clonotype have CDR3 
sequences that are at least 90% identical. 
In yet a further embodiment there is provided a method for 
determining antibody V or V. sequences to an antigen in a 
biological fluid of a Subject, comprising: a) obtaining nucleic 
acid, and the corresponding amino acid, sequence informa 
tion of the V or V, gene repertoires of a Subject; b) obtaining 
mass spectra of peptides derived fromantibodies in biological 
fluids of the subject, wherein the peptides have been modified 
with a peptide modifying agent (e.g., a cysteine modifying 
agent); and c) using the sequence information and the mass 
spectra from (a) and (b) to determine the amino acid sequence 
of the V or V, of one or more antibodies in a biological fluid 
of the Subject, wherein step a) or b) comprises obtaining a 
sample from the Subject. For example, in Some aspects, the 
peptides (of step b) from a portion of the sample have been 
modified with a peptide modifying agent and peptides from a 
portion of the sample have not been modified with a peptide 
modifying agent (or have been modified with a second pep 
tide modifying agent). Accordingly, in Some aspects, step c) 
comprises using a threshold filter for eliminating false pep 
tide identifications by determining whether the difference in 
mass spectra of modified peptides from unmodified peptides 
or peptides modified with a second peptide modifying agent 
is equal to the expected mass change resulting from the modi 
fying agent. In still further aspects, step c) further comprises 
determining the average mass deviation (AMD) between 
observed and estimated peptide masses, for modified and 
unmodified peptides for the peptides and retaining sequence 
with an AMD less than a threshold value as correct peptide 
identifications. For example, the threshold value can be 5.0 
ppm, 3.0 ppm, 2.5 ppm, 2.0 ppm, 1.5 ppm, 1.0 ppm, or 0.5 
ppm. 
Certain aspects of the embodiments concern obtaining 
nucleic acid, and the corresponding amino acid, sequence 
information of the V and natively paired V, gene. In some 
aspects, such a method comprises co-isolating nucleic acid 
encoding V, and V, genes from single B-cells (e.g., as exem 
plified herein). Thus, in some aspects, a method of the 
embodiments does not require (and does not comprise) 
screening for nucleic acids that encode that encode functional 
antibodies (e.g., screening the V and V chains pairs that 
bind to an antigen). 
Various aspects of the embodiments concern identifying a 
repertoire V chains, V, chains orantibodies. For example, in 
certain aspects, a method comprises identifying at least 5, 10. 
15 or 20 distinctantibody chains or antibodies in a repertoire. 
For example, a method of the embodiments can comprise 
identifying 20, 40, 60, 80 or 100 to 250V chains, V, chains 
or antibodies in a repertoire. In some aspects, a method com 
prises identify essentially all of the antibodies (binding to a 
given antigen) in a Subject. 
In still a further embodiment, a method is provided for 
determining antibody V or V, Sequences in a Subject com 
prising (a) obtaining nucleic acid, and the corresponding 













toires of a subject; (b) obtaining mass spectra of peptides 
derived from serum antibodies of the subject wherein the 
peptides were obtained by proteolytically cleaving antibodies 
of the Subject and isolating peptides corresponding to the 
CDRH3 or CDRL3 domain using an antibody that specifi 
cally binds to a CDRH3-JH or CDRL3-JK, sequence; (c) 
using the sequence information and the mass spectra to deter 
mine the amino acid sequence of the V or V of one or more 
antibodies in the Subject, wherein step (a) or (b) comprises 
obtaining a sample from the Subject. In certain aspects, pro 
teolytically cleaving antibodies comprises digesting the anti 
bodies with a protease enzyme (e.g., trypsin). For example, 
the protease can be selected using the sequence information 
from the subject to identify enzymes that cleave antibodies 
adjacent to the CDR3 region. In certain aspects, an antibody 
that specifically binds to a CDRH3-JH or CDRL3-JK. 
sequence is immobilized on a Support (e.g., on a column or a 
bead). 
In yet a further embodiment, an isolated antibody that 
specifically binds to a CDRH3-JH or CDRL3-JK.J. sequence 
is provided. In certain aspects, the antibody specifically binds 
to a mammalian CDRH3-J sequence, such as a human 
sequence. For example, the antibody can specifically bind to 
a polypeptide comprising a GTLVTVSS (SEQ ID NO: 77), 
GTMVTVSS (SEQ ID NO: 78), or GTTVTVSS (SEQ ID 
NO: 79) sequence. In further aspects the antibody can be an 
avian (e.g., chicken) antibody, Such as an IgY antibody. 
In still yet a further embodiment, a method is provided for 
purifying peptides corresponding to an antibody comprising 
(a) contacting a sample comprising antibody peptides with an 
antibody that specifically binds to a CDRH3-J or CDRL3-J 
peptide to generate an immunocomplex; and (b) isolating the 
immunocomplexes to thereby purify peptides corresponding 
to an antibody CDRH3 domain. For example, the antibody 
can specifically bind to a CDRH3-JH or CDRL3-JK. 
Sequence. 
In yet still a further embodiment, there is provided a 
method for generating an antibody, or antigen-binding frag 
ment thereof, comprising (a) obtaining the sequence of an 
antibody V, or V, sequence that was determined in accor 
dance with the present embodiments; (b) identifying the V 
or V, binding partner of the sequence of step (a); and (c) 
generating an antibody or antigen-binding fragment thereof 
that comprises the V and V sequences of steps (a) and (b). 
For example, identifying the V or V, binding partner can 
comprise coexpression of the sequences and screening for V. 
and V, pairs that exhibit antigen binding. In further aspects, 
identifying the V or V, binding partner can comprise iden 
tifying V, and V, pairs in circulation that have similar abun 
dance. 
In yet a further embodiment, there is provided a method for 
generating an antibody V or V comprising (a) obtaining the 
sequence of an antibody V or V. sequence that was deter 
mined in accordance with the present embodiments; and (b) 
generating an antibody V or V comprising the obtained 
Sequence. 
In an additional embodiment, there is provided a method 
for generating antibodies comprising (a) obtaining sequence 
and abundance information of amino acid sequences of V. 
and V regions of antibodies in a serum-containing sample of 
a Subject; and (b) generating one or more antibodies that 
comprise V and V regions of the serum antibodies based on 
the sequence and abundance information. 
In a certain embodiment, there may also be provided a 
method for preparing CDR3-containing peptide fragments 
from antibodies of a Subject comprising (a) obtaining nucleic 
acid, and corresponding amino acid, sequence information of 
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at least the CDR3 of V, and V, genes in mature B cells of a 
Subject; (b) using the sequence information to select a pro 
tease; and (c) preparing CDR3-containing peptide fragments 
from serum antibodies of the subject with the protease. Such 
a protease may predominantly not cleave CDR3 of the Vand 
V, peptides. For example, the protease may cleave at sites 
adjacent to the CDR3 regions, leaving the CDR3 regions 
Substantially intact. 
Certain aspects of the embodiments concern obtaining a 
sample from a subject. Samples can be directly taken from a 
subject or can be obtained from a third party. Samples 
include, but are not limited to, serum, mucosa (e.g., saliva), 
lymph, urine, stool, and solid tissue samples. Similarly, cer 
tain aspects of the embodiments concern biological fluids and 
antibodies and/or nucleic acids therefrom. For example, the 
biological fluid can be blood (e.g., serum), cerebrospinal 
fluid, maternal breast milk, umbilical cord blood, synovial 
fluid, peritoneal fluid, mucosal Secretions, tears, nasal, secre 
tions, saliva, milk, or genitourinary secretions 
In some aspects, antibody genes for sequencing antibody 
can be genes in B cells, such as B cells from a selected organ, 
such as bone marrow. For example, the B cells can be mature 
B cells, such as bone marrow plasma cells, spleen plasma 
cells, or lymph node plasma cells, or cells from peripheral 
blood or a lymphoid organ. In certain aspects, B cells are 
selected or enriched based on differential expression of cell 
surface markers (e.g., Blimp-1, CD138, CXCR4, or CD45). 
In some cases, sequences of a selected class of antibodies are 
obtained. Such as IgG, IgM, IgG, or IgA sequences. 
In further aspects, a method of the embodiments may com 
prise immunizing the Subject. The method may further com 
prise isolation of a lymphoid tissue. The lymphoid tissue 
isolation may at least or about 1, 2, 3, 4, 5, 6, 6, 8, 9, 10 days 
or any intermediate ranges after immunization. The method 
may further comprise obtaining a population of nucleic acids 
of lymphoid tissue, preferably without separating B cells 
from the lymphoid tissue. The lymphoid tissue may be a 
primary, secondary, or tertiary lymphoid tissue. Such as bone 
marrow, spleen, or lymph nodes. The Subject may be any 
animal. Such as mammal, fish, amphibian, or bird. The mam 
mal may be human, mouse, primate, rabbit, sheep, or pig. 
The nucleic acid pool of antibody variable regions may be 
a cDNA pool. Obtaining the nucleic acid pool may comprise 
the use of reverse transcriptase. The method for obtaining the 
nucleic acid pool, for example, may comprise rapid cDNA 
end amplification (RACE), PCR amplification, or nucleic 
acid hybridization. Without separation of B cells from the 
lymphoid tissue, the nucleic acid population of the lymphoid 
tissue may contain other non-B-cell nucleic acids as well as 
non-antibody nucleic acids. For the antibody sequence sepa 
ration, antibody-specific primers or probes may be used. Such 
as primers or probes based on known antibody constant 
region cDNA sequences. In alternative aspects, the nucleic 
acid pool may be a genomic nucleic acid pool. 
A method may further comprise determining sequences 
and occurrence frequency of antibody variable region nucleic 
acids in the pool. In a further embodiment, the method may 
comprise identifying abundant variable region sequences. In 
specific embodiments, the method may further comprise 
identifying CDR3 sequences of the antibody variable region 
nucleic acid sequences, such as by homolog searching. Since 
CDR3 is the most variable region, variable region sequence 
frequency is preferably based on corresponding CDR3 fre 
quency. Particularly, the occurrence frequency of a selected 
variable region sequence may be further defined as the Sum of 
the occurrence frequency of any variable region sequences 














selected variable region sequence. The similar CDR3 
sequences may be at least about 90%, 91%, 92%, 93%, 94%, 
95%, 96%, 97%, 98%, 99% similar or any intermediate 
ranges. For example, variable region sequences may be 
grouped based on the same or similar CDR3 sequences and 
each group has the same frequency as defined by the sum of 
the frequency of all the sequences in the same group. In other 
aspects, the frequency of variable region sequences may be 
the frequency of each different variable region sequence or 
based on similarity of full-length variable regions, which 
contain CDR1, CDR2, and CDR3. 
In certain aspects, identification of abundant CDR3 
sequences may be performed, followed by identification of 
full-length variable regions containing the identified abun 
dant CDR3 sequences. For example, primers or probes may 
be generated based on the abundant CDR3 sequences and 
used to enrich or amplify antibody variable region sequences 
encoding the abundant CDR3 sequences. 
In exemplary aspects. Such abundant sequences may occur 
in total at a frequency of at least 0.1%, 0.2%, 0.3%, 0.4%, 
0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 2.5%, 3%, 
3.5%, 4%, 4.5%. 5%, 6%, 7%, 8%, 9%, 10% or any interme 
diate ranges in the sequences so determined. The abundant 
variable region sequences so identified may be candidate 
antigen-specific sequences. 
For generation of antigen-specific antibody or antibody 
fragments, the method may further comprise selecting a pair 
comprising nucleic acid sequences of a Vanda V, at similar 
abundance levels or a pair comprising nucleic acid sequences 
that belong to a cluster of nucleic acid sequences comprising 
similar abundance. For example, the V nucleic acid 
sequence in the pair is the most abundantV sequence and the 
V, nucleic acid sequence in the pair is the most abundant V, 
sequence. Alternatively, the Vanda V at similar abundance 
levels may be any V, and a V, having the same relative rank 
order in the V or V. Subpopulation, respectively, or similar 
concentration levels. For example, the third most abundant 
V may be paired with the third most abundant V. In still 
further aspects, a V and/or V may be aligned with other 
identified V or V, sequences to identify clusters of highly 
homologous sequences (e.g., sequences differing by the 
results of hypermutation) the clusters are then ranked and the 
V can be paired with a V that belongs to a cluster of similar 
rank. 
The method may further comprise generating antibody or 
antibody fragments comprising amino acid sequences 
encoded by the paired nucleic acid sequences of V, and V. 
At least one of the generated antibody or antibody fragments 
may bind the antigen that the Subject has been exposed to, 
Such as the immunization agent used to immunize the Subject. 
For example, the abundant variable region sequences may be 
directly chemically synthesized, such as by an automatic 
synthesis method. The method may further comprise express 
ing the abundant variable region sequences (e.g., synthe 
sized) in an in vitro expression system or a heterologous cell 
expression system. 
The Subject may be any animal, preferably a mammal or a 
human. The Subject may have a disease or a condition, includ 
ing a tumor, an infectious disease, or an autoimmune disease, 
or have been immunized. In certain aspects, the Subject may 
recover or Survive from a disease or a condition, such as a 
tumor, an infectious disease, or an autoimmune disease. In 
further aspects, the Subject may be under or have completed 
prevention and treatment for a disease or a condition, Such as 
cancer therapy or infection disease therapy, or vaccination. 
For example, the Subject has or has been exposed to an anti 
gen that is an infectious agent, a tumor antigen, a tumor cell, 
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an allergen, or a self-antigen. Such an infectious agent may be 
any pathogenic viruses, pathogenic bacteria, fungi, protozoa, 
multicellular parasites, and aberrant proteins, such as prions, 
as wells as nucleic acids or antigens derived therefrom. An 
allergen could be any nonparasitic antigen capable of stimu 
lating a type-I hypersensitivity reaction in individuals, such as 
many common environmental antigens. 
A tumor antigen can be any substance produced in tumor 
cells that triggers an immune response in the host. Any pro 
tein produced in a tumor cell that has an abnormal structure 
due to mutation can act as a tumor antigen. Such abnormal 
proteins are produced due to mutation of the concerned gene. 
Mutations of protooncogenes and tumor Suppressors that lead 
to abnormal protein production are the cause of the tumor, and 
thus Such abnormal proteins are called tumor-specific anti 
gens. Examples of tumor-specific antigens include the abnor 
mal products of the ras and p53 genes. 
Obtaining the nucleic acid sequence information may com 
prise determining the nucleic acid sequences and optionally 
the corresponding amino acid sequences in the B cells or in 
lymphoid tissues, or in other aspects, obtaining Such infor 
mation from a service provider or a data storage device. In 
further aspects, such nucleic acid sequence information may 
be used for determining the amino acid sequences of the 
serum antibodies. 
For determining the nucleic acid sequences (e.g., in the B 
cells or in lymphoid tissues), any nucleic acid sequencing 
methods known in the art may be used, including high 
throughput DNA sequencing. Non-limiting examples of 
high-throughput sequencing methods comprise sequencing 
by-synthesis (e.g., 454 sequencing), sequencing-by-ligation, 
sequencing-by-hybridization, single molecule DNA 
sequencing, multiplex polony sequencing, nanopore 
sequencing, or a combination thereof. 
In certain aspects, there may be provided methods for 
obtaining sequence information of amino acid sequences of at 
least the CDR3 of the V and V, regions of antibodies in a 
biological sample of a Subject. Obtaining sequence informa 
tion may comprise determining amino acid or nucleic acid 
sequences or obtaining such information from a service pro 
vider or a data storage device. 
Such amino acid sequence determination methods may 
comprise obtaining mass spectra of peptides derived from 
serum antibodies of the subject. To separate peptides derived 
from serum antibodies, any chromatography methods may be 
used. Such as high-performance liquid chromatography 
(HPLC). 
For determining amino acid sequences, there may be pro 
vided methods comprising isolating or enriching a selected 
class of serum antibodies, such as IgG, IgM, IgA, IgE, or 
other major Ig classes, isolating or enriching serum antibod 
ies that bind to a predetermined antigen, and/or isolating or 
enriching CDR3-containing fragments of serum antibodies. 
In further aspects, the methods may comprise preparing 
CDR3-containing peptide fragments from antibodies using a 
protease that is identified based on the sequence information 
of nucleic acid sequences and corresponding amino acid 
sequences of at least the CDR3 of V and V regions in 
mature B cells of the subject. For example, the protease 
cleaves V and V, peptides at the site outside or adjacent to 
CDR3, thus leaving CDR3 regions substantially intact. 
In certain aspects, there may also be provided a method 
comprising enriching or purifying CDR3-containing peptide 
fragments. For example, Such methods may comprise conju 
gating CDR3-containing peptide fragments with a labeled 
thiol-specific conjugating agent for specific conjugation of 














ods of enriching or purifying conjugated CDR3-containing 
peptide fragments may be based on the label on the conju 
gated CDR3-containing peptide fragments. Examples of the 
label include biotin. 
Certain aspects of the invention are based, in part, on the 
discovery that highly abundant antibody cDNAs in plasma 
cells or in a lymphoid tissue are correlated with antibody 
specificity toward an antigen related to a disease or a condi 
tion in the Subject, Such as a tumor. In additional aspects, there 
may be provided methods comprising determining the abun 
dance level of the amino acid sequences of the serum anti 
bodies or of the nucleic acid sequences of V and V, genes in 
the B cells or in a lymphoid tissue, for example, by an auto 
mated method. For the determination of abundance level of 
the amino acid sequences of serum antibodies, a quantitative 
method for mass spectrometry may be used. 
In certain methods, there may be provided methods com 
prising identifying antibody amino acid sequences that 
exhibit at least a threshold level of abundance. For example, 
the threshold level of abundance is a concentration of about, 
at least, or at most 5, 10, 20, 30, 40, 50, 100, 200, 300, 400, 
500 g/mL (or any range derivable therein) or a level of any 
one of the about 20,30,40, 50, 60, 70,80,90, 100,200 (or any 
numerical range derivable therein) most abundant CDR3 
containing amino acid sequences of the serum antibodies. 
In certain methods, there may be provided methods com 
prising identifying antibody nucleic acid sequences that 
exhibit at least a threshold level of abundance. Such threshold 
level of abundance may be at least 0.5%, 1%, 2%. 3%, 4%, 
5%, 6%, 7%, 8%, 9%, 10%, or 15% of frequency in an 
antibody gene pool of the Subject, for example, antibody 
genes in a B-cell population or a lymphoid tissue. Such a 
B-cell population may be a specific mature B-cell population, 
Such as a population of mature B cells from a selected lym 
phoid tissue, like bone marrow, spleen, or lymph nodes. 
In certain further aspects, there may be provided methods 
comprising reporting any of the determination or identifica 
tion described above. For example, such report may be in a 
computer-accessible format. 
In certain aspects, there may also be provided methods 
comprising generating one or more antibodies or antigen 
binding fragments comprising one or more of the amino acid 
sequences as described above. Generation of antibodies or 
antigen-binding fragments may comprise chemical synthesis 
of V and V coding regions corresponding to abundant V 
and V, amino acid sequences of serum antibodies that exhibit 
at least a threshold level of abundance, or comprise, in other 
aspects, chemical synthesis of abundant nucleic acid 
sequences of V and V, genes in B cells or in a lymphoid 
tissue. 
For example, the antibodies or antigen-binding fragments 
So generated may bind an antigen the Subject has or has not 
been exposed to. The antigen may be an infectious agent, a 
tumor antigen, a tumor cell, or a self-antigen. Such binding 
may have a monovalent affinity of at least or about 100, 200, 
103, 10, 10 pM, or 1, 2, 3, 4, 5uM or any range derivable 
therein. 
There may be further provided methods comprising evalu 
ating the generated antibody orantigen-binding fragments for 
binding affinity or specificity to a predetermined antigen, 
Such as an infectious agent, a tumor antigen, a tumor cell, or 
a self-antigen. 
In a preferable aspect, each of the antibodies or antigen 
binding fragments so generated comprises similarly abundant 
amino acid or nucleic acid sequences of V and V. For 
example, a V sequence may have a level of abundance 
ranked as the 3" most abundant V, sequence in a serum 
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containing sample, which may be paired with a V sequence 
that has a similar rank level of abundance (for example, 3", 
4", or 5") in the same sample. The inventors determined that 
pairing V genes with V, genes having a rank-order abun 
dance within +/-3 (e.g., the 3' most abundant V, with any of 
the 1'-6" most abundant V,) results in antigen-specific anti 
bodies at a frequency greater than 50%. 
Embodiments discussed in the context of methods and/or 
compositions of the invention may be employed with respect 
to any other method or composition described herein. Thus, 
an embodiment pertaining to one method or composition may 
be applied to other methods and compositions of the inven 
tion as well. 
As used herein the terms “encode' or “encoding with 
reference to a nucleic acid are used to make the invention 
readily understandable by the skilled artisan; however, these 
terms may be used interchangeably with “comprise' or “com 
prising.” respectively. 
As used herein the specification, “a” or “an may mean one 
or more. As used herein in the claim(s), when used in con 
junction with the word “comprising, the words “a” or “an 
may mean one or more than one. 
The use of the term 'or' in the claims is used to mean 
“and/or unless explicitly indicated to refer to alternatives 
only or the alternatives are mutually exclusive, although the 
disclosure Supports a definition that refers to only alternatives 
and “and/or.” As used herein “another may mean at least a 
second or more. 
Throughout this application, the term “about is used to 
indicate that a value includes the inherent variation of error 
for the device, the method being employed to determine the 
value, or the variation that exists among the study subjects. 
Other objects, features, and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indicat 
ing preferred embodiments of the invention, are given by way 
of illustration only, since various changes and modifications 
within the spirit and scope of the invention will become 
apparent to those skilled in the art from this detailed descrip 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present specifica 
tion and are included to further demonstrate certain aspects of 
the present invention. The invention may be better understood 
by reference to one or more of these drawings in combination 
with the detailed description of specific embodiments pre 
sented herein. 
FIG. 1: Occurrences of tryptic sites (K/R) in flanking 
CDRH3 region. X represents the potential trypsin cleavage 
site that in 91% of instances exhibits the amino acid R/K 
(SEQ ID NO:89). 
FIG. 2: Monoclonal phage ELISA of antigen-specific 
scEvs containing the V genes corresponding to select abun 
dant iCDRH3s. Sclvs were isolated by three rounds of phage 
display of libraries constructed by pairing each of the Syn 
thetic V, genes with the cDNAV, library from the immu 
nized animal (Table 6 for V-V, sequences). 5A2 and 5F4 
represent two clones with the same heavy chain, but paired to 
a different light chain sequence. 
FIG. 3: CDR3-J peptide sequence (in red) based on the 
rabbit CDRH3 region. The peptide sequence consists of the 
C-terminal portion of the rabbit J region and four residues 
from the CH1 region (SEQID NO:89). 














FIG. 5: Schematic of an example CDRH3-J peptide isola 
tion pipeline. 
FIG. 6: Schematic shows an example cysteine alkylation of 
the embodiments and resulting mass spectra obtained from 
differentially alkylated peptides. 
FIG. 7A-B: A, plot shows the observed protein-spectrum 
match scores for peptides analyzed by mass spectrometry. 
Grey line indicates the average mass accuracy for “true posi 
tive' results. Black line indicates the average mass accuracy 
for “false positive' results. B. plot shows the density of spec 
tra vs. AMD for all peptides, “true positives” and “false posi 
tives. True positives show a clustered density below 1 ppm 
AMD, while false positives show a density that only slightly 
decreases across the entire range of AMD depicted. 
FIG. 8: Determination of the paired VH:VL genes in 
peripheral B lymphocytes. The specific embodiment in 
Example 11 refers to B cells isolated from a volunteer immu 
nized with the tetanus toxoid vaccine. Cells are deposited in 
pI wells containing poly(dT) beads, wells are covered with a 
dialysis membrane and equilibrated with lysis buffer, then the 
beads with captured mRNA from lysed cells are recovered 
and emulsified for cDNA synthesis and linkage PCR to pro 
duce a VH:VL product. NextGen sequencing is then used to 
determine linked VH:VL pairs. 
FIG. 9: A mass spectral count heat map of proteomically 
identified TT-specific serum IgG clonotypes in a healthy 
donor (HD2) across each of the four time points examined. 
The heat map is vertically split into two populations of TT 
specific IgG clonotypes. Clonotypes that are identified in the 
top 80% (by frequency of mass spectral counts) of any of the 
four time points are included in the top heat map, whereas 
clonotypes not present at the 80% cutoffat any time point are 
considered “swarm clonotypes that are only present at very 
low levels. This donor exhibited 54 IgG clonotypes persistent 
across all four time points, representing 77% of the heavy 
chain CDR3-peptide mass spectral counts in the TT affinity 
column elution fraction at day 256 (steady state after vacci 
nation). An additional 18 new clonotypes (12% of day 256 
mass spectral counts) are identified at day 256 were not 
present at day 0. A number of short lived clonotypes are also 
identified at earlier time points, but are not detected at steady 
state post-vaccination. 
DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
I. Introduction 
This year marks the 100th anniversary of the first Nobel 
Prize in Medicine to Emil von Behring who, in collaboration 
with Kitasato Shibasaburo and also Paul Ehrlich, discovered 
serum anti-toxins (Browning et al. 1955; Kantha 1991). 
Remarkably, after 100 years of intense research in immunol 
ogy, there is practically nothing known about the clonality, 
relative concentrations, amino acid sequences, and binding 
properties of the antibodies that comprise the antigen-specific 
immunoglobulin pool in serum. For both clinical and research 
purposes, antibody responses are characterized only in terms 
of the serum titer that is sufficient to detect binding to antigens 
in ELISAs or other related assays. Being able to determine the 
clonality of the response, and to sequence, produce, and char 
acterize the antigen-binding affinities of the constituent 
monoclonal antibodies in serum samples, is of utmost impor 
tance for immunology and biomedical research. Such infor 
mation can provide invaluable insights on the molecular 
nature of the protective responses following challenge with a 
pathogen or following vaccination, help the identification of 
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physiologically relevant antibodies, i.e., those present at Suf 
ficient concentrations in serum to be important for protection 
against disease (or alternatively, those that may contribute to 
a disease state in the case of autoimmunity) and finally, estab 
lish the link between the well studied programs for B-cell 
differentiation with the most important end-point of humoral 
immunity, namely antibody production. 
Several fundamental technical limitations have so far pre 
cluded the molecular analysis of serological responses. First, 
most circulating antibodies are produced by plasma cells, 
which are terminally differentiated B lymphocytes that are 
able to survive only in specialized niches within lymphoid 
organs and thus cannot be readily accessed in living individu 
als (Radbruch et al., 2006). Second, even in instances where 
the totality of immunoglobulins expressed by bone marrow 
plasma cells is interrogated post-mortem using high-through 
put DNA sequencing (Reddy et al., 2010), it is immensely 
challenging to correlate the immune repertoire expressed by 
plasma cells with the composition of the serum polyclonal 
pool, since antibodies remain in circulation for many days. 
Third, proteomic analysis of serum immunoglobulins pre 
sents formidable challenges for several reasons: (i) antibody 
genes are not simply encoded in the germline but are exten 
sively diversified by somatic recombination, revision, and/or 
mutation, and therefore, the sequence database required for 
the interpretation of mass spectra is not available a priori 
(Dekkeret al., 2011; de Costa et al., 2010) from genomic data; 
(ii) because antibodies share a high degree of identity, pro 
teolytic digestion yields numerous non-informative and very 
similar peptides, producing very complex mass spectra that 
are difficult to interpret; and (iii) mass spectrometry methods 
for the de novo sequencing of peptides and their absolute 
quantification in a complex mixture have not been available 
until relatively recently (Malmstroem et al., 2009; Olsen et 
al., 2007). 
Aspects of the invention provide methods for the molecular 
deconvolution of antibody responses in humans and other 
animals. For example, high-throughput sequencing and pro 
teomic and/or bioinformatic analyses can be combined to 
identify the sequence and relative abundance of highly rep 
resented immunoglobulins (Igs) in circulation or in lymphoid 
tissues. In certain further embodiments, the genes for the 
variable domains of these antibodies can then be synthesized, 
the respective Igs or antibody fragments, such as Schvs. 
expressed and purified, and then the antibodies or antibody 
fragments analyzed for binding to an antigen in the source of 
the Subject, such as infectious agents or cancer cells of inter 
eSt. 
In general, molecular deconvolution of antibody response 
from serum comprises three steps: 
(1) high-throughput sequencing (e.g., NextGen sequenc 
ing) of portions of V gene cDNAs from a subject. For 
example, high-throughput sequencing of B lymphocyte 
cDNAs to generate a database of class-switched antibody 
variable domain heavy chain (V) or light chain (V) 
sequences in a particular subject; 
(2) proteomic analysis of the immunoglobulin fraction 
from a subjects serum. A protein biochemistry and shot-gun 
mass spectrometry (MS) proteomic pipeline is used for 
preparation and sequence assignment of information-rich 
peptides from which the identity of the corresponding V 
and/or V, polypeptides can be deduced. In certain aspects it 
may be preferred that antigen-specific V, polypeptides are 
used because the immunoglobulin heavy chain is subject to 
more extensive sequence diversification than the light chain 
and plays a far more significant role in antigen recognition for 













(3) comparison of sequence and proteomic information 
from steps (1) and (2). Proteomic information obtain is com 
pared to the sequence information to identify (and in some 
aspects quantify) V, and/or V, sequences that are circulating 
in the subject. 
In certain aspects, proteomic analysis of the immunoglo 
bulin of a subject can be focused on the CDRH3 and/or 
CDRL3 regions of the V domain, which typically display the 
greatest sequence diversity and are the primary determinants 
of binding specificity. In these aspects, CDR3-containing 
peptides are selectively purified prior to proteomic analysis. 
For example, antibody polypeptides can be fragmented by a 
protease selected to cleave close to, but not within, the CDR3 
domain of the V and/or V. Resulting fragment sequences 
can then be purified by use of an antibody that binds to the J 
domain adjacent to the CDR3. After such isolation, proteomic 
analysis is significantly more efficient, as the amount of 
“background peptide has been greatly reduced. 
In a further independent aspect, antibody preparations can 
be treated with two or more Cys-modifying agents prior to 
proteomic analysis. For example, preparations of antigen 
specific F(ab) fragments including alkylation (e.g., car 
boxymethylation) of free Cys residues with two different 
reagents (e.g., iodoethanol and iodoacetamide) can be ana 
lyzed in parallel, followed by proteolytic fragmentation into 
peptides Suitable for quantitative, shot-gun analysis by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). 
The data obtained from these analyses are then compared to 
identify (and in some embodiments quantify) the sequence of 
antibodies expressed in the Subject. In particular, mis-identi 
fied peptides can be revealed when cysteine containing pep 
tides are differentially alkylated (e.g., with either iodoethanol 
or iodoacetamide), which results in a mass difference. In the 
case of iodoethanol and iodoacetamide the expected mass 
difference is 13.00 Da. Peptides with correlated spectra that 
exhibit a mass difference across treatments but are identified 
as different peptide sequences are considered misidentifica 
tions and removed from analysis. Likewise, peptides that 
exhibited the mass difference signature should contain a Cys 
in the identified sequence, and those that did not can thus also 
be deemed incorrect. Again, removal of non-informative pep 
tides is achieved, which significantly enhances the efficiency 
of the analysis. 
In still a further aspect, proteomic analysis of serum or 
secretory immunoglobulins can be enhanced by identifying 
uninformative peptide fragments by determining the average 
observed masses of peptides that are measured (e.g., by LC 
MS/MS) and comparing these values to the expected mass 
values based on the amino acid sequence. This comparison 
yields an average mass deviation (AMD). In this case, when 
the AMD of a peptide is above a certain threshold value, such 
as about 3 ppm, then the indicated peptide is not informative 
and not considered in the analysis. Again by Sorting the pep 
tide results using peptide AMD analysis, the “background of 
the assay can be greatly reduced and the efficiency increased. 
Accordingly, entire repertoires of V and/or V, Sequences 
can be determined and quantified for a Subject. In certain 
aspects, identified V and/or V. sequences can then be 
expressed either individually or in combination. In some 
embodiments, the relative abundance of V and V, domains 
can be used to identify antigen-specific antibodies by pairing 
relevant V, and V, chains. Alternatively or additionally, V 
and V, chains identified by the instant methods can be 
screened by a combinatorial affinity assay (e.g., ELISA) to 
identified paired chains. 
II. Definitions 
Unless defined otherwise, all technical and scientific terms 
used herein have the meaning commonly understood by one 
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of ordinary skill in the art relevant to the invention. The 
definitions below supplement those in the art and are directed 
to the embodiments described in the current application. 
The term “antibody' is used herein in the broadest sense 
and specifically encompasses at least monoclonal antibodies, 
polyclonal antibodies, multi-specific antibodies (e.g., bispe 
cific antibodies), naturally polyspecific antibodies, chimeric 
antibodies, humanized antibodies, human antibodies, and 
antibody fragments. An antibody is a protein comprising one 
or more polypeptides Substantially or partially encoded by 
immunoglobulin genes or fragments of immunoglobulin 
genes. The recognized immunoglobulin genes include the 
kappa, lambda, alpha, gamma, delta, epsilon, and mu con 
stant region genes, as well as myriad immunoglobulin vari 
able region genes. 
Antibody fragments' comprise a portion of an intact anti 
body, for example, one or more portions of the antigen-bind 
ing region thereof. Examples of antibody fragments include 
Fab, Fab'. F(ab'), and Fv fragments, diabodies, linear anti 
bodies, single-chain antibodies, and multi-specific antibodies 
formed from intact antibodies and antibody fragments. 
Average mass deviation” or AMD' refers to a method for 
analysis of peptide mass spectrometry information. AMD can 
be determined by comparing the average observed masses of 
peptides obtained by mass spectrometry to the expected 
masses based on the amino acid sequence to thereby deter 
mine the average difference between obtained and expected 
peptide masses. 
An “intact antibody is one comprising full-length heavy 
and light-chains and an Fc region. An intact antibody is also 
referred to as a “full-length, heterodimeric' antibody or 
immunoglobulin. 
The term “variable” refers to the portions of the immuno 
globulin domains that exhibit variability in their sequence and 
that are involved in determining the specificity and binding 
affinity of a particular antibody. 
As used herein, “antibody variable domain refers to a 
portion of the light and heavy chains of antibody molecules 
that include amino acid sequences of Complementarity 
Determining Regions (CDRs; i.e., CDR1, CDR2, and 
CDR3), and Framework Regions (FRs; i.e., FR1, FR2, FR3, 
and FR4). FRs include the amino acid positions in an anti 
body variable domain other than CDR positions as defined 
herein. V. refers to the variable domain of the heavy chain. 
V, refers to the variable domain of the light chain. 
As used herein, the term "complementary nucleotide 
sequence” refers to a sequence of nucleotides in a single 
stranded molecule of DNA or RNA that is sufficiently 
complementary to that on another single strand to specifically 
hybridize to it with consequent hydrogen bonding. 
An “expression vector” is intended to be any nucleotide 
molecule used to transport genetic information. 
III. Antibody Variable Domains 
Certain aspects of the invention provide methods for iden 
tifying antibody variable domains or variable domain-coding 
sequences that are over-represented in serum or B cells. Such 
skewed representation of antibody variable domains is useful 
to identify novel antigen-binding molecules having high 
affinity or specificity. The present invention is based, in part, 
on the discovery that abundancy levels of regions of an anti 
body variable domain that form the antigen-binding pocket, 
for example CDR3 regions, could correlate with the desired 
affinity specificity or biological function. 
For identifying desired antibody variable domains, certain 













ing sequences and distributions of antibody complementarity 
determining regions (CDRS). Specifically, the sequences of 
one to six of the CDRs on V and/or V, could be determined 
by MS proteomics and nucleic acid sequencing methods. The 
level of abundancy of variable domains or CDRs could be 
determined as an absolute level, like a concentration, or a 
relative level, like a rank-order. 
Antibodies are globular plasma proteins (~150 kDa) that 
are also known as immunoglobulins. They have Sugar chains 
added to some of their amino acid residues. In other words, 
antibodies are glycoproteins. The basic functional unit of 
each antibody is an immunoglobulin (Ig) monomer (contain 
ing only one Ig unit); secreted antibodies can also be dimeric 
with two Ig units as with IgA, tetrameric with four Ig units, 
like teleost fish IgM, or pentameric with five Ig units, like 
mammalian IgM. 
The Ig monomer is a “Y”-shaped molecule that consists of 
four polypeptide chains; two identical heavy chains and two 
identical light chains connected by disulfide bonds. Each 
chain is composed of structural domains called Ig domains. 
These domains contain about 70-110 amino acids and are 
classified into different categories (for example, variable or 
IgV, and constant or IgC) according to their size and function. 
They have a characteristic immunoglobulin fold in which two 
beta sheets create a “sandwich' shape, held together by inter 
actions between conserved cysteines and other charged 
amino acids. 
There are five types of human Ig heavy chain denoted by 
the Greek letters: C, Ö, e, Y, and L. The type of heavy chain 
present defines the class of antibody; these chains are found in 
IgA, Ig), IgE, IgG, and IgM antibodies, respectively. Distinct 
heavy chains differ in size and composition: Ig heavy chains 
C. and Y contain approximately 450 amino acids, while Land 
e have approximately 550 amino acids. Other animals encode 
analogous immunoglobulin heavy chain classes. 
Each heavy chain has two regions, the constant region and 
the variable region. The constant region is identical in all 
antibodies of the same isotype, but differs in antibodies of 
different isotypes. Heavy chains Y. C., and ö have a constant 
region composed of three tandem (in a line) Ig domains, and 
a hinge region for added flexibility; heavy chains Lande have 
a constant region composed of four immunoglobulin 
domains. The variable region of the heavy chain differs in 
antibodies produced by different B cells, but is the same for 
all antibodies produced by a single B cell or B-cell clone. The 
variable region of each heavy chain is approximately 110 
amino acids long and is composed of a single Ig domain. 
In humans (and mice) there are two types of immunoglo 
bulin light chain, which are called lambda (W) and kappa (K). 
A light chain has two Successive domains: one constant 
domain and one variable domain. The approximate length of 
a light chain is 211 to 217 amino acids. Each antibody con 
tains two light chains that are always identical; only one type 
of light chain, K or W, is present per antibody in these species. 
The antigen-binding fragment (Fab fragment) is a region 
on an antibody that binds to antigens. It is composed of one 
constant and one variable domain of each of the heavy and the 
light chain. These domains shape the paratope—the antigen 
binding site—at the amino terminal end of the monomer. 
The two variable domains bind the epitope on their specific 
antigens. The variable domain is also referred to as the F 
region and is the most important region for binding to anti 
gens. More specifically, variable loops, three each on the light 
(V) and heavy (V) chains, are responsible for binding to the 
antigen. These loops are referred to as the complementarity 
determining regions (CDRS). 
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A complementarity determining region (CDR) is a short 
amino acid sequence found in the variable domains of antigen 
receptor (e.g., immunoglobulin and T cell receptor) proteins 
that complements an antigen and therefore provides the 
receptor with its specificity for that particular antigen. CDRs 
are supported within the variable domains by conserved 
framework regions (FRs). 
Each polypeptide chain of an antigen receptor contains 
three CDRs (CDR1, CDR2, and CDR3). Since the antigen 
receptors are typically composed of two polypeptide chains, 
there are six CDRS for each antigen receptor that can come 
into contact with the antigen (each heavy and light chain 
contains three CDRs), twelve CDRs on a single antibody 
molecule, and sixty CDRS on a pentameric IgM molecule. 
Since most sequence variation associated with immunoglo 
bulins and T cell receptors are found in the CDRs, these 
regions are sometimes referred to as hyperVariable domains. 
Among these, CDR3 shows the greatest variability as it is 
encoded by a recombination of the VJ (VDJ in the case of 
heavy chain) regions. 
IV. Antibody Variable Region Analysis 
In certain aspects of the invention, antibody variable gene 
(V gene) sequences derived from cDNA may be analyzed. For 
example, information from Such analysis may be used to 
generate a database of the V genes (V gene database) that give 
rise to circulating antibodies so that mass spectrometry (MS) 
spectra of peptides derived from serum antibodies can be 
assigned and in turn used to identify the respective full-length 
V genes in the database encoding those peptides. In another 
embodiment, the sequence information may be used to iden 
tify abundant variable gene nucleic acids, such as mRNA 
transcripts, and generate antibody or antibody fragments 
based on the abundant variable genes. The abundant variable 
genes so identified may correspond to antibodies or antibody 
fragments that have desired specificity or affinity. 
From the nucleotide sequences determined by the initial 
sequencing, putative amino acid sequences for the V and V, 
regions can be determined using standard algorithms and 
software packages (e.g., see the World Wide Web at mrc 
limb.cam.ac.uk/pubseq/, the Staden package and Gap4 pro 
grams). These can be further characterized to determine the 
CDR (Complementarity Determining Region) parts of the V, 
and V, sequences, particularly CDR1, CDR2, and CDR3. 
Methods for determining the putative amino acid sequences 
and identifying CDR regions are well known in the art. In one 
particular embodiment, CDR3 sequences are identified by 
searching for a highly conserved sequence motif at the N-ter 
minal region preceding the CDR3. This method could cor 
rectly identified >90% of the CDR3 sequences in antibodies. 
The putative amino acid sequence derived based on the 
nucleic acid sequencing of B-cell clNA could be used for the 
shot gun proteomic analysis of serum antibodies in some 
embodiments. 
A variety of methods have been developed for the immor 
talization or cloning of antibodies from individual B cells. 
These techniques include hybridoma technology, memory 
B-cell immortalization by viral (EBV) infection, the engi 
neering of memory B cells that express both Surface and 
secreted antibodies, and the cloning of antigen-specific, anti 
body genes from transient ASC populations, from memory B 
cells, or from splenic plasma cells. Recently, microfluidic and 
nanopatterning devices have been used to increase the 
throughput of B cells interrogated for antigenbinding and for 














While invaluable for the isolation of monoclonal antibod 
ies, these techniques have several drawbacks. First, most have 
focused on and, in some cases, are only compatible with 
certain stages of the B-cell life cycle. This leaves unresolved 
the central issue of whether a particular antibody isolated 
from B cells is represented at a significant amount in the 
serum of that individual. Also, there is evidence that plasma 
cells in the bone marrow are the main compartment for anti 
body synthesis and are selected on the basis of their affinity 
and perhaps protective function. Second, single B-cell clon 
ing methods are still not efficient enough to provide complete 
information on the diversity of antibodies in serum, espe 
cially with respect to serum concentration and abundancy of 
specific antibody clones. Third, current attempts to pool 
recombinant mAbs in order to reconstitute a polyclonal anti 
body that displays higher therapeutic efficacy cannot possibly 
capture the true protective effect of sera since the mixing of 
cloned antibodies is completely ad hoc. The present invention 
could avoid one or more of these problems by the methods 
described herein. 
In certain embodiments, the mRNA from B cells or directly 
from one or more lymphoid tissues could be isolated and 
converted to cDNA. In further embodiments, the cDNA may 
be subject to VandV, gene isolation. For example, the genes 
encoding the variable heavy and the variable light (V, and 
VK.W) genes could be amplified using specific primers that 
hybridize to the 5' and 3' ends of the cDNA. Depending on the 
primers used for cDNA construction, V genes of different Ig 
classes could be distinguished. For example, the V and V. 
gene isolation may be based on Ig classes either by using 
known primer sets of variable gene amplification or, prefer 
ably by 5' RACE (rapid amplification of cDNA ends) using a 
class-specific 3' primer. For example, the class-specific 3' 
primer may hybridize to the C domain. 
V. Lymphoid Tissues 
In certain embodiments, there may be provided methods of 
identifying antigen-specific variable region sequences by 
obtaining nucleic acid sequences directly from lymphoid tis 
Sues. In optional aspects, B cells may not be separated from 
the lymphoid tissue where the B cells reside. The method may 
comprise isolation of primary, secondary, or tertiary lym 
phoid tissues. Any methods known for isolation of lymphoid 
tissues may be used. 
Lymphoid tissue associated with the lymphatic system is 
concerned with immune functions in defending the body 
against the infections and spread of tumors. It consists of 
connective tissue with various types of white blood cells 
enmeshed in it, most numerous being the lymphocytes. 
The lymphoid tissue may be primary, secondary, or tertiary 
depending upon the stage of lymphocyte development and 
maturation it is involved in. The tertiary lymphoid tissue 
typically contains far fewer lymphocytes, and assumes an 
immune role only when challenged with antigens that result 
in inflammation. It achieves this by importing the lympho 
cytes from blood and lymph. 
The central or primary lymphoid organs generate lympho 
cytes from immature progenitor cells. The thymus and the 
bone marrow constitute the primary lymphoid tissues 
involved in the production and early selection of lympho 
cytes. 
Secondary or peripheral lymphoid organs maintain mature 
naive lymphocytes and initiate an adaptive immune response. 
The peripheral lymphoid organs are the sites of lymphocyte 
activation by antigen. Activation leads to clonal expansion 
and affinity maturation. Mature lymphocytes recirculate 
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between the blood and the peripheral lymphoid organs until 
they encounter their specific antigen. 
Secondary lymphoid tissue provides the environment for 
the foreign or altered native molecules (antigens) to interact 
with the lymphocytes. It is exemplified by the lymph nodes 
and the lymphoid follicles in tonsils, Peyer's patches, spleen, 
adenoids, skin, etc. that are associated with the mucosa-asso 
ciated lymphoid tissue (MALT). 
A lymph node is an organized collection of lymphoid tis 
Sue, through which the lymph passes on its way to returning 
to the blood. Lymph nodes are located at intervals along the 
lymphatic system. Several afferent lymph vessels bring in 
lymph, which percolates through the Substance of the lymph 
node, and is drained out by an efferentlymph vessel. 
The substance of a lymph node consists of lymphoid fol 
licles in the outer portion called the “cortex, which contains 
the lymphoid follicles, and an inner portion called “medulla.” 
which is surrounded by the cortex on all sides except for a 
portion known as the “hilum.” The hilum presents as a depres 
sion on the surface of the lymph node, which makes the 
otherwise spherical or ovoid lymph node bean-shaped. The 
efferentlymph vessel directly emerges from the lymph node 
here. The arteries and veins Supplying the lymph node with 
blood enter and exit through the hilum. 
Lymph follicles are a dense collection of lymphocytes, the 
number, size, and configuration of which change in accor 
dance with the functional state of the lymph node. For 
example, the follicles expand significantly upon encountering 
a foreign antigen. The selection of B cells occurs in the 
germinal center of the lymph nodes. 
Lymph nodes are particularly numerous in the mediasti 
num in the chest, neck, pelvis, axilla (armpit), inguinal 
(groin) region, and in association with the blood vessels of the 
intestines. 
VI. B Cell Sample Preparation 
In certain embodiments, B cells may be extracted for iso 
lation of variable region nucleic acid sequences. In other 
embodiments, B cells may not need to be separated from a 
lymphoid tissue, thus saving cost and time for B-cell isola 
tion. Without B-cell separation, lymphoid tissues may be 
directly used to obtain a pool of antibody variable gene 
sequences, for example, by using antibody-specific primers 
or probes, such as primers or probes based on antibody con 
stant region sequences. 
In one embodiment, mature, circulating B-cells (memory 
cells and/or antigen secreting cells (ASCs)) in peripheral 
blood (for example, about or at least or up to 3, 4, 5, 6, 7, 8, 9. 
10, 15, 20 mL or any ranges derivable therefrom) may be 
used. The circulating B cells may be separated by magnetic 
sorting protocols (Jackson et al., 2008; Scheid et al., 2009; 
Smith et al., 2009; Kwakkenbos et al., 2010) as described in 
the Examples. Alternatively, plasma cells, which are termi 
nally differentiated B cells that reside in the bone marrow, 
spleen, or in secondary lymphoid organs, could be isolated 
and used for the determination of the B-cell repertoire in an 
individual animal or human. In particular aspects, plasma 
cells could be mobilized from the bone marrow into circula 
tion, e.g., by administration of G-CSF (granulocyte colony 
stimulating factor), and isolated. 
ASC are terminally or near terminally differentiated B cells 
(including plasma cells and plasmablasts) that are demar 
cated by Surface markers (for example, Syndecan-1). They 
lack surface IgM and Ig) and other typical B-cell surface 
markers (e.g., CD19) and importantly, they express the 













regulate PaX-5. Antibody secreting cells can be generated 
from: (i) B1 cells that produce low specificity “innate-like' 
IgM, (ii) B cells that do not reside in the follicles of lymphoid 
organs (extrafollicular) and include marginal Zone (MZ. 
IgM, Iglo", CD27) cells that generally produce lower affin 
ity antibodies (the latter mostly in the absence T-cell help), 
and finally, (iii) cells of the B2 lineage that have circulated 
through the lymphoid follicles. B2 cells progress to the 
plasma stage either directly from the germinal centers where 
they undergo selection for higher antigen affinity (following 
somatic hypermutation) or after they have first entered the 
memory compartment. Regardless of their precise origin, 
these cells express high affinity antibodies predominantly of 
the IgG isotype and constitute the major component of the 
protective immune response following challenge. 
Plasma cells are typically unable to proliferate or de-dif 
ferentiate back to earlier B-cell lineages. Most plasma cells 
are short-lived and die within a few days. In contrast, a frac 
tion of the plasma cells occupy "niches' (primarily in bone 
marrow) that provide an appropriate cytokine microenviron 
ment for Survival and continued antibody secretion that may 
last from months to years; i.e., these are the cells that produce 
antibodies primarily involved with protection to re-challenge 
and constitute the "humoral memory’ immune response. 
A particularly preferred site for ASC isolation is the bone 
marrow where a large number of plasma cells that express 
antibodies specific for the antigen are found. It should be 
noted that B cells that mature to become plasma cells and to 
reside in the bone marrow predominantly express high affin 
ity IgG antibodies. Mature plasma cells in the bone marrow 
are selected based on cell surface markers well known in the 
field, e.g., CD138", CXCR4", and CD45". Mature 
plasma cells can also be isolated based on the high expression 
level of the transcription factor Blimp-1; methods for the 
isolation of Blimp-1" cells, especially from transgenic ani 
mals carrying reporter proteins linked to Blimp-1, are known 
in the art. 
On the other hand, memory B cells are formed from acti 
vated B cells that are specific to the antigen encountered 
during the primary immune response. These cells are able to 
live for a long time, and can respond quickly following a 
second exposure to the same antigen. In the wake of first 
(primary response) infection involving a particular antigen, 
the responding naive (ones which have never been exposed to 
the antigen) cells proliferate to produce a colony of cells, most 
of which differentiate into plasma cells, also called effector B 
cells (which produce antibodies), and clear away with the 
resolution of infection, and the rest persist as the memory 
cells that can survive for years, or even a lifetime. 
VII. Nucleic Acid Sequencing 
Any sequencing methods, particularly high-throughput 
sequencing methods, may be used to determine one or more 
of the V and V, nucleotide sequences in the B-cell reper 
toire. For example, the nucleotide sequence of the V and V, 
could be determined by 454 sequencing (Fox et al., 2009) 
with a universal primer and without amplification to allow 
accurate quantitation of the respective mRNAS. Reads longer 
than 300 bp may be processed for further analysis (Weinstein 
et al., 2009). Non-limiting examples of high-throughput 
sequencing technologies are described below. 
High-throughput sequencing technologies are intended to 
lower the cost of DNA sequencing beyond what is possible 
with standard dye-terminator methods. Most of such 
sequencing approaches use an in vitro cloning step to amplify 
individual DNA molecules, because their molecular detec 
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tion methods are not sensitive enough for single molecule 
sequencing. Emulsion PCR isolates individual DNA mol 
ecules along with primer-coated beads in aqueous droplets 
within an oil phase. Polymerase chain reaction (PCR) then 
coats each bead with clonal copies of the DNA molecule 
followed by immobilization for later sequencing. Emulsion 
PCR is used in the methods by Marguilis et al. (commercial 
ized by 454 Life Sciences), Shendure and Porreca et al. (also 
known as “Polony sequencing), and SOLiD sequencing, 
(developed by Agencourt, now Applied Biosystems). Another 
method for in vitro clonal amplification is bridge PCR, where 
fragments are amplified upon primers attached to a solid 
Surface, used in the Illumina Genome Analyzer. Alternatively, 
single-molecule methods developed by Stephen Quake's 
laboratory (later commercialized by Helicos) and by others 
use bright fluorophores and laser excitation to detect pyrose 
quencing events from individual DNA molecules fixed to a 
Surface, eliminating the need for molecular amplification. 
In parallelized sequencing, DNA molecules are physically 
bound to a surface, and sequenced in parallel. Sequencing by 
synthesis, like dye-termination electrophoretic sequencing, 
uses a DNA polymerase to determine the base sequence. 
Reversible terminator methods (used by Illumina and Heli 
cos) use reversible versions of dye-terminators, adding one 
nucleotide at a time and detecting fluorescence at each posi 
tion in real time by repeated removal of the blocking group to 
allow polymerization of another nucleotide. Pyrosequencing 
(used by Roche 454 and others) also uses DNA polymeriza 
tion, adding one nucleotide species at a time and detecting 
and quantifying the number of nucleotides added to a given 
location through the light emitted by the release of attached 
pyrophosphates. 
Sequencing by ligation uses a DNA ligase to determine the 
target sequence. Used in the polony method and in the SOLiD 
technology, it uses a pool of all possible oligonucleotides of a 
fixed length, labeled according to the sequenced position. 
Oligonucleotides are annealed and ligated; the preferential 
ligation by DNA ligase for matching sequences results in a 
signal informative of the nucleotide at that position. 
In microfluidic Sanger sequencing the entire thermocy 
cling amplification of DNA fragments, as well as their sepa 
ration by electrophoresis, is done on a single glass wafer 
(approximately 10 cm in diameter) thus reducing the reagent 
usage as well as cost. 
Sequencing by hybridization is a non-enzymatic method 
that uses a DNA microarray. A single pool of DNA whose 
sequence is to be determined is fluorescently labeled and 
hybridized to an array containing known sequences. Strong 
hybridization signals from a given spot on the array identify 
the sequence of the DNA. Mass spectrometry may be used to 
determine mass differences between DNA fragments pro 
duced in chain-termination reactions. 
DNA sequencing methods currently under development 
include labeling the DNA polymerase (Scheid et al., 2009), 
reading the sequence as a DNA strand transits through nan 
opores, and microscopy-based techniques, such as atomic 
force microscopy (AFM) or electron microscopy that are used 
to identify the positions of individual nucleotides within long 
DNA fragments (>5,000 bp) by nucleotide labeling with 
heavier elements (e.g., halogens) for visual detection and 
recording. 
The inventors found that less than 10 reads for each of the 
V and V pools could be sufficient to provide information on 
the variable gene sequences that correspond to the most abun 
dant antibodies found in serum. 
VIII. Sequence Abundancy Determination 
Bioinformatic methods for the automated analysis of 













error analysis, and finally identification and classification of 
CDRs, especially of CDR3, the most hypervariable region in 
antibodies, have been developed by the inventors. 
In certain embodiments, for example, to account for 
sequencing/PCR uncertainties, antibody sequences, particu 
larly CDR3 sequences, could be grouped into families, with 
each family consisting of all the CDR3 sequences differing by 
one or two nucleotides or amino acids. 
For example, the abundancy level of antibody variable 
region sequences may be based on the CDR3 sequences as 
identifiers. The sequences for determination of a level of 
abundancy may be a family, including an identical CDR3 
sequence (amino acid sequence or nucleic acid sequence) and 
a CDR3 sequence having at least 80% homology, for example 
85%, 90%, 95%, 96%, 97%, 98%, or 99% homology there 
with. Sequence homology is as determined using the 
BLAST2 program (Tatusova et al., 1999) at the National 
Center for Biotechnology Information, USA (World Wide 
Web at ncbi.nlm.nih.gov) with default parameters. For 
example, the sequences occurring in total at a relative level of 
abundancy represented by a frequency at least 1 percent in the 
set of sequences may be a combination of the CDR3 
sequences or a sequence having 1 or 2 amino acid changes 
therefrom. For example, a first sequence may occur at a 
frequency of 0.7 percent, and second, third, and fourth 
sequences each having a single amino acid change therefrom 
each occur at a frequency of 0.1%—the total occurrence in 
abundancy is therefore 1.1% and the dominant antibody 
sequence (occurring at a frequency of 0.7%) is therefore a 
candidate CDR3 sequence that could be used for antibody 
generation/characterization. 
IX. Use of Antibody Variable Sequence Information 
In addition to providing a reference database for interpret 
ing mass spectra data of serum antibody analysis, the nucleic 
acid information through analysis of the variable region, 
especially CDR, sequence and abundancy could also be used 
to provide potential antigen-specific antibody or antibody 
fragments. In certain aspects, the resulting V, and V.K. uli 
braries based on the abundant variable region especially CDR 
information could be inserted into an appropriate expression 
vector suitable for the production of either full-length IgG 
proteins or of antibody fragments (scFv or Fab or single 
domain antibodies comprised of only the V or the VK, w 
chain). Libraries comprising V and VK, w could result in 
combinatorial pairing of the heavy and light chains. 
Some of the randomly paired V and VK, w chains may be 
active while others will not give rise to functional antibodies. 
However, the inventors have found that, because of the very 
high representation of antigen-specific plasma cells in bone 
marrow, a large fraction of the resulting clones following 
challenge with an immunogen or pathogen express functional 
and high affinity recombinant antibodies. In one example, in 
a scFv library constructed from V and V.K., W genes isolated 
from bone marrow plasma cells, >5% of the clones contained 
antigen-specific antibodies. 
For example, the inventors analyzed V and V, transcript 
levels in bone marrow plasma cells isolated five days after 
booster immunization (incomplete Freund's adjuvant) with 
four different protein antigens in two mice each. Patterns of 
V-D-Jusage and somatic hypermutation were determined and 
correlated with representation within the bone marrow 
plasma cell population. Consistent with the pivotal role of 
bone marrow plasma cells on antibody secretion, antigen 
specific V, and V, cDNA levels were found to be highly 
enriched to between 1% and 20% of the total Ig RNA. For 
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each of the four antigens tested, 2-4V, and V, cDNAs were 
represented at frequencies >4% of the total V. cDNA pool. 
The four most abundant V and V genes for each antigen and 
from each mouse were synthesized, the heavy and light 
chains paired as discussed below, and the resulting antibody 
fragments were expressed in bacteria. Importantly, on aver 
age, >80% of the antibody fragments corresponding to the 
most highly expressed V and V, genes in the immunized 
animals were found to be antigen-specific by ELISA (en 
Zyme-linked immunosorbent assay) and BIACore analysis. 
Thus, the inventors have found that manual ELISA screen 
ing of a few hundred clones from such libraries is sufficient to 
allow the generation of antibodies with high affinity and 
specificity. Manual ELISA screening of additional clones can 
be used to reveal different combinations of V, and VK, a 
genes that give rise to a diverse set of antibodies. This method 
is simple and fast, and the inventors believe that it is likely to 
replace the hybridoma technology for the isolation of anti 
bodies from animals. 
X. Quantitative Serum Antibody Analysis 
To identify a pool of abundant amino acid sequences of 
CDR regions, especially CDR3 regions of circulating anti 
bodies, MS shotgun proteomics or protein sequencing meth 
ods may be used to determine the amino acid sequences. 
Any protein sequencing methods determining the amino 
acid sequences of its constituent peptides may be used. The 
two major direct methods of protein sequencing are mass 
spectrometry and the Edman degradation reaction. It is also 
possible to generate an amino acid sequence from the DNA or 
mRNA sequence encoding the protein, if this is known. How 
ever, there are also a number of other reactions that can be 
used to gain more limited information about protein 
sequences and can be used as preliminaries to the aforemen 
tioned methods of sequencing or to overcome specific inad 
equacies within them. 
For example, a shotgun proteomic strategy based on 
digesting proteins into peptides and sequencing them using 
tandem mass spectrometry and automated database searching 
could be the method of choice for identifying serum antibody 
sequences. "Shotgun proteomics' refers to the direct analysis 
of complex protein mixtures to rapidly generate a global 
profile of the protein complement within the mixture. This 
approach has been facilitated by the use of multidimensional 
protein identification technology (MudPIT), which incorpo 
rates multidimensional high-pressure liquid chromatography 
(LC/LC), tandem mass spectrometry (MS/MS), and data 
base-searching algorithms. 
A. IgG Fractionation 
Ig proteins of a particular class could be isolated, for 
example, by affinity chromatography using protein A (or 
anti-IgA and anti-IgM antibodies for affinity purification of 
the other major Ig classes). 
In certain aspects, antibodies or antibody fragments, such 
as Fab fractions from digestion of purified Igs with papain and 
Fab purification, could be affinity enriched for binding to 
desired antigen or pathogen (e.g., a cancer cell, a tumor anti 
gen, or an infection agent), or host tissue for the isolation of 
antibodies Suspected to have a role in autoimmunity. Anti 
bodies may be eluted under denaturing conditions. In further 
embodiments, several fractions or pools of serum-derived 













for antigen, (b) enriched for host tissue, and (c) antibodies 
with unrelated or unknown specificities. 
B. Proteolytic Fragmentation 
For quantitative shotgun proteomics mass spectrometry 
analysis, antibodies orantibody fragments, such as Fab, could 
be digested using proteases that cleave after amino acids/ 
amino acid pairs that are under-represented in CDR3 but 
present in the adjacent framework regions. The appropriate 
proteases for proteomic processing may be identified by bio 
informatic analysis of the V gene sequence database. 
In one example, the Fab fractions are subjected to proteoly 
sis with proteomics grade trypsin (Sigma) at 37°C. for 4 h. As 
an alternate method, a combination of other proteases, such as 
Gluc (NEB) and LysC (Sigma), could be used in place of 
trypsin to generate a distinct set of proteolytic peptides that in 
computational tests provide better coverage of the CDR3s 
(i.e., so that cleavage occurs at positions flanking the CDR3s 
and therefore peptides with intact CDR3s are produced). 
In certain embodiments, CDR3 peptides could be enriched 
from unrelated peptides via specific conjugation of the unique 
Cys at the end of the CDR3 sequence with a thiol-specific 
reagent that allows the purification of Such peptides. 
The inventors have developed protocols that deploy a com 
bination of appropriate proteases for peptide generation and 
Cys-specific pull down of thiol-containing CDR3 peptides 
that result in a peptide mixture comprising of at least 30% 
CDR3 peptide sequences. In one example, CDR3 peptides 
are enriched via reversible thiol-specific biotinylation. In 
another example, CDR3 peptides are reacted with special 
chromophores that allow their specific excitation and detec 
tion during MS analysis. Using appropriate proteases, CDR3 
peptides almost universally (>99%) containing cysteine can 
be generated and, a biotinylated thiol-specific cross-linking 
agent is then used to affinity isolate these peptides for mass 
spectral analysis thus greatly simplifying the complexity of 
the spectra. 
C. Shotgun MS (Mass Spectrometry) Proteomics 
In certain exemplary aspects, the peptides of antibody mol 
ecules could be resolved by reverse phase chromatography 
and in-line nanoelectrospray ionization/high-resolution tan 
dem mass spectrometry, using well-established protocols 
(Ong and Mann, 2005; Pandey and Mann, 2000; Shevchenko 
et al., 1996; Hunt et al., 1986; Link et al., 1999: Washburnet 
al., 2001: Lu et al., 2007) and Fourier-transform LTQ-Orbi 
trap mass spectrometry (Hu et al., 2005) to collect hundreds 
of thousands of tandem mass spectra from CDR3 and other 
Fab-derived peptides. 
For example, peptides were separated on a reverse phase 
Dionex Acclaim C-18 column (Thermo Scientific) running an 
elution gradient from 5% to 38% acetonitrile, 0.1% formic 
acid. Peptides were eluted directly into an Orbitrap Velos 
mass spectrometer (Thermo Scientific) by nano-electrospray 
ionization. Data-dependant ion selection could be enabled, 
with parention mass spectra (MS1) collected at 100k resolu 
tion. Ions with known charge >+1 may be selected for CID 
fragmentation spectral analysis (MS2), with a maximum of 
20 parent ions selected per MS1 cycle. Dynamic exclusion is 
activated for 45 seconds with ions selected for MS2 twice 
within 30 sec. Ions identified in an LC-MS/MS run as corre 
sponding to peptides from the constant regions of the heavy 
and light chains may be excluded from data-dependent selec 
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tion in Subsequent experiments in order to increase selection 
of peptides from the variable region. 
D. MS Proteomic Data Analysis 
The variable gene sequencing data from B cells of the same 
Subject are employed to Supplement the protein sequence 
database for interpreting peptide mass spectra in shotgun 
proteolysis (Marcotte, 2007). With the aid of the sample 
specific sequence database, CDR3 peptides were identified 
from the tandem mass spectra controlling for false discovery 
rate using standard methods (Keller et al., 2002; Nesvizhskii 
et al., 2009). 
Several recent advances in shotgun proteomics enable pro 
tein quantification to ~2-fold absolute accuracy without intro 
ducing additional requirements for isotope labels or internal 
calibrant peptides (Lu et al., 2007; Malmstrom et al., 2009: 
Silva et al., 2006a; Vogel and Marcotte, 2008: Ishihama et al., 
2005; Liu et al., 2004). Among these approaches, two are 
well-suited to quantification of individual IgGs: the APEX 
approach is based upon weighted counts of tandem mass 
spectra affiliated with a protein (the weighting incorporates 
machine learning estimates of peptide observability (Lu et al., 
2007; Vogel, 2008), and the average ion intensity approach is 
based on mass spectrometry ion chromatogram peak volumes 
(Silva et al., 2006a). For example, both methods could be 
employed to measure abundances of each of the identified 
antigen-specific IgGs in the serum-containing sample. Com 
binations (Malmstrom et al., 2009) and single peptide quan 
titation methods could also be used as alternatives. Algo 
rithms for subtraction of non-CDR3 peptides could be used. 
On the basis of these measured abundances, at least the 50 or 
100 most highly abundant V, and V, proteins in the sample 
could be rank-ordered. 
For example, sample-specific protein sequence databases 
are created from high-throughput V region cNA transcript 
data. VH and VL genes represented by >2 reads by 454 
sequencing are compiled into a database that in turn is added 
to a database of all known protein-coding sequences for the 
Subject organism, as well as a database containing common 
sample contaminants. The LC-MS/MS data is searched 
against this database using the Sequest search algorithm as 
part of the Proteome Discoverer software package (Thermo 
Scientific). The confidence of peptide identifications is deter 
mined using the Percolator algorithm in Proteome Discoverer 
(Thermo Scientific). In certain embodiments, the amino acid 
sequence analysis coupled with the nucleic acid information 
from various V gene pools of different B-cell sources (e.g., 
the particular organ-specific ASC population that expresses 
V and V, genes whose products are found in serum) could be 
employed to identify whether a particular serum antibody 
originated preferentially in the bone marrow, in secondary 
lymphoid tissues (as is likely to be the case early in the 
immune response), or in the case of persistent infection, pos 
sibly in tertiary lymphoid tissues. The possibility that a par 
ticular antibody is secreted by plasma cells that have migrated 
to different tissues could also be addressed. At a systems 
level, the inventors could employ this information to estimate 
the contribution of different compartments to humoral immu 
nity in a quantitative fashion and could generate antibody or 
antibody fragments involved in different stages of the 
immune response. 
XI. Antibody Generation and Characterization 
Certain embodiments described above lead to the identifi 













est or the most abundant variable region sequences in B cells 
or in a selected lymphoid tissue. Such information may be 
used to develop antibody or antibody fragments that have 
desired binding affinity or antigen response. In certain 
aspects, their binding specificities or therapeutic utility could 
be evaluated. For example, antibody or antibody fragments 
that are cytotoxic towards cancer cells could be generated 
from the abundant serum polyclonal antibody pool. In further 
embodiments, antibody or antibody-specific fragments that 
are specific for the antigen used to immunize any animal may 
be provided by analyzing sequence and abundance informa 
tion of variable region nucleic acids in B cells or directly from 
lymphoid tissues. 
A. Gene Synthesis for Antibody Generation 
To generate antibody or antibody fragments with the 
desired binding specificity, the V genes could be synthesized, 
assembled into Fab or IgG, and expressed. V, and V, genes 
may be generated by high-throughout gene synthesis based 
on the sequence information obtained by the methods 
described above. 
For example, automated gene synthesis could be used. 
Briefly, gene fragments (lengths from 200 to 500 nucleotides) 
are generated using inside-out nucleation PCR reactions 
under carefully controlled conditions to ensure construction 
of the desired final fragment. Subsequently stitch-overlap 
extension PCR is used to synthesize the gene of interest. The 
design of these fragments and relevant overlaps is automated, 
with oligonucleotide synthesizer worklists and robot opera 
tion scripts for synthesis and assembly. Alignment of 
sequences so as to maintain maximal conservation and Sub 
sequent "padding of the sequences at either end to maintain 
identical length permits the use of a generic overlapping 
oligonucleotide assembly strategy and also ensures the most 
oligonucleotide re-use. Currently throughput stands at 50 V. 
and 50 V, genes (i.e. >38,000 bp of DNA) synthesized and 
validated for correct ORF by one researcher within a week 
and at a reagent cost <$2,000. 
B. Pairing of V, and V, 
For expression, a particular V has to be paired with cog 
nate V. The pairing problem could be addressed as follows: 
First, the inventors have empirically found that the correct 
pairings of V, and Vs in a sample correlate well with the 
rank-ordered abundancy of the proteins in the sample. For 
example, the fifth most abundant V pairs with the fifth most 
abundant V. So far with this approach, using V and V. 
bioinformatic rank-ordering information for pairing, the 
inventors have achieved 75% success in pairing V and V. 
genes to produce high affinity antigen-specific antibodies 
from four different mice. Further, the inventors have found 
that even if the optimal VL for pairing is not the one having 
similar abundancy based on proteomic analysis and because 
antigen recognition is dominated by the V sequence, antigen 
binding could be still observed, albeit with lower affinity. 
In certain aspects, V and V chains can be identified by 
grouping together related V and V sequences. For example, 
identified V, and/or V, sequences can be aligned and clus 
tered base on the relatedness of the sequences. For example, 
each group may comprise antibody sequences that differ from 
each other only by the result of somatic hypermutation. In 
Some cases, clusters of sequences can be ranked and the rank 
of the clusters used to guide paring between V and V. 
Sequences. 
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In still further aspects, V and V chains can be paired 
based on combinatorial library screening where oneV gene is 
synthesized and the second V gene that comprises a func 
tional antibody is obtained via the screening of a combinato 
rial library comprising said synthetic V gene paired with 
cDNA encoding all V genes in an individual. In this case, V. 
and V, pairs for testing can be guided by abundance ranking 
and/or by clustering of related sequences as outlined above. 
The pairing could also be addressed or confirmed by other 
approaches. For example, in situ hybridization (ISH) of fixed 
plasma cells with V and candidate V, probes, for example, 
identified from the abundancy analysis. ISH can easily be 
applied in a high-throughput manner using appropriate 
robotic automation. Alternatively, ESI-MS (electrospray ion 
ization mass spectrometry) of the FAB pool, coupled with 
matching of these spectra to the expected molecular weight, 
can in certain cases determine V and V pairing. 
C. Antibody Expression 
In further aspects, the synthesized V, and V, genes may be 
inserted into appropriate vectors for expression, for example, 
as Fabs in E. coli or as full-length IgGs in E. coli or by 
transient transfection of HEK293 cells. 
Binding between candidate antibody or antibody frag 
ments and antigen could then be evaluated by any methods for 
binding detection and quantification, particularly ELISA. For 
example, cancer-specific antibodies or antibody fragments 
could be characterized by cancer and host cell binding by 
fluorescence-activated cell sorting (FACS) following fluores 
cent labeling of antibodies. 
Antibodies, according to certain aspects of the invention, 
may be labeled with a detectable label or may be conjugated 
with an effector molecule, for example, a drug, e.g., an anti 
bacterial agent or a toxin or an enzyme, using conventional 
procedures, and the invention extends to Such labeled anti 
bodies or antibody conjugates. 
Antibodies usable or produced in the present invention 
may be a whole antibody or an antigen-binding fragment 
thereof and may in general belong to any immunoglobulin 
class. Thus, for example, it may be an IgM oran IgG antibody. 
The antibody or fragment may be of animal, for example, 
mammalian origin and may be, for example, of murine, rat, 
sheep, or human origin. Preferably, it may be a recombinant 
antibody fragment, i.e., an antibody orantibody fragment that 
has been produced using recombinant DNA techniques. Such 
recombination antibody fragments may comprise prevalent 
CDR or variable domain sequences identified as above. 
Particular recombinant antibodies or antibody fragments 
include (1) those having an antigenbinding site at least part of 
which is derived from a different antibody, for example, those 
in which the hyperVariable or complementarity determining 
regions of one antibody have been grafted into the variable 
framework regions of a second, different antibody (as 
described in, for example, EP2394,00); (2) recombinant anti 
bodies or fragments wherein non-Fv sequences have been 
substituted by non-Fv sequences from other, different anti 
bodies (as described in, for example, EP171496, EP173494, 
and EP 194276); or (3) recombinant antibodies or fragments 
possessing Substantially the structure of a natural immuno 
globulin but wherein the hinge region has a different number 
of cysteine residues from that found in the natural immuno 
globulin but wherein one or more cysteine residues in a Sur 
face pocket of the recombinant antibody or fragment is in the 
place of another amino acid residue present in the natural 
immunoglobulin (as described in, for example, WO 89/01782 













Teachings of texts, such as Harlow and Lane (1998), fur 
ther detail antibodies, antibody fragments, their preparation, 
and use. 
The antibody or antibody fragment may be of polyclonal or 
monoclonal origin. It may be specific for at least one epitope. 
Antigen-binding antibody fragments include, for example, 
fragments derived by proteolytic cleavage of a whole anti 
body, such as F(ab'), Fab', or Fab fragments, or fragments 
obtained by recombinant DNA techniques, for example, FV 
fragments (as described, for example, in WO 89/02465). 
XII. Therapeutic Applications 
The present invention may involve methods that have a 
wide range of therapeutic applications, such as cancer 
therapy, enhancing immune response, vaccination, or treat 
ment of infectious disease or autoimmune diseases. 
In some embodiments, the present methods may be used 
for the quantitative molecular deconvolution of antibody 
response in cancer patients in remission to identify the 
sequence and abundancy of the highly represented antibodies 
in circulation that may contribute to the eradication of the 
tumor in the patient. Such antibodies could be very useful as 
therapeutic agents on their own or for the identification of new 
antigens on cancer cells that can serve as therapeutic targets. 
Similarly in some embodiments the present methods can be 
used to identify antibodies that can protect patients from a 
particular infectious agent. Such antibodies may be identified 
either from patients that had been infected and then recovered 
from the infection or alternatively, from vaccinated patients. 
These antibodies or antibody fragments could be produced 
and their specificity and cytotoxicity toward cancer cells or 
neutralization potency towards infectious agents could be 
evaluated. The ability to deconvolute the serum polyclonal 
response by characterizing the relative abundancy and amino 
acid sequences of its antibody components and then to indi 
vidually evaluate cancer cell binding and cytotoxicity could 
provide an unprecedented wealth of information on the nature 
of adaptive immune responses to malignancies. Such identi 
fied antibodies could lead to the discovery of potent cytotoxic 
cancer therapeutics and the identification of novel tumor anti 
gens used for cancer detection and therapy. 
For example, therapeutic antibodies for leukemia, via the 
deconvolution of antibody responses in patients in remission 
following allogeneic hematopoietic stem cell (HSC) trans 
plantation, could be identified by the methods described 
above. Promising antibodies could then be taken through 
pharmacological engineering and animal evaluation. 
Certain aspects of the present invention may involve the 
passive transfer of antibody or antibody fragments generated 
by certain aspects of the present invention to non-immune 
individuals (e.g., patients undergoing chemo/radio therapy, 
immunosuppression for organ transplantation, patients 
immunocompromised due to underlying conditions, such as 
diabetes, trauma etc., and the very young or very old). For 
example, the sequences of antibodies conferring immunity 
can be determined by looking for over-represented V and V. 
sequences in patients who have overcome infection. These 
protective antibodies can be re-synthesised at the genetic 
level, over-expressed in E. coli (or other expression systems) 
and purified. The resultant purified recombinant antibody can 
then be administered to patients as a passive immunotherapy. 
Antibodies can also be ordered from commercial Suppliers, 
such as Operon Technologies Inc., USA (on the World Wide 
Web at operon.com), by simply Supplying them with the 
sequence of the antibody to be manufactured. 
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Vaccination protects against infection by priming the 
immune system with pathogen-derived antigenCs). Vaccina 
tion is effected by a single or repeated exposure to the patho 
gen-derived antigen?s) and allows antibody maturation and 
B-cell clonal expansion without the deleterious effects of the 
full-blown infectious process. T cell involvement is also of 
great importance in effecting vaccination of patients. Certain 
aspects of the present invention can also be used to monitor 
the immunization process with experimental vaccines along 
with qualitative and quantitative assessment of antibody 
response. For example, one or more subjects are given the 
experimental vaccine, V and V, Sequences are amplified 
from the Subjects, and the serum antibodies that are specific 
for the immunogen and the V antibody repertoires in the 
vaccines are analyzed as described above. The respective 
antibodies can be produced in Viro and their neutralization 
potency and breadth can be determined. Knowing the clonal 
ity and time course of the change in the concentration of 
monoclonal antibodies that comprise the polyclonal response 
can be of great significance for evaluating vaccine efficacy. 
XIII. Examples 
The following examples are included to demonstrate pre 
ferred embodiments of the invention. It should be appreciated 
by those of skill in the art that the techniques disclosed in the 
examples which follow represent techniques discovered by 
the inventor to function well in the practice of the invention, 
and thus can be considered to constitute preferred modes for 
its practice. However, those of skill in the art should, in light 
of the present disclosure, appreciate that many changes can be 
made in the specific embodiments which are disclosed and 
still obtain a like or similar result without departing from the 
spirit and scope of the invention. 
Example 1 
Processing of Serum Antibodies from an Immunized 
Rabbit for Mass Spectrometry Analysis 
High titer immunized mammal serum (2.5 mL, e.g., Con 
cholepas concholepas hemocyanin (CCH), Pierce, Ill.) was 
diluted 4-fold in PBS and IgG proteins were purified by 
affinity chromatography using a protein Aagarose (Pierce, 
Ill.) column in gravity mode. Diluted serum was recycled six 
times through the protein A affinity column and then the 
column was washed with PBS followed by elution of IgG 
using 100 mM glycine, pH 2.7. 
Approximately 10 mg of protein A-purified serum IgG was 
digested with pepsin to produce F(ab) fragments using 500 
uL of immobilized pepsin agarose (Pierce, Ill.) in 20 mM 
Sodium acetate, pH 4.5, and digestion was allowed to proceed 
for seven hours, shaking vigorously at 37°C. The degree of 
digestion was evaluated by non-reducing 4%-20% SDS 
PAGE (FIG. 1). 
Affinity chromatography for the isolation of antigen-spe 
cific IgG-derived F(ab) was carried out by coupling the 100 
mg antigen, CCH, onto 1 g of dry N-hydroxySuccinimide 
(NHS)-activated agarose (Pierce, Ill.) by overnight incuba 
tion at 4°C. The coupled agarose beads were washed with 
PBS and unreacted NHS groups were blocked with 1 M 
ethanolamine, pH 8.3 for 60 min at room temperature, 
washed with PBS, and packed into a chromatography col 
umn. IgG F(ab) fragments were applied to the antigen affin 














and reapplied to the column five times. The column was 
subsequently washed with PBS and eluted using 100 mM 
glycine, pH 2.7. 
Protein fractions from the antigen affinity chromatography 
flow through, wash buffer, and elution were L-Cys alkylated 
with 2-iodoethanol and then digested with trypsin in the pres 
ence of urea. Specifically, protein was first denatured in 8 M 
urea. The denatured protein was then dissolved in a solution 
containing (final concentrations): 2.4 M urea, 200 mM 
ammonium carbonate, pH 11.0, 48.75% v/v acetonitrile, 65 
mM iodoethanol as the Cys alkylating agent, and 8.5 mM 
triethylphosphine as the reducing agent. The final pH of the 
solution was adjusted to 10 and then it was incubated at 37°C. 
for 60 min. To avoid urea carbamylation, urea solutions were 
made freshly and deionized on AG-501-X8 resin (Biorad, 
CA) just before use. Samples were dewatered using a Speed 
vac(R) and resuspended in 100 mM Tris-HCl, pH 8.5 to reach 
a final urea concentration of 1.6M prior to trypsin digestion. 
Trypsin digestion was carried out by adding trypsin at a ratio 
of 1:75 trypsin: protein and incubating at 37°C. for five hours. 
Lowering the pH with 1% V/v formic acid was employed to 
deactivate the trypsin. 
For differential L-Cys labeling, protein fractions from the 
antigen affinity chromatography flow through, wash buffer, 
and elution were separately alkylated withiodoacetamide and 
then digested with trypsin in the presence of 2.2.2-trifluoro 
ethanol (TFE, Sigma). Specifically, protein fractions follow 
ing antigen affinity chromatography were mixed with reac 
tion solution that consisted of (final concentrations): 50% V/v 
TFE, 50 mMammonium bicarbonate, and 10 mM DTT at 55° 
C. for 60 min. TFE denatured, reduced F(ab'), were then 
L-Cys alkylated by incubation with 32 mM iodoacetamide 
(Sigma, Mo.) for one hour at room temperature and then the 
alkylation reaction was quenched by addition of 7.7 mMDTT 
for one hour at room temperature. Samples were diluted with 
water to reach a final TFE concentration of 5% V/v. Trypsin 
digestion was carried out by adding trypsin at a ratio of 1:75 
trypsin-protein and incubating at 37°C. for 5 hours. Lowering 
the pH with 1% V/v formic acid was employed to deactivate 
the trypsin. 
Peptides derived from differential labeling of cysteine resi 
dues with either iodoacetamide or iodoethanol followed by 
proteolytic digestion were subject to chromatographic sepa 
ration on a C18 reverse phase column using an acetonitrile 
elution gradient. Peptides were eluted onto an LTQ Orbi 
trapTMVelos mass spectrometer (Thermo Scientific) using a 
Nano-spray source. The LTQ Orbitrap Velos was operated in 
the data dependent mode with scans collected at 60,000 reso 
lution. Ions with charge D+1 were selected for fragmentation 
by collision-induced dissociation (CID) with a maximum of 
20 fragmentation scans per full scan, or alternatively by 
higher energy collision dissociation (HCD) with a maximum 
of 10 fragmentation scans per full scan. 
Example 2 
Detection of MS Peptide Mis-Identification by 
Exploiting Differential L-Cys Labeling 
The resulting spectra from Example 1 were searched 
against a protein sequence database consisting of a rabbit full 
protein-coding sequence database (OryCun2) and common 
contaminant proteins combined with in-house rabbit V and 
V, sequences, using SEQUESTR) and Percolator (Proteome 
Discoverer 1.2. Thermo Scientific) to generate a high-confi 
dence dataset of top-ranked protein-spectrum matches 
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(PSMs) at <1% FDR as determined by Percolator. Only V. 
and V, sequences with 22 reads were included in the search. 
The search specified tryptic peptides with up to two missed 
tryptic cleavages allowed. A precursor mass tolerance of 5 
ppm was used, with fragment mass tolerance set to 0.5 Da for 
spectra generated by CID and 0.02 Da for spectra generated 
by HCD. Static cysteine modifications of either carbamidom 
ethylation (iodoacetamide, +57.021) or ethanolyl (iodoetha 
nol, +44.026) were included based on which modifying 
reagent was used. Oxidized methionine was allowed as a 
dynamic modification. 
Following SEQUESTR) sequence assignment, identified 
peptides were subject to further analysis to determine their 
consistency with secondary sequence information derived 
from differential cysteine labeling. The monoisotopic differ 
ence in mass between the iodoacetamide modification (car 






bamidomethyl) and iodoethanol modification (ethanolyl) is 
12.995 Da. Thus, parent ions of peptides containing a cys 
teine residue would exhibit a shift corresponding to ~13.00 
Dabetween the differentially labeled samples (FIG. 6). Pairs 
of parent ions exhibiting this mass difference between 
samples, and exhibiting similar relative elution profiles were 
flagged as putative cysteine-containing peptides. Corre 
sponding fragmentation spectra from differentially-labeled 
ions of flagged peptides were compared for consistency to 
confirm that the spectra were derived from the same parent 
peptide. Spectral pairs identified as the same peptide (inher 
ently requiring the presence of a cysteine to match) were 
flagged as a “true positives', while parent ions exhibiting a 
confirmed 13 Damass shift butan assigned peptide sequence 
lacking cysteine residues were deemed “false positives' 
(Table 1). 
TABL E 1. 




(SEQ ID NO: 1) 
(SEQ ID NO: 2) 
ETGGGLVOPGGSLTLSCK 
(SEQ ID NO : 3) 
MTSLTAADTATYFCAR 
(SEQ ID NO : 4) 
LTAADTATYFCAR 
(SEO ID NO; 5) 
Misidentifications 
DGGIYGTMFNFWGPGTLWTVSSGOPK 
(SEQ ID NO : 6) 
NYGGAASYOmDLWGPGTLVTVSSGOPK 
(SEO ID NO: 7) 
Iodoethanol Iodoacetamide A Mass 
1586.7791 1599.7743 12.9952 
2176 . OfS9 21.89. Of 45 12.9956 
1747.8899 1760.885.1 12.995.3 
1766.8093 1779. 8049 12.9956 
1447. 6896 1460. 6842 12.99.46 
27162971 12.99.49 
2729. 
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Example 3 
Development of Novel Bioinformatic Filters for the 
Correct Identification of Peptide Sequences from 
High-Resolution Mass Spectrometry Data of Serum 
Antibodies 
Standard bioinformatics filters for mass spectrometry 
analysis of highly complex peptide mixtures involve evalua 
tion of individual spectra independent of cumulative infor 
mation derived from related spectra originating from the 
same parention. By grouping spectra based on relation to one 
another, more precise filters can be employed to better dis 
criminate between correct and incorrect sequence identifica 




same peptide sequence were grouped, and an average was 
calculated for the difference between the observed experi 
mental mass of parent ions and the theoretical mass of the 
sequence. This average mass deviation (AMD) was effective 
in differentiating between “true’ and “false' identifications 
determined by differential cysteine labeling (FIG. 6), and was 
used as a filter to distinguish between high-confidence pep 
tide sequence identifications and dubious sequence identifi 
cations that were Subsequently removed from the dataset. 
Employing a filter cut-off of AMD <1.5 ppm, sequences 
previously flagged by differential cysteine labeling as misi 
dentifications were removed from the dataset. Table 2 shows 
representative AMD data for the top 20 most abundant 
CDRH3 peptides. Those marked with a “*” display an AMD 
above the threshold and were flagged as misidentifications. 
TABLE 2 
Top 20 most abundant unique CDRH3 - containing 
peptides and their respective average mass 
deviation (AMD). 
SEQ 
ID Awe Spectral AMD is 1.5 
Sequence NO : ppm Count ppm 
MDSHSDGFDPWGPGTLVSVSSGOPK 8 O. O996 245 
WCGMDLWGPGTLWTVSSGOPK 9 O 3839 232 
DGGIYGTMFNFWGPGTLVTVSSGOPK O - 4 O523 97 k 
NWAGYLCAPAFNFR 1. O. 4799 84 
NFKLWGPGTLVTVSSGOPK 2 O. 51.46 52 
NFGLWGPGTLVTVSSGOPK 3 O. 3818 4 O 
ELTGNGIYALK 4. O. 6036 29 
AFNLWGPGTLVTVSSGOPK 5 O. O.338 25 
SPSSGSSNLWGPGTLWTVSSGOPK 6 O.2109 O6 
GMDLWGPGTLVTVSSGOPK 7 -1. 1565 O5 
GAGWVDYSLWGPGTLVTVSSGOPK 8 O. 4812 99 
YAPFNLWGPGTLWTVSSGOPK 9 2.97.29 99 k 
GYGSSSDGWLTR 2 O - O. O.177 94 
AFTLWGPGTLVTVSSGOPK 21 O3959 91 
NPGGTSNLWGPGTLVTVSSGOPK 22 O. 2329 87 
APAASTNYGYDLWGPGTLVTVSSGOPK 23 O. 1546 85 
NSGSASNLWGPGTLVTVSSGOPK 24 O. 9042 83 
FDFWGPGTLVTVSSGOPK 25 O. O334 82 
KFNLWGPGTLVTVSSGOPK 26 O. 2351 77 
NYGGAASYCMDLWGPGTLVTVSSGOPK 27 2. OOf8 77 k 
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Following filtering to remove peptide sequence misidenti 
fications, the remaining high-confidence peptide sequences 
were classified as informative CDRH3 (iCDRH3) peptides 
and non-iCDRH3 (niCDRH3). The iCDRH3 peptides were 
defined as proteolytic fragmentation products of Sufficient 
length and uniqueness to identify a single CDRH3 in the V 
sequence database used for LC-MS/MS analysis (defined as 
the set of NextGen sequences with 22 reads). As an example, 
a peptide corresponding to a unique CDRH3 sequence in the 
36 
database is classified an iCDRH3 peptide whereas an anti 
body proteolytic fragmentation product containing amino 
acids from the J-D region that are found in many CDRH3s is 
a niCDRH3. Identification of an iCDRH3 thus enables the 
determination of the corresponding V gene(s) from the DNA 
database. Only high-confidence iCDRH3 peptide sequences 
were deemed legitimate candidates for further analysis (Table 
3). 
TABLE 3 
Top 20 most abundant high-confidence iCDRH3s 
identified by the analysis pipeline. Amino acids 
that are designated in lower case indicates that 
a post translation modification was detected 
Full w 
SEO Gene CDR3 Total 
ID Degen- Degen - Peptide AMD 
Peptide Sequence NO: erate erate Count (ppm) 
MDSHSDGFDPWGPGTLVSVSSGOPK 28 1. 245 O. O996 
VcGMDLWGPGTLVTVSSGOPK 29 2 232 O 3839 
NWAGYLCAPAFNFR 3 O 1. 184 O. 4799 
NFKLWGPGTLWTVSSGOPK 31 13 152 O. 51.46 
ELTGNGIYALK 32 1. 129 O. 6036 
AFNLWGPGTLWTVSSGOPK 33 1. 117 O. O.338 
SPSSGSSNLWGPGTLWTVSSGOPK 34 2 106 O.2109 
GMDLWGPGTLWTVSSGOPK 35 3 104 -1. 1565 
GAGWVDYSLWGPGTLVTVSSGOPK 36 5 99 O. 4812 
GYGSSSDGWLTR 37 1. 94 - O. O.177 
NPGGTSNLWGPGTLWTVSSGOPK 38 1. 87 O. 2329 
APAASTNYGYDLWGPGTLVTVSSGOPK 39 1. 85 O. 1546 
NSGSASNLWGPGTLWTVSSGOPK 4 O 2 83 O. 9042 
FDFWGPGTLVTVSSGOPK 41 1. 82 O. O334 
KFNLWGPGTLWTVSSGOPK 42 3 77 O. 2351 
SDEINDYNLWGPGTLWTVSSGOPK 43 3 74 O. 1766 
AFTLWGPGTLWTVSSGOPK 44 9 70 O3959 
NFGLWGPGTLWTVSSGOPK 45 1. 69 O. 3818 
NAGTASNLWGPGTLWTVSSGOPK 46 1. 61 O. 5918 
NWGLWGPGTLWTVSSGOPK 47 1. 55 O. O854 
DAGDAGYHLTLWGPGTLVTVSSGOPK 48 1. 55 O. 4637 
TDSSDHTYFILWGPGTLVTVSSGOPK 49 1. 51 O. 1340 
AAGYGADAYAWNLWGPGTLVTVSSGOPK 5 O 2 51 O. 2310 
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Example 4 
Validation of the Antigen Specificity of the 
Proteomically-Predicted V, Sequences 
Select full-length V genes identified by the proteomic 
pipeline in Example 3 above were synthesized by in-house 
automated gene synthesis (Cox et al., 2007) with the follow 
ing modifications. The coding sequences for the selected V 
genes were designed using GeneFab Software. After reverse 
translation of the primary amino acid sequences for each V. 
using an E. coli class II codon table, the coding sequences 
were built with a designed (GGGGS) (SEQ ID NO: 192) 
polyglycine-serine linker at the C-terminus for overlap reas 
sembly scFv construction. A 5' Sfil restriction endonuclease 
site was added to facilitate cloning of the Sclv constructs into 
the p AK200 phage display vector (Hayhurst et al., 2003). The 
V genes were aligned using the sequence encoding the com 
mon Gly-Serlinker sequence and a universal randomly gen 
erated stuffer sequence was applied to the ends of the V 
sequences to ensure that all of the constructs were of the same 
length. The V genes were synthesized from overlapping 




anced inside-out nucleation PCR (Gao et al., 2003). The 
80-mer oligonucleotides necessary for the construction of the 
various scFv genes were designed using the GeneFab Soft 
ware with a minimal overlap of 30 nucleotides between oli 
gonucleotide fragments. The oligonucleotides were synthe 
sized using standard phosphoramidite chemistry at a 50 nmol 
scale using a Mermade 192 oligonucleotide synthesizer (Bio 
automation, TX, USA) using synthesis reagents from EMD 
Chemical and phosphoramidites from Glen Research. All of 
the oligonucleotide liquid-handling operations necessary for 
assembling the various genes were done on a Tecan Evo 200 
workstation (Tecan, CA, USA) with reagent management and 
instrument control done through the FabMgr software com 
ponent of the PFA platform (Malmstroem et al., 2009). Gene 
assembly PCR was performed using KOD-Hotstart poly 
merase using the buffers and reagents Supplied with the 
enzyme (Novagen, Mass., USA). Table 4 lists the full 
sequences of the seven V genes that were synthesized, 
notated by the corresponding iCDRH3 peptide identified in 
the proteomics and mass spectrometry in Example 3. These 
represent a sample of the highest ranked iCDRH3 that were 
identified to be antigen-specific based on exclusivity to the 
elution fraction during affinity chromatography against the 
target antigen CCH. 
TABLE 4 
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TABLE 4 - continued 
40 
Vl, clenes synthesized. 
iCDRH3 
iCDRH3 Peptide 
Rank Sequence W. Gene Sequence 
TACCCTGGTTACCGTTTCTTCTGGTGGTGGCGGTAGCGGTGGT 
SEO ID NO. 58) 
5 NPGGTS ATGGCCCAGCCGGCCATGGCGCAGTCTCTGGAAGAATCTGGTGA 
NLWGPG CTGGTTAAACCGGGTTCTTCTCTGACCCTGACCTGCACCGGTTC 
(SEQ ID G 










(SEQ ID NO: 6O) 




(SEQ ID GGTTCTGGTTCTACCAACTACGCTTCTTGGGCTAAAGGTCGTTTC 





(SEQ ID NO: 62) 




(SEQ ID GTCTGCTGACACCACCTACTACGCTTCTTGGGCTAAAGGTCGTTT 





(SEQ ID NO: 64) 
Phage Panning Library Construction. 
To analyze the antigen binding affinity and specificity of 
the identified V requires that a V, be paired to produce a 
full-length antibody fragment that can then be tested for bind 
ing against the target antigen CCH. Combinatorial pairing of 
the cDNA with each of the synthesized V genes was 
employed to construct a scFv library that was screened for 
antigen specificity by phage panning. This methodology 
yielded V, genes that paired with the synthetic V genes to 
give antibodies with high antigen affinity and specificity. 
Rarefaction analysis and species richness estimation (Chao 
et al., 2009) on the bone marrow (BM) CD138" V, high 
throughput sequencing data from the immunized animal 
revealed that the V, repertoire encoded by bone marrow 
CD138' cells consisted of an estimated 10.252 unique 
CDRL3. Species richness estimation of a sample size (e.g., 
library size) comprising approximately 10 clones captures 
99% of the V, repertoire. AV, library was prepared by ampli 
fication of periferial blood cell PBC and BM cDNA in a 
reaction containing: 40.25 uD, H2O, 5 L 10x Advantage-2 
buffer, 2 LL clNA, 0.75 uL Advantage-2 polymerase mix, 1 
uL 10 mM dNTP mix, 0.5uL 100 uMRLR1/RLR2 equimolar 
degenerate primer mix, and 0.5uIL 100 uM FLR1 degenerate 
primer. The PCR program used for V amplification 
described above was used. The PCR product (~400 bp) was 







eter. DNA encoding each of the synthetic V genes was 
heated, hybridized, and treated with the SURVEYOR muta 
tion detection kit (Transgenomic, NE, USA) according to the 
manufacturer's protocol. The undigested full-length product 
for each V reaction was gel-purified and quantified using an 
ND-1000 spectrophotometer. schv overlap reassembly PCR 
libraries were prepared in reactions containing: 100 ng of 
full-length synthetic V gene DNA, 50 ng each of gel-purified 
V, PCR product from BM CD138" and PBC CD138", 5 uL 
10x. Thermopol buffer (NEB, MA, USA), 0.5 uL Taq DNA 
polymerase (NEB), 200 uM dNTP mix, 1 uM rabbit V, 
forward primer, 1 uMOE-R primer, and filled to 50 LL final 
volume withddH.O.The PCR thermocycle program was 94° 
C. for 1 min, 25 cycles of amplification (94°C. for 15 sec, 60° 
C. for 15 sec, 72°C. for 2 min), and a final 72° C. extension 
for 5 min. The overlap PCR product (-750 bp) was gel 
purified twice, digested with Sfil (NEB), and ligated into the 
pAK200 phage display vector (Krebber et al., 1997). The 
ligation product was transformed into XL1-Blue E. coli (re 
cA1 end Algyra 96 thi-1 hsdR17 supE44 relAllac F" proAB 
lacIqZAM15 Tn 10 (Tetr)) to give seven separate libraries 
(one for each synthesized V.) comprising between 10° and 
10 transformants each. 




Primers used for V, and full length scFV library construction. 
Primer Sequence 
RLR1 GATGACGATGCGGCCCCCGAGGCCTTGATTTCYA 
CMTTGGTGCCAG primer mix 
(SEO ID NO: 65) 
RLR2 GATGACGATGCGGCCCCCGAGGCCTYGACSACCA 
CCTCGGTCCCTC primer mix 
(SEQ ID NO: 66) 
FLR1 GGTGGTGGTGGTAGCGGTGGTGGTGGCAGCGMN 
NHHGWDMTGACCCAGACTS primer 
(SEO ID NO: 67) 
WHF- GGCCCAGCCGGCCATGGCTCAGCAGCTGGAAG 
QQL (SEQ ID NO: 68) primer (s 
WHF- GGCCCAGCCGGCCATGGCTCAGGAACAGCTG 
QEQ (SEQ ID NO: 69) primer (s 
WHF- GGCCCAGCCGGCCATGGCTCAGTCTCTGGAAG 
QSL (SEO ID NO: 7O) primer (s 
OE-R GATGACGATGCGGCCCCCGAG 
(SEO ID NO : 71.) primer 
Phage Panning of the V-Restricted scFv Libraries. 
Cells for the seven Schv libraries, each comprising a syn 
thetic V gene joined to the amplified V, cDNA library, were 
scraped from agar plates containing LB, chloramphenicol (35 
ug/mL), and 1% w/v glucose and then diluted into 25 mL of 
2YT growth media supplemented with chloramphenicol (35 
ug/mL), tetracycline (10 g/mL), and 1% w/v glucose to a 
final ODoo-0.1. Cells were grown at 37°C. with shaking at 
250 rpm until they reached log phase growth (ODoo-0.5), 
then infected with 100 MOI of M13KO7 helper phage, and 
incubated without shaking at 37° C. for one hour. The cells 
were pelleted and resuspended in 25 mL of fresh 2YT media 
with chloramphenicol (35 g/mL), kanamycin (35 g/mL). 
1% w/v glucose, and 0.5 mMIPTG. Cultures were grown at 
25°C. with shaking at 250 rpm overnight (-14 hours). The 
cells were pelleted by centrifugation and phage were isolated 
from the supernatant by PEG-NaCl precipitation. For pan 
ning, immunotubes were coated overnight at 4°C. with either 
BSA or antigen (CCH) resuspended in PBS at 10 ug/mL and 
then blocked for two hours at room temperature with either 
2% milk dissolved in PBS or 3% BSA in PBS (blocking 
Solutions were alternated during sequential rounds of pan 
ning) Phage-sch v (dissolved in PBS) were diluted into 2% 
milk to input 10" phage into each of two BSA-coated, 
blocked immunotubes and rotated end-over-end at room tem 
perature for 1.5 h. One immunotube of the depleted phage 
schv was then directly transferred into a CCH-coated blocked 
immunotube and the other to a BSA-coated, blocked immu 
notube. Each immunotube was subsequently rotated at room 
temperature for two hours for binding of the phage-scFv. The 
Description of Use 
Rabbit V repertoire reverse 
(equimolar) 







Rabbit V, repertoire forward 
scFv V gene forward 
scFv V gene forward 
scFv VH gene forward 
ScFW gene reverse 
immunotubes were then washed six times with 4 mL PBST 
(0.05% v/v Tween 20) and four times with 4 mL PBS. Elution 
was accomplished using 1 mL 100 mM triethylamine, rotat 
ing at room temperature for 8 min, and then immediately 
transferring the Solution to a 2 mL microcentrifuge tube con 
taining 700 uL 1.5 M Tris-HCl, pH 8.0. Subsequently, 250 uL 
of Tris-HCl, pH 8.0 was added directly into the emptied 
immunotube to neutralize any residual elution solution. Both 
elution fractions (700 uL and the residual 250 uL) were used 
to infect 12 mL of log phase E. coli XL 1-Blue cells, with 3 mL 
of the culture placed in the neutralized immunotubes to cap 
ture remaining bound phage. After one hour at 37° C., the 
infected culture was plated onto LB agar plates containing 
chloramphenicol (35ug/mL) and 1% w/v glucose for titering 
both the BSA-specific elution and the CCH-specific elution. 
The entire CCH-specific elution solution (~12 mL infected 
culture spun down and resuspended in 2 mL 2YT) was spread 
onto large LB-chloramphenicol-glucose plates and incubated 
overnight 37°C. Colonies were scraped and cells were resus 
pended and used for Subsequent rounds of phage amplifica 
tion and panning. After three rounds of panning, 10-20 clones 
were sequenced from each V-restricted library. For four of 
the seven V examined, a single (or in one case two highly 
related) V, was found to pair with each unique V. These V, 
were each unique to their respective V, and likely represent a 
native V pairing of the V in the immunized animal. Table 6 
lists the full-length scFv amino acid sequences of the five 
dominant clones (panned from four V-restricted libraries) 
with the iCDRH3 peptide sequence bolded and the CDRL3 
sequence underlined. 
TABLE 6 
Sequences of the five dominant full-length clones isolated 





scFv Amino Acid Sequence 
OEOLEESGDLVKPGASLTLTCTASGFSFSSSYYMAWVROAPGKGLEWIGCMNS 
GGDTAYASWAKGRFSISKTSSTTMTLOLTSLTAADTATYFCARNVAGYLCAP 




Sequences of the five dominant full-length clones isolated 
from three rounds of phage panning on the V-restricted 
libraries. 
V/Clone 




(SEO ID NO: 72) 





(SEO ID NO: 73) 























(SEO ID NO: 76) 
RFKGSGSGTESTILTISD 
Monoclonal ELISA of Full-Length V-V, Clones Panned 
from the V-Restricted schv Libraries. 
To evaluate binding of the clones obtained by phage pan 
ning, single colonies from each V-V, library were inocu 
lated into 150 uL 2YT media with chloramphenicol (35 
ug/mL), tetracycline (10 g/mL), and 1% w/v glucose to a 
final ODoo of -0.5 in a 96-well round bottom plate. Each 
culture was then infected with 100 MOI of M13KO7 helper 
phage and incubated at 37° C. for one hour. Cells were then 
pelleted by centrifugation and resuspended in 25 mL 2YT 
media with chloramphenicol (35 ug/mL), kanamycin (35 
ug/mL), 1% w/v glucose, and 0.5 mMIPTG. Phage display 
ing schvantibodies were produced by growing the cells at 25° 
C. with shaking at 250 rpm overnight (-14 hours). Cells were 
pelleted by centrifugation and 50LL of Supernatant was trans 
ferred to ELISA plates previously coated with CCH (10 
ug/mL overnight at 4°C.) and blocked with 2% milk in PBS 
(two hours, room temperature). An equal Volume of 2% milk 
in PBS was added to each well and phage-scFv were allowed 
to bind with gentle shaking for one hour. After binding, 
ELISA plates were washed three times with PBST and incu 
bated with 50 uL of anti-M13-HRP secondary antibody 
(1:5000, 2% milk in PBS) for 30 min at 25° C. Plates were 
washed three times with PBST, then 50 uL Ultra TMB sub 
strate (Thermo Scientific) was added to each well and incu 
bated 25°C. for 5 min. Reactions were stopped using equal 
volume of 1 MHSO and absorbance was read at 450 nm. 
(BioTek, VT, USA). Dilution series of the purified phage 










licates of a 7-fold serial dilution of each of the five winners 
analyzed. The averaged ELISA signals at each phage titer are 
shown in FIG. 2. 
Example 5 
J Peptide Synthesis and C.-CDR3-J Peptide Antibody 
Production 
CDRH3 is the most hypervariable region in immunoglo 
bulins and is overwhelmingly responsible for antigen speci 
ficity. Accordingly, the quantitation and sequence determina 
tion of CDRH3 peptides was a primary focus of study. 
Isolating peptides exhibiting intact CDRH3 regions from a 
complex peptide mixture improves signal/noise ratio when 
applying IgG protease digestion products to LC-MS/MS 
analysis. It was found that CDRH3 containing peptides can be 
selectively enriched from other antibody proteolytic frag 
ments by affinity chromatography using antibodies specific 
for J region peptides, i.e., peptides encoded by a portion of the 
J segment of the V(D)J locus comprising the region of the V 
gene adjacent to the CDRH3. 
Generating peptides including intact CDRH3 regions was 
based on the selection of the proper proteases. Bioinformatic 
analysis of the V domain protein sequences revealed that 
combinations of known proteases can cleave V gene polypep 
tides in a manner that results in the generation of peptides that 
cleave N- and C-terminal of the CDR3, leaving the CDR3 
sequence largely intact in most sequences. For example, 
inspection of the V gene database from the immunized rabbit 
used in Example 1 verified that digestion with trypsin, which 
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cleaves after R/K, should be sufficient to generate peptide 
fragments comprising amino acids from the CDRH3 region 
and of lengths appropriate for identification for most of the 
putative immunoglobulins expressed by the immunized ani 
mal (e.g., 91.4% of the putative immunoglobulins expressed 
by the CCH-immunized rabbit, FIG. 1). 
In one embodiment proteolytic cleavage was accom 
plished using sequencing grade trypsin (Sigma) at 37°C. for 
5 h. In a separate embodiment combinations of proteases, 
Such as Gluc (Sigma) and LySC (Sigma), were used to gen 
erate a distinct set of proteolytic peptides that in computa 
tional tests provide better coverage of the CDR3. 
Anti-CDRH3-J peptide antibodies were produced in 
chickens (Gallus Gallus domesticus) in order to avoid cross 
reactivity between the antibody that was generated and the 
peptides that were being affinity purified. The J regions of 
various species were analyzed and lowest similarity was 
found between J regions of chicken IgY and those of other 
mammals (Table 7). The N-terminal residues from the CH1 
region of these species were different from the chicken CH1 
regions as well (Table 8). 
TABLE F 
J regions by species. 
Species J Family Sequence 
Human GHJ1 GTLWTVSS 
(SEO ID NO : 77) 
GHJ2 GTLWTVSS 
(SEQ ID NO: 77) 
GHT3 GTMVTVSS 
(SEO ID NO : 78) 
GHJ4 GTLWTVSS 
(SEO ID NO : 77) 
GHJ5 GTLWTVSS 
(SEO ID NO : 77) 
GHT6 GTTWTVSS 
(SEO ID NO : 79) 
Rabbit GHJ1 GTLWTISS 
(SEQ ID NO: 80) 
GHJ2 GTLWTVSS 
(SEO ID NO : 77) 
GHT3 GTLWTVSS 
(SEO ID NO : 77) 
GHJ4 GTLWTVSS 
(SEO ID NO : 77) 
GHJ5 GTLWTVSS 
(SEO ID NO : 77) 
GHT6 GTLWTVSS 
(SEO ID NO : 77) 
Mouse GHJ1 GTTWTVSS 
(SEO ID NO : 79) 
GHJ2 GTTLTWSS 
(SEQ ID NO: 81) 
GHT3 GTLWTWSA 
(SEQ ID NO: 82) 
GHJ4 GTSWTVSS 















J rections by Species. 
Species J Family Sequence 
Chicken IGHT1 GTEWIWSS 
(SEQ ID NO: 84) 
TABLE 8 
N-terminal sequence of the CH1 
domain by species. 
Species Sequence 
Human ASTK 
(SEO ID NO: 85) 
Rabbit GOPK 




(SEO ID NO : 87) 
CDR3-J peptide sequence was designed to exhibit amino 
acids from the C-terminal portion of the CDRH3 segment, 
full FR4, and the N-terminal portion of the constant region 
CH1 (FIG. 3). The sequence CG was padded to the N-termi 
nal of the peptide for conjugation of a carrier protein (e.g., 
Keyhole Limpet Hemocyanin (KLH, Pierce, Ill.)). The pep 
tide NH2-CGGTLVTVSSGQPK-COOH (SEQ ID NO:88) 
was synthesized, purified, and the amino acid sequence was 
validated by MS (Abgent Inc., CA). This peptide was conju 
gated to KLH as a carrier and the conjugate was used to 
immunize chickens for IgY production (Ayes Labs Inc., OR). 
To evaluate the binding affinity of the chicken anti 
CDRH3-J peptide antibodies, an ovalbumin-conjugate of the 
CDRH3-J peptide was first absorbed onto the ELISA plates at 
a concentration of 1 ug/mL in phosphate-buffered isotonic 
saline (PBS). After an overnight incubation at 4°C., a 1:100 
dilution of BlokHenR (Ayes Labs, diluted in PBS) was added 
to each well for a two hour incubation at room temperature to 
block nonspecific sites. After thorough washing, wells on the 
plate were incubated with varying concentrations of either 
purified pre-immune IgY (i.e., purified from eggs collected 
prior to the first injection) or affinity-purified IgY. After a 
two-hour incubation at 4° C., the plate was washed thor 
oughly and then incubated with HRP-labeled goat anti 
chicken IgY (1:5000 dilution, Ayes Labs) for another one 
hour incubation period at room temperature (with rocking). 
The plate was then washed thoroughly, and HRP activity 
bound to the plate was determined using ortho-phenylenedi 
amine and stable peroxide substrate buffer (Pierce), following 
the manufacturers instructions. Finally, the plate was read by 
measuring absorbance at 450 nm (FIG. 4). 
Example 6 
Proteomic Pipeline for CDRH3-J Peptide Isolation 
Purified IgG proteins were denatured in 50% 2.2.2-trifluo 
roethanol (TFE), 10 mM dithiothreitol was added to reduce 
proteins, samples were incubated at 55° C. for 60 min fol 
lowed by alkylation with 32 mMiodoacetamide for 60 minat 
room temperature, and samples were quenched by addition of 
7.7 mM DTT for 60 min at room temperature. Samples were 
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diluted 10-fold to 5% TFE concentration and subjected to 
digestion by appropriate proteases that preserve the CDR3 
domains largely intact (e.g., Trypsin, Gluc). 
Affinity chromatography for the isolation of CDRH3-J 
peptides was carried out by coupling 100 mg of IgYonto 1 g 
of dry N-hydroxysuccinimide (NHS)-activated agarose 
(Pierce, Ill.) by overnight incubation at 4°C. The coupled 
agarose beads were washed with PBS, incubated with 1 M 
ethanolamine, pH 8.3 for 60 minat room temperature to block 
unreated NHS groups, washed with PBS, and packed into a 
chromatography column. Digested IgG fragments were 
applied to the affinity column ingravity mode with the flow 
through collected and reapplied to the column five times. The 
column was subsequently washed with PBS and eluted using 
100 mM glycine, pH 2.7. MS analysis of the eluent peptide 
mixture was carried out using the bioinformatics filters 
described in Example 3. 
In a separate embodiment, purified serum IgG was first 
enriched towards antigen-specific IgGs as described in 
Example 1, followed by anti-CDRH3-J peptide affinity chro 
matography. In both embodiments, fractions from the affinity 
chromatography flow through, wash, and elution were col 
lected for LC-MS/MS analysis (FIG. 5). 
Example 7 
Preparation of Variable Light (V) and Variable 
Heavy (V) Genes for High-Throughput DNA 
Sequencing 
RNA Isolation. 
CD138"CD45R bone marrow plasma cells or peripheral 
ASC and B cells isolated as described in Examples 2 and 3 
above were centrifuged at 2000 rpm and 4°C. for 5 min. Cells 
were then lysed with TRI reagent and total RNA was isolated 
according to the manufacturer's protocol in the Ribopure 
RNA isolation kit (Ambion). mRNA was isolated from total 
RNA through with oligo(dT) resin and the Poly(A) purist kit 
(Ambion) according to the manufacturer's protocol. mRNA 
concentration was measured with an ND-1000 spectropho 
tometer (Nanodrop). 
PCR Amplification. 
The isolated mRNA was used for first strand cDNA syn 
thesis by reverse transcription with the Maloney murine leu 
kemia virus reverse transcriptase (MMLV-RT. Ambion). For 
cDNA synthesis, 50 ng of mRNA was used as a template and 
oligo(dT) primers were used. RT-PCR was performed using a 
Retroscript kit (Ambion) according to the manufacturers 
protocol. Following cDNA construction, PCR amplification 
was performed to amplify the V, and V genes using 2 LL of 
unpurified cDNA product and established V, and V. degen 
erate primer mixes (Krebber et al., 1997: Mazor et al., 2007). 
A 50LL PCR reaction consisted of 0.2 mM of forward and 
reverse primer mixes, 5uL of Thermopol buffer (NEB), 2 ul 
of unpurified cDNA, 1 uL of Taq DNA polymerase (NEB), 
and 39 uL of double distilled HO. The PCR thermocycle 
program was 92°C. for 3 min; 4 cycles of 92°C. for 1 min, 50° 
C. for 1 min, and 72°C. for 1 min: 4 cycles of 92°C. for 1 min, 
55° C. for 1 min, and 72° C. for 1 min; 20 cycles of 92° C. for 
1 min, 63°C. for 1 min, and 72°C. for 1 min; 72°C. for 7 min: 
and 4°C. storage. PCR gene products were gel purified and 
submitted to SeqWright (Houston, Tex.) and the Genomic 
Sequencing and Analysis Center at the University of Texas 
Austin for Roche GS-FLX 454 DNA sequencing. 
Rapid cDNA End (RACE) Amplification. 
Alternatively, a cDNA amplicon library specific for the 













structed from the isolated mRNA. To start, first-strand cDNA 
was synthesized from mRNA using the SMARTScribe Mal 
oney murine leukemia virus reverse transcriptase (MMLV 
RT, Clonetech). The cDNA synthesis utilized 25 ng mRNA 
and template Switching specific 5" primers and 3' gene-spe 
cific primers. Buffers and reaction conditions were used 
according to manufacturer's protocol. Primers were used that 
already incorporated 454 sequencing primers (Roche) on 
both 5' and 3' ends along with multiplex identifiers (MID) so 
that the cDNA synthesized and amplified could be directly 
used in the 454 emPCR step. The 5' forward primer utilized 
MMLV-RT template switching by the addition of three 
cytosine residues at the 3' end offirst-strand cDNA along with 
a portion of the 5' sequencing Primer B of 454 Titanium 
(SRpit 1). For the reverse primer, primers were used to 
amplify the V, gene and a small portion of the 3' end of the 
light chain constant region CKalong with the Primer A of 454 
Titanium including 3 unique MIDs (SRpi2.3.4). Similarly, 
V genes were amplified along with a small portion of the 3' 
end of the heavy chain constant 1 (CH1) region along with the 
Primer A of 454 Titatnium including 3 unique MIDs (SRpi5, 
6,7). 
Following first-strand cDNA synthesis, PCR was per 
formed to amplify cDNA with primers based on the 5' and 3' 
ends of the added 454 sequencing primers (SRpi8 and 9. 
respectively; note that 5' forward primer SRpi8 was biotiny 
lated on the 5' end). Standard PCR conditions were used 
according to the Advantage 2 PCR kit (Clontech). The cDNA 
samples were then run on a 1% agarose gel and the bands 
corresponding to V, or V at ~450 and ~500 bp, respectively, 
were extracted and further purified (Zymogen). cDNA con 
centration was measured using a Nanodrop spectrophotom 
eter. Five hundred nanograms of cDNA per sample was then 
used for 454 sequencing. 
High-Throughput Sequencing of V, and V. Repertoires. 
V gene repertoires isolated from BMCD138" of eight mice 
were sequenced using high-throughput 454 GS-FLX 
sequencing (University of Texas, Austin, Tex.; SeqWright, 
Houston, Tex.). In total, 415,018 sequences were generated, 
and 454 data quality control filtered and grouped >97% of the 
sequences into datasets for each mouse according to their 
Multiplex Identifiers (MID) usages. 
Example 8 
Statistical Methods for Determining Antibody 
Clonotype 
AV clonotype is the set of genes that derive from the same 
B cell lineage, and it is generally accepted that members of a 
clonotype share identical germline V and J segments and 
show up to 10 or 20% variation within the CDR3 at the amino 
acid level. The determination of the clonotypes encoded 
within a set of V gene DNA sequences is critical for the 
interpretation of IgG proteomic data. Antibodies that belong 
to the same clonotype are expected to be derived from the 
same progenitor B cell and to have the same epitope speci 
ficity. The proteomic analysis described in this application 
enable the determination of antibody clonotypes present in 
serum via the identification of CDR3 peptides that map to a 
particular clonotype, as set forth in example 10. 
The present example discloses preferred embodiments for 
the informatics determination of clonotyopes. 
To determine the clonotype groupings from sequencing 
data, CDR3 amino acid sequences were clustered using a 
variety methods. UCLUST, part of the USEARCH package, 
returned fragmented clusters that artificially split true-seem 
ing clonotypes at the 80% (amino acid) identity threshold. 
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Because it is a greedy hierarchical algorithm and calculates 
distance only between a single seed CDR3 and potential 
members, members of one cluster often matched more 
closely those of another. This lead to miscalculation of the 
clonotypes from the analysis of peptide MS from serum IgGs. 
To address this problem, single-linkage hierarchical cluster 
ing was implemented using the following algorithm: 
1. Pick an arbitrary CDR3 amino acid (or nucleotide) 
sequence not belonging to a cluster to seed a new cluster 
2. Find all CDR3 amino acid (or nucleotide) sequences 
above a given similarity to seed and add them to the 
cluster 
3. Mark the seed CDR3 as complete and choose a new seed 
as the next incomplete CDR3 in cluster 
4. Repeat steps 2, 3 until all CDR3s in the cluster are 
marked as searched 
5. Repeat from step 1 until no CDR3s are left unclustered 
Additionally the following rules were implemented to 
improve the accuracy of clonotype determination: CDR3s of 
length 1 to 5 amino acids must be identical, those between 6 
and 10 amino acids are allowed a single mismatch, and those 
of above 10 amino acids must show 90% identity. These 
requirements allow for length variation of a single residue for 
CDR3s ranging from 11 to 19 amino acids and two residues 
for those up to 29 in length. 
In addition to the scheme outlined above, dynamic cluster 
ing methods such as k-means provide an alternative to the 
hierarchical methods above and can alternatively be 
employed for determining the V gene clonotypes encoded by 
a set of High throughput V gene sequencing data. 
Example 9 
Deep Sequencing of Human B Cell Populations from 
the Peripheral Blood at Different Times after Tetanus 
Toxoid Vaccination 
In this example the methodology set forth in this applica 
tion is demonstrated as applied to human samples and spe 
cifically to the analysis of the serum antibody repertoire 
observed after boost immunization with tetanus toxoid. 
Two healthy human donors, a 52 year old male and a 35 
year old female, each received a booster vaccination against 
tetanus toxoid (TT)/diphteria toxoid (TD; 201.E. TT and 2 
I.E. diphteria toxoid, Sanofi Pasteur MSD GmbH, Leimen, 
Germany). Approximately 40 mL of blood was collected 
pre-vaccination (day 0) and subsequently at days 7,56, 109, 
and ~9 months after vaccination. 10 mL of peripheral blood 
was collected into a single K-EDTA collection tube (BD 
Vacutainer REF367525). The additional 30 mL of peripheral 
blood was collected into three (3x10 mL) serum collection 
tubes (BDVacutainer SST II serum tube, REF 367953), with 
approximately 15 mL of serum resultant at each time point. 
Collection of PBCs from the K-EDTA blood was performed 
by density gradient centrifugation over Histopaque 1077 
(Sigma) according to the manufacturer's protocol. 
The antibody response to vaccination is probed through 
establishing a database of the B cell sequences from which the 
antibody sequence and clonality (origin) is matched via pro 
teomic approaches described in example 11. The relevant B 
cell populations in the peripheral blood consist of, but are not 
necessarily limited to: antigen-sorted plasmablasts, total 
plasmablasts, pre-class Switched memory B cells, and post 













sequenced with IgG/IgA-specific primers to garner sequence 
information from total class-switched B cells without prior 
cell sorting. 
FACS Analysis and Sorting of B Cell Populations. 
For the two donors receiving the tetanus/diphtheria booster 
vaccination, PBCs were stained for 15 minutes in PBS/0.2% 
BSA at 4°C. in the dark using the following antibodies: 
anti-CD3-Pacific Blue (PacB; clone UCHT1, Becton Dick 
inson (BD), San Jose, Calif., USA), anti-CD14-PacB (clone 
M5E2, BD), anti-CD19-Phycoerythrin-Cyanine-7 (PECy7, 
clone SJ25C1, BD), anti-CD27-Cy5 (clone 2E4, BD), anti 
CD38-PE (clone HIT2, BD), anti-CD20-Pacific Orange 
(clone HI47, Invitrogen Corporation, Frederick, Md., USA) 
and anti-IgE)-Peridinin-chlorophyll-protein complex-Cy5.5 
(clone L27. BD). TT-specific B cells were identified by bind 
ing to TT labelled with digoxigenin (TT-Dig; Novartis 
Behring, Marburg, Germany), washed in PBS/0.2% BSA, 
and bound by the secondary antibody anti-Dig-fluorescein 
isothiocyanate (FITC: Roche Diagnostics GmbH, Man 
nheim, Germany). Specificity of the staining was confirmed 
each time by blocking with pure TT 4.6 diamidino-2-phe 
nylindole (DAPI; Molecular Probes, Eugene, Oreg., USA) 
was added before cell sorting to exclude dead cells. The 
following B-cell populations were sorted using a FacSAriaII 
cell sorter (BD): CD3-CD14-CD19+CD27++CD38++ 
CD20- plasma cells (PC), CD3-CD14-CD19+CD27+ 
CD20+Ig|D- memory B cells (mBC), CD3-CD14-CD19+ 
CD27+CD20+Ig|D+ mBC, and CD3-CD14-CD19+ 
CD27++CD38++CD20-TT+ plasma cells (TT+PC). 
These B-cell populations were sorted and collected into 
PBS/0.2% BSA, centrifuged at 500xg for 10 minutes, aspi 
rated, and then resuspended in TRI Reagent Solution (Life 
Technologies, San Diego, Calif., USA) and then frozen at 
-80° C. Serum was collected from whole blood by centrifu 
gation at 1100xg for 10 min and then frozen at-80°C. B cell 
populations of PC, mBC, TT+PC, and TT depleted PC were 
examined at day 7 after vaccination. At day 109, B cell popu 
lations of PC, mBC, and total PBC were sorted/isolated. 
Further analysis of extended time points after vaccination will 
allow further analysis of the temporal changes in these B cell 
populations long into the steady state anti-TT B cell and IgG 
response. 
Amplification of the VHandVL Repertoires from B Cells. 
Beginning with B cells lysed and frozen in TRI Reagent, 
whole RNA was prepared, first-strand cDNA generated, and 
PCR amplicon libraries generated for Roche 454 or Illumina 
deep sequencing as previously described (Ippolito et al., 
PLoS ONE, 2012). Briefly, total RNA was isolated according 
to the manufacturer's RiboPure Kit protocol (Life Technolo 
gies). First-strand cDNA generation was performed with 500 
ng of isolated total RNA using SuperScript RT II kit (Invit 
rogen) and Oligo-dT primer. After cDNA construction, PCR 
amplification was performed to amplify the V, V, and V. 
genes separately with a respective standard mix of primers as 
described (Ippolito et al., PLoS ONE, 2012) and as listed in 
Table 9. PCR reactions were carried out using Taq poly 
merase with Thermpol reaction buffer (New England 
Biolabs, MA, USA) and the following cycling conditions: 92 
C. denaturation for 3 min: 92°C. 1 min, 50° C. 1 min, 72° C. 
1 min for 4 cycles: 92° C. 1 min, 55° C. 1 min, 72° C. 1 min 
for 4 cycles: 92° C. 1 min, 63° C. 1 min, 72° C. 1 min for 20 
cycles; and a final extension of 72° C. for 7 minutes. PCR 
products were gel-purified before sequencing. 
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TABLE 9 
Primers used for amplification of the 
VH and VL human repertoires from B cells 
SEQ 
Primer SEQUENCE ID 
Name (5' -> 3') NO : 
W 
WH1-fwo CAGGTCCAGCTKGTRCAGTCTGG 9 O 
WH157-fwo CAGGTGCAGCTGGTGSARTCTGG 91 
WH2-f wo CAGRTCACCTTGAAGGAGTCTG 92 
WH3-fwo GAGGTGCAGCTGKTGGAGWCY 93 
WH4 - fic CAGGTGCAGCTGCAGGAGTCSG 94 
WH4 - DP 63-fwd CAGGTGCAGCTACAGCAGTGGG 95 
WH6-fwo CAGGTACAGCTGCAGCAGTCA 96 
WH3N-fwo TCAACACAACGGTTCCCAGTTA 97 
IgM-rev GGTTGGGGCGGATGCACTCC 98 
IgG-all-rev SGATGGGCCCTTGGTGGARGC 99 
IgA- all-rev GGCTCCTGGGGGAAGAAGCC OO 
W 
WK1-fwo GACATCCRGDTGACCCAGTCTCC O1 
WK24 6-fwd GATATTGTGMTGACBCAGWCTCC O2 
WK3-fwo GAAATTGTRWTGACRCAGTCTCC O3 
WK5-fwo GAAACGACACTCACGCAGTCTC O4 
WK1 - rew TTTGATTTCCACCTTGGTCC O5 
WK2-rew TTTGATCTCCASCTTGGTCC O6 
WK3 - rew TTTGATATCCACTTTGGTCC O7 
WKS - rew TTTAATCTCCAGTCGTGTCC O8 
W. 
WL1-fwd CAGTCTGTSBTGACGCAGCCGCC O9 
WL1459-fwd CAGCCTGTGCTGACT CARYC O 
WL1591 O-fwd CAGCCWGKGCTGACTCAGCCMCC 1. 
WI2 -fwd CAGTCTGYYCTGAYTCAGCCT 2 
WI3 -fwd TCCTATGWGCTGACWCAGCCAA 3 
WI3 - DPL 16-fwd TCCTCTGAGCTGASTCAGGASCC 4. 
WI3 - 38-fwd TCCTATGAGCTGAYRCAGCYACC 5 
WL6-fwd AATTTTATGCTGACTCAGCCCC 6 
WL78-fwo CAGDCTGTGGTGACYCAGGAGCC 7 
WL1 - rew TAGGACGGTSASCTTGGTCC 8 
WLF- rew GAGGACGGTCAGCTGGGTGC 9 
High-throughput sequencing of VH and VL repertoires. V 
gene repertoires isolated from sorted B cell populations of 
both vaccinated human donors were sequenced using high 
throughput 454 GS-FLX sequencing (University of Texas, 
Austin, Tex.; SeqWright, Houston, Tex.). In total, between 













and >16,000 VL sequences were generated after raw 454 
nucleotide data passed quality control and length cutoff fil 
ters. Both VH and VL sequences were subsequently grouped 
according to unique full length V gene amino acid sequence 
for generation of the sequence database utilized for proteomic 
bioinformatics. Sequences were also further grouped by 
unique CDR-H3 amino acid sequence for clonotype analysis. 
Example 10 
Proteomic Analysis of the Serum Antibodies to 
Tetanus Toxoid in Human Volunteers 
Serum was collected from human volunteers at day 0 (pre 
immune), day 7, day 109 and day 256 following immuniza 
tion with tetanus toxoid as described in example 8. For each 
time point, ~7-10 mL of serum was diluted 4-fold with Pro 
tein G binding buffer (Pierce, Ill.), filtered, and passed over a 
Protein G affinity column. The diluted serum was recycled 
three times over the column, which was Subsequently washed 
with 15 volumes of PBS, and eluted with 5 volumes of 100 
mM glycine-HCl, pH 2.7. The purified IgG was dialyzed into 
20 mM sodium acetate, pH 4.5 and concentrated to 10 
mg/mL. Approximately 40-80 mg of protein G-purified IgG 
was digested with 1 mL immobilized pepsin resin (Pierce, 
Ill.) per 10 mg of IgG in 20 mM sodium acetate. Pepsin 
digestion was allowed to proceed for seven hours, shaking 
vigorously at 37°C. The digestion of the IgG into F(ab) was 
monitored by SDS-PAGE to ensure >95% cleavage. 
Affinity chromatography for the isolation of antigen-spe 
cific F(ab) was carried out by coupling 5 mg of the antigen, 
TT, onto 0.25 g of dry N-hydroxysuccinimide (NHS)-acti 
vated agarose (Pierce, Ill.) by overnight incubation at 4°C. 
The coupled agarose beads were washed with PBS and unre 
acted NHS groups were blocked with 1 Methanolamine, pH 
8.3 for 30 min at room temperature, washed with PBS, and 
packed into a chromatography column. The column was then 
washed with 5 volumes of 100 mM glycine, pH 2.7 to elute 
non-specifically bound (unconjugated) antigen and then 5 
volumes of PBS to equilibrate. F(ab) fragments (from ~40 
80 mg of IgG) were applied to the antigen affinity column in 
gravity mode, with the flow-through collected and reapplied 
to the column three times. The column was Subsequently 
washed with 15 volumes of PBS, 5 volumes of ddH2O, and 
eluted using 1 mL fractions of 20 mM HCl, pH 1.7. The 
flow-through, wash, and each 1 mL elution fraction (neutral 
ized with NaOH/Tris) were analyzed by indirect ELISA 
against TT to monitor affinity purification. Elution fractions 
showing an ELISA signal were combined and concentrated 
under vacuum to ~0.5 mL. Volume and the combined, concen 
trated affinity column elution was desalted into ddHO using 
a 2 mL Zeba spin column (Pierce, Ill.). 
The combined, desalted elution and an aliquot of the flow 
through from the antigen affinity chromatography were each 
denatured in 50% V/v TFE, 50 mMammonium bicarbonate, 
and 10 mM DTT at 60° C. for 60 min. The denatured, reduced 
F(ab') were then alkylated by incubation with 32 mM 
iodoacetamide (Sigma, Mo.) for one hour at room tempera 
ture and then quenched by addition of 20 mM DTT for one 
hour at room temperature. Denatured, alkylated F(ab'), 
samples were diluted 10-fold into 50 mM sodium bicarbonate 
to reach a final TFE concentration of 5% V/v. Trypsin diges 
tion was carried out by adding trypsin at a ratio of 1:35 
trypsin-protein and incubated overnight at 37°C. Digestion 
was halted by addition of formic acid to 1% final concentra 
tion. 
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Peptides derived from proteolytic digestion were subject to 
chromatographic separation on a C18 reverse phase tip, 
eluted with 60% acetonitrile in 0.1% TFA. C18 elution was 
dried under vacuum to ~5 ul and diluted to ~50 ul to 5% 
acetonitrile in 0.1%TFA. Peptides were injected onto an LTQ 
OrbitrapTM Velos mass spectrometer (Thermo Scientific) 
using a Nano-spray source. The LTQ Orbitrap Velos was 
operated in the data dependent mode with scans collected at 
60,000 resolutions. Ions with charge >+1 were selected for 
fragmentation by collision-induced dissociation with a maxi 
mum of 20 fragmentation scans per full scan. 
The resulting spectra from above were searched against a 
protein sequence custom database consisting of a human full 
protein-coding sequence database (ENS64) combined with 
in-house human V, and V, sequences, using SEQUESTR 
(Proteome Discoverer 1.2. Thermo Scientific). The search 
specified tryptic peptides with up to two missed tryptic cleav 
ages allowed. A precursor mass tolerance of 5 ppm was used, 
with fragment mass tolerance set to 0.8 Da. Static cysteine 
modifications carbamidomethylation (iodoacetamide) was 
included as well as oxidized methionine was allowed as a 
dynamic modification. The confidence of peptide identifica 
tions was determined using the Percolator algorithm as part of 
the Proteome Discoverer software package (Thermo Scien 
tific), with only top-ranked peptide identifications at <1% 
FDR considered. 
Following filtering to remove peptide sequence misidenti 
fications, the remaining high-confidence peptide sequences 
were classified as informative CDRH3 (iCDRH3) peptides 
and non-iCDRH3 (niCDRH3). The iCDRH3 peptides were 
defined as proteolytic fragmentation products of Sufficient 
length and uniqueness to identify a TT specific clonotype in 
the V sequence database (See example 8 for definition and 
determination of clonotype) used for LC-MS/MS analysis. 
As an example, a peptide corresponding to a unique clono 
type in the database is classified an iCDRH3 peptide whereas 
an antibody proteolytic fragmentation product containing 
amino acids from the J-D region that are found in many 
clonotypes is a niCDRH3. Identification of an iCDRH3 thus 
enables the determination of the corresponding V gene(s) 
from the DNA database. Only high-confidence iCDRH3 pep 
tide sequences were deemed legitimate candidates for further 
analysis (top-ranked protein-spectrum matches (PSMs) at 
<1% FDR as determined by Percolator). Additionally, to fur 
ther increase confidence in the identification of the pro 
teolytic peptides, only peptides observed in 3 injections were 
considered as legitimate and clonotype frequencies within 
each sample were calculated using peptides derived only 
from the CDRH3 region. 
Following analysis of proteomic high confidence identified 
peptides, a heatmap was constructed to reflect the temporal 
changes of clonotypes (as shown in FIG. 9). Over 250 VH 
genes were identified with high confidence as shown in FIG. 
9. Clonotypes were grouped into the following groups: i) 
persistent clonotypes that appear at all time points; ii) new 
clonotypes that do not appear in the sample taken pre-immu 
nization; iii) short lived clonotypes that do not appear at 
steady state time point (day 256) and iv) low abundance (or 
low frequency) 'swarm’ colonotypes that appear at low fre 
quencies in any time point. Groups i-iii accounted for pep 
tides that comprise 80% of the spectral counts in the sample 















High Throughput Determination of the VLAmino 
Acid Sequences Natively Paired with VHSequences 
Determined by MS Proteomic Analysis 
The method of Example 10 describes the proteomic deter 
mination of antibody VH chains. To generate functional anti 
bodies it is important to also identify the cognizantVL chains 
that pair properly with the identified V chains to give fully 
functional antibodies. One such method was described in 
Example 4. The methodset forward in this Example describes 
an alternate method for identifying the native VV, pairs 
encoded by single B lymphocytes. Briefly the native VV, 
pairs encoded by single B lymphocyte cells in a population 
are determined by first capturing V, and V, mRNA from 
single cells on beads, the carrying out reverse transcription 
and linking PCR to generate an approximately 850 bp DNA 
product that comprises the V and V, nucleotide sequences 
and then using high throughput (NextGen.) DNA sequencing 
to determine the sequence of the V, and V, genes from single 
cells (FIG. 8). Once a set of native V and V, genes derived 
from individual B cells in a B lymphocyte population has 
been determined then the resulting database of VV pairs is 
employed to identify a V, gene that natively pairs with a V 
sequence, the later having been identified proteomically as 
described in Example 10 above. 
Specifically, at 7 days post tetanus toxoid immunization, 
EDTA blood was withdrawn and PBC isolated by density 
gradient separation. PBCs were stained in PBS/BSA at 4°C. 
for 15 min with anti-human CD3/CD14-PacB (clone UCHT1 
and M5E2, respectively, Becton-Dickinson, BD), CD19 
PECy7 (clone SJ25C1, BD), CD27-Cy5 (clone 2E4, kind gift 
from Rene vanLier, Academic Medical Centre, University of 
Amsterdam, The Netherlands, labelled at the Deutsches 
Rheumaforschungszentrum (DRFZ), Berlin), CD20-PacO 
(clone HI47. Invitrogen), Ig)-PerCpCy5.5 (clone, L27, BD), 
CD38-PE (clone HIT2, BD), and TT-Digoxigenin (labeled at 
the DRFZ) for 15 minutes at 4°C. Cells were washed and a 
second staining was performed with anti-Digoxigenin-FITC 
(Roche, labeled at the DRFZ) and DAPI was added prior to 
sorting. CD19" CD3 CD14 CD38++CD27* CD20 TT 
plasmablasts were sorted using a FACSAria II sorter system 
(BD Biosciences). A portion of sorted cells were washed and 
cryopreserved in DMSO/10% FCS for high-throughput 
VH:VL pairing. 
One vial containing approximately 2,000 frozen TT plas 
mablasts was thawed and recovered by centrifugation at 
250xg for 10 minutes. Cells were resuspended in 300 LL 
RPMI-1640 supplemented with 1x GlutaMAX, 1x non-es 
sential amino acids, lx sodium pyruvate and 1x penicillin/ 
streptomycin (all from Life Technologies) and incubated at 
37° C. for 13 hours in a 96-well plate. Recovered cells were 
centrifuged again at 250xg for 10 minutes and resuspended in 
400 L PBS, and 6 uL were withdrawn for cell counting with 
a hemocytometer. 
Cells were deposited by gravity into 125 pl. wells molded 
in polydimethylsiloxane (PDMS) slides (each slide contained 
1.7x10 wells). Poly(dT) magnetic beads with a diameter of 
2.8 nm were Subsequently deposited into the microwells at an 
average of 55 beads/well and the slide were covered with a 
dialysis membrane (FIG. 8). 25 uL of poly(dT) magnetic 
beads (Invitrogen mRNA Direct Kit) were resuspended in 50 
uL PBS and distributed over each PDMS slide surface, (mean 
of 55 poly(dT) beads per well). The magnetic beads were 
allowed to settle into wells by gravity for approximately 5 
minutes, then a BSA-blocked dialysis membrane (12,000-14. 
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000 MWCO regenerated cellulose, 25 mm flat width, Fisher 
Scientific) that had been rinsed in PBS was laid over each 
slide Surface, sealing the microwells and trapped cells and 
beads inside. Excess PBS was removed from the slide and 
membrane surfaces using a 200 uL pipette. 500 u, of cell 
lysis solution (500 mM LiCl in 100 mM tris buffer (pH 7.5) 
with 1% lithium dodecyl sulfate, 10 mM EDTA, and 5 mM 
DTT) was applied to the dialysis membranes for 20 min at 
room temperature. Time-lapse microscopy revealed that all 
cells are fully lysed within 1 minute. Subsequently the slides 
were incubated at 4°C. for 10 min at which point a Dynal 
MPC-S magnet was placed underneath the PDMS microwell 
device to hold magnetic beads inside the microwells as the 
dialysis membrane was removed with forceps and discarded. 
The PDMS slides were sequentially inverted in a Petri dish 
containing 2 mL of cold lysis solution and the magnet was 
applied to force the beads out of the microwells. Subse 
quently 1 ml aliquots of the lysis solution containing resus 
pended beads were placed into Eppendorf tubes and beads 
were pelleted on a Dynal MPC-S magnetic rack and washed 
once without resuspension using 1 mL per tube of wash 
Buffer 1 (100 mM Tris, pH 7.5, 500 mM LiCl, 1 mM EDTA, 
4°C.). Beads were resuspended inwash Buffer 1, pelleted and 
resuspended in Wash Buffer 2 (20 mM Tris, pH 7.5, 50 mM 
KC1, 3 mM MgCl) and pelleted again. Finally beads were 
suspended in 2.85 mL cold RT-PCR mixture (Quanta 
OneStep Fast, VWR) containing 0.05 wt % BSA (Invitrogen 
Ultrapure BSA, 50 mg/mL) and primer sets for VH and VL 
amplification (Table 10) The Suspension containing the poly 
(dT) magnetic beads was added dropwise to a stirring IKA 
dispersing tube (DT-20. VWR) containing 9 mL chilled oil 
phase (molecular biology grade mineral oil with 4.5% Span 
80, 0.4% Tween 80, 0.05% Triton X-100, v/v % (Sigma 
Aldrich, St. Louis, Mo.), and the mixture was agitated for 5 
minutes at low speed. The resulting emulsion was added to 
96-well PCR plates with 100LL emulsion per well and placed 
in a thermocycler. The RT step was performed under the 
following conditions: 30 minutes at 55°C., followed by 2 min 







ing conditions: four cycles of 94°C. for 30s denature, 50° C. 
for 30s anneal, 72°C. for 2 min extend; four cycles of 94° C. 
for 30 S denature, 55° C. for 30s anneal, 72° C. for 2 min 
extend; 22 cycles of 94° C. for 30s denature, 60° C. for 30s 
anneal, 72°C. for 2 min extend; then a final extension step for 
7 min at 72° C. After thermal cycling the emulsion was 
collected and centrifuged at room temperature for 10 minutes 
at 16,000xg, the mineral oil upper phase was discarded, and 
1.5 mL diethyl ether was added to extract the remaining oil 
phase and break the emulsion. The upper ether layer was 
removed, two more ether extractions were performed and 
residual ether was removed in a SpeedVac for 25 minutes at 
room temperature. The aqueous phase was diluted 5:1 in 
DNA binding buffer and passed through a silica spin column 
(DNA Clean & Concentrator, Zymo Research, Irvine, Calif.) 
to capture the cDNA product. The column was washed twice 
with 300 uL wash buffer (Zymo Research Corp) and cDNA 
was eluted into 40 uL nuclease-free water. Finally a nested 
PCR amplification was performed (ThermoPol PCR buffer 
with Taq Polymerase, New England Biosciences, Ipswich, 
Mass.) in a total volume of 200LL using4LL of eluted cDNA 
as template with 400 nM primers (Table 11) under the fol 
lowing conditions: 2 min initial denaturation at 94°C., dena 
turation at 94°C. for 30s for 39 cycles, annealing at 62°C. for 
30s and extension at 72°C. for 20s, final extension at 72°C. 
for 7 min. The approximately 850 bp linked product was 
extracted by agarose gel electrophoresis and sequenced using 
the 2x250 paired end MiSeq NextGen platform (Illumina, 
San Diego, Calif.). 
The -850 base pair (bp)linked V.VL DNA product (com 
prising 5'-->3' a sequence encoding the N-terminal end of 
CH1, the V, a linker region, the V, and the N-terminal of CK 
or CW) is generated and the most informative 500 bp of this 
fragment encompassing the CDR-H3 and CDR-L3 was 
sequenced on 2x250 IlluminatM MiSeq (providing also the 
FR3 and FR4 and constant region N-termini amino acid 
sequences for isotype assignment). CDR-H3:CDR-L3 
sequences and thus the corresponding VV, pairs derived 
from single lymphocytes) were identified. 
TABL E 1 O 















hIgKC-rev - OE-BRHO6 GCGGATAACAATTTCACACAGG GATGAAGACAGATGGTGCAG 
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RT-PCR primer mix for single cell WH; VL linkage 
(SEQ ID NOS : 159-186 respectively) 
Primer ID Sequence 
hWH6-fwd- OE TATTCCCATGGCGCGCCCAGGTACAGCTGCAGCAGTCA 
hWH3N-fwo- OE TATTCCCATGGCGCGCCTCAACACAACGGTTCCCAGTTA 
hWK1-fwd- OE GGCGCGCCATGGGAATAGCCGACATCCRGDTGACCCAGTCTCC 
hWK2-fwc - OE GGCGCGCCATGGGAATAGCCGATATTGTGMTGACBCAGWCTCC 
hWK3-fwd- OE GGCGCGCCATGGGAATAGCCGAAATTGTRWTGACRCAGTCTCC 
hWK5-fwo- OE GGCGCGCCATGGGAATAGCCGAAACGACACTCACGCAGTCTC 
hWL1-fwd- OE GGCGCGCCATGGGAATAGCCCAGTCTGTSBTGACGCAGCCGCC 
hWL1459-fwd-OE GGCGCGCCATGGGAATAGCCCAGCCTGTGCTGACT CARYC 
hWL1591 O-fwo- OE GGCGCGCCATGGGAATAGCCCAGCCWGKGCTGACTCAGCCMCC 
hWL2-fwc - OE GGCGCGCCATGGGAATAGCCCAGTCTGYYCTGAYTCAGCCT 
hWI3 -fwd- OE GGCGCGCCATGGGAATAGCCTCCTATGWGCTGACWCAGCCAA 
hWL-DPL16-fwo- OE GGCGCGCCATGGGAATAGCCTCCTCTGAGCTGASTCAGGASCC 
hWI3 - 38-fwd-OE GGCGCGCCATGGGAATAGCCTCCTATGAGCTGAYRCAGCYACC 
hWL6-fwd- OE GGCGCGCCATGGGAATAGCCAATTTTATGCTGACTCAGCCCC 
hWL/8-fwd-OE GGCGCGCCATGGGAATAGCCCAGDCTGTGGTGACYCAGGAGCC 
TABLE 12 10) were synthesized usinggBlocksTM Gene Fragments (IDT. 
integrated DNA technologies). Synthesized V, and V, were 
N.E.R. iii. . tige cloned separately into pMAZ-IgH and pMAZ-Ig|L vector 
backbone (1), using Gibson Assembly TM Master Mix (2) and 
Primer ID Sequence transformed into E. coli Jude-1 Strain and sequence was vali 
hIgG-all-rev- ATGGGCCCTGSGATGGGCCCTTGGTGGARGC dated. - 
OEnested 40 After sequence validation, 20g of each V and V, were 
purified, sequence verified and co-transfected into HEK293F 
high-rev- ATGGGCCCTGCTTGGGGCTGGTCGGGGATG cells following the Freestyle MAX expression system 
instructions (Invitrogen, NY, USA). HEK 293F cells were 
hIgM-rev - OEnested ATGGGCCCTGGGTTGGGGCGGATGCACTCC grown for 6 days after transfection and medium was har 
hIgKC-rev-OEnested GTGCGGCCGCAGATGGTGCAGCCACAGTTC Vested by centrifugation and IgG was purified by a protein-A 
agarose (Pierce, Ill., USA) chromatography column. 
hIgLC-rev-oEnested GTGCGGCCGCGAGGGYGGGAACAGAGTGAC IgG affinities for Tetanus toxoid (TT) were determined by 
competitive ELISA using different concentrations of IgG in a 
serial dilution of antigen, ranging from 50 nM to 0.02 nM in 
Example 12 50 the presence of 2% milk in PBS. The list of V, and V, 
sequences are shown in Table 13. The concentrations of IgG 
Construction and Characterization of Proteomically used Were chosen based O the signal given in an initial 
Identified Tetanus Toxoid Specific Antibodies indirect ELISA in which a dilution series of each IgG WaS 
analyzed, with the IgG concentrations analyzed being in the 
This example describes the evaluation of the antibodies 55 late of the initial ELISA. Each E. with 
identified by proteomic analysis of the VH chains as set forth overnight at room temperature to equilibrate. Plates were 
- - - - coated overnight at 4°C. with 10 ug/mL of TT in 50 mM 
1. example 10. Since antibodies comprise of a Vg and V, carbonate buffer, pH 9.6. Coated plates were washed three 
chain construction of antibodies requires the identification of times in 0.1% PBST and blocked with 2% milk in PBS for two 
the correct V, Sequence. For this purpose we took advantage 60 hours at room temperature. Equilibrated samples were then 
of the database of natively paired V and V, genes in single B added to the block plate and incubated for one hour at room 
cell lymphocytes disclosed in Example 11 above. In other temperature. After binding, ELISA plates were washed 3x 
words, the VH gene is first identified proteomically and then with 0.1% PBST and incubated with 50 ul of anti-human 
the natively paired VL gene encoded by a clonal B cell is kappa-HRP secondary antibody (Sigma, 1:2,500 in 2% milk 
identified as set forth in Example 11. To evaluate the antigen 65 in PBS) for 30 min, 25°C. Plates were washed 3x with 0.1% 
binding affinity of the V and V, Sequences, proteomically 
identified V genes and their natively paired V, genes (Table 
PBST, then 50 ul Ultra TMB substrate (Thermo Scientific) 
was added to each well and incubated 25° C. for 5 min. 
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TABLE 13 - continued 
Amino acid sequences of synthesized WH and WL polypeptides 
specific for tetanus toxoid and identified by proteomic 
analysis of the serum from vaccinated patients. 
Name Sequence SEQ ID NO: 
WL- 6 DIRVTOSPESLGMSLGERATLNCKSNOSLLYTSKNYLAWYOOKPGOPP 38 
KLLIYWASTROSGVPARFSGSGSGTDFTLTISSLEAEDVAVYYCOOYYD 
TPSFGPGTKVDIK 
VL-7 DIRLTOSPSSLSASVGDRVTITCRSSOTISTYLNWYOOKPGEAPKILIYA 39 
ASSLHTGVPSRFSGSGSGTDFTLTITSLOPEDFAIYHCOOSYSTPYTFGO 
GTKVEIK 
WL-8 DIOMTOSPSTLSASVGDSVTITCRASOSITRWLAWYOOKPGKAPKLLIY 4 O 
KASLLESGVPSRFSGSGSGTEFTLTISSLOPDDFATYYCOOYNSYSPWTF 
GPGTKLEIK 
















TABLE 1.4 TABLE 14 - continued 
Antibodies specific to tetanus toxoid Antibodies specific to tetanus toxoid 
identified by proteomic deconvolution identified by proteomic deconvolution 
of the serum IgG response as specified of the serum IgG response as specified 
in Examples 10-12. WH genes encoding 40 in Examples 10-12. WH genes encoding 
serum IgG antibodies induced by Tetanus 
toxoid immunization were identified 
proteomically as set forth in example 
10, the native VL genes encoded by B 
B lymphocytes expressing these WH genes 
were identified as in the Example 11, 
serum IgG antibodies induced by Tetanus 
toxoid immunization were identified 
proteomically as set forth in example 
10, the native VL genes encoded by B 
B lymphocytes expressing these WH genes 
then the WH and VL genes were synthe- 45 were identified as in the Example 11, 
sized, cloned into IgG expression then the WH and VL genes were synthe 
vectors, expressed in HEK293F cells sized, cloned into IgG expression 
purified and the affinities were vectors, expressed in HEK293F cells 
measured by competition ELISA as purified and the affinities were 
set forth in Example 12. measured by competition ELISA as 
50 set forth in Example 12. 
K (nM) 
Equilibrium Standard CDR3 K (nM) 
Dissociation error in (CDR3 Length; Equilibrium Standard CDR3 
mAb Constant KD (nM) SEO ID NO: ) Dissociation error in (CDR3 Length; 
mAlo Constant KD (nM) SEQ ID NO: ) 
TT-1 1.6 O. O4 AKAPIIGPKYYFYMDW 55 
(16; 146) 
TT-6 O. 6 O. O3 ARDYFHSGSOYFFDY 
TT-2 22.6 9 CGKSYDYIRENLDS 
(15; 152) 
(14; 147) 
TT-3 3.7 O 5 AKDRWRVWOAATTLDF 60 TT-7 O 5 O. O1 ARARNYGFPHFFDF 
(16; 148) (14; 153) 
TT-4 3.2 O 5 ARGWWPAGIPFD TT-8 2.8 O3 ARKGMGHYFDF 
(12; 149) (11; 154) 
TT-5 18.1 3.. 6 ARLHPTCASTRCPENYGM 65 TT 9 O. 1 O. O.O8 ARGEDCWGGSCYSAD 
(18; 15O) (15; 155) 
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14- Continued TABLE 
Antibodies specific to tetanus toxoid 
identified by proteomic deconvolution 
of the serum IgG response as specified 
in Examples 10-12. WH genes encoding 
serum IgG antibodies induced by Tetanus 
toxoid immunization were identified 
proteomically as set forth in example 
10, 
B lymphocytes expressing these WH genes 
the native VL genes encoded by B 
were identified as in the Example 11, 
then the WH and VL genes were synthe 
sized, cloned into IgG expression 
vectors, expressed in HEK293F cells 
purified and the affinities were 
measured by competition ELISA as 
set forth in Example 12. 
K (nM) 
Equilibrium Standard CDR3 
Dissociation error in (CDR3 Length; 
mAb Constant KD (nM) SEO ID NO: ) 
TT-1 O O. 9 O. O3 AKAPIIGPKHYFYMDWW 
(17; 156) 
TT-11 1 .. 6 O. OS ARKPRFYYDTSAWFEF 
(16; 158) 
All of the methods disclosed and claimed herein can be 
made and executed without undue experimentation in light of 
the present disclosure. While the compositions and methods 
of this invention have been described in terms of preferred 
embodiments, it will be apparent to those of skill in the art that 
variations may be applied to the methods and in the steps or in 
the sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
More specifically, it will be apparent that certain agents which 
are both chemically and physiologically related may be Sub 
stituted for the agents described herein while the same or 
similar results would beachieved. All such similar substitutes 
and modifications apparent to those skilled in the art are 
deemed to be within the spirit, scope and concept of the 
invention as defined by the appended claims. 
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SEQUENCE LISTING 
<16O is NUMBER OF SEO ID NOS : 192 
<210s, SEQ ID NO 1 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 1 
Asn Val Ala Gly Tyr Lieu. Cys Ala Pro Ala Phe Asn. Phe Arg 
1. 5 1O 
<210s, SEQ ID NO 2 
&211s LENGTH: 21 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 2 
Val Cys Gly Met Asp Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser 
1. 5 1O 15 
Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 3 
&211s LENGTH: 18 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 3 
Glu Thr Gly Gly Gly Lieu Val Glin Pro Gly Gly Ser Lieu. Thir Leu Ser 
1. 5 1O 15 
Cys Llys 
<210s, SEQ ID NO 4 
&211s LENGTH: 16 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 4 
Met Thr Ser Lieu. Thir Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg 
1. 5 1O 15 
<210s, SEQ ID NO 5 
&211s LENGTH: 13 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 5 
Lieu. Thir Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg 
1. 5 1O 
<210s, SEQ ID NO 6 
&211s LENGTH: 26 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
66 
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- Continued 
<4 OOs, SEQUENCE: 6 
Asp Gly Gly Ile Tyr Gly Thr Met Phe Asin Phe Trp Gly Pro Gly Thr 
1. 5 1O 15 
Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 7 
&211s LENGTH: 27 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 7 
Asn Tyr Gly Gly Ala Ala Ser Tyr Gly Met Asp Lieu. Trp Gly Pro Gly 
1. 5 1O 15 
Thr Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 8 
&211s LENGTH: 25 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 8 
Met Asp Ser His Ser Asp Gly Phe Asp Pro Trp Gly Pro Gly Thr Lieu. 
1. 5 1O 15 
Val Ser Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 9 
&211s LENGTH: 21 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 9 
Val Cys Gly Met Asp Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser 
1. 5 1O 15 
Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 10 
&211s LENGTH: 26 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 10 
Asp Gly Gly Ile Tyr Gly Thr Met Phe Asin Phe Trp Gly Pro Gly Thr 
1. 5 1O 15 
Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 11 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
68 
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- Continued 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 11 
Asn Val Ala Gly Tyr Lieu. Cys Ala Pro Ala Phe Asn. Phe Arg 
1. 5 1O 
<210s, SEQ ID NO 12 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 12 
Asn Phe Llys Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 13 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 13 
Asn Phe Gly Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 14 
&211s LENGTH: 11 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 14 
Glu Lieu. Thr Gly Asn Gly Ile Tyr Ala Lieu Lys 
1. 5 1O 
<210s, SEQ ID NO 15 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 15 
Ala Phe Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 16 
&211s LENGTH: 24 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 16 
Ser Pro Ser Ser Gly Ser Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val 
1. 5 1O 15 
Thr Val Ser Ser Gly Glin Pro Llys 
70 
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- Continued 
<210s, SEQ ID NO 17 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 17 
Gly Met Asp Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 18 
&211s LENGTH: 24 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 18 
Gly Ala Gly Trp Val Asp Tyr Ser Leu Trp Gly Pro Gly Thr Lieu Val 
1. 5 1O 15 
Thr Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 19 
&211s LENGTH: 21 
212. TYPE PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 19 
Tyr Ala Pro Phe Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser 
1. 5 1O 15 
Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 12 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 2O 
Gly Tyr Gly Ser Ser Ser Asp Gly Trp Lieu. Thir Arg 
1. 5 1O 
<210s, SEQ ID NO 21 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 21 
Ala Phe Thr Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 22 
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- Continued 
&211s LENGTH: 23 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 22 
Asn Pro Gly Gly Thr Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr 
1. 5 1O 15 
Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 23 
&211s LENGTH: 27 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 23 
Ala Pro Ala Ala Ser Thr Asn Tyr Gly Tyr Asp Lieu. Trp Gly Pro Gly 
1. 5 1O 15 
Thr Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 24 
&211s LENGTH: 23 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 24 
Asn Ser Gly Ser Ala Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr 
1. 5 1O 15 
Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 25 
&211s LENGTH: 18 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 25 
Phe Asp Phe Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly Glin 
1. 5 1O 15 
Pro Llys 
<210s, SEQ ID NO 26 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 26 
Llys Phe Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 27 
&211s LENGTH: 27 
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- Continued 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 27 
Asn Tyr Gly Gly Ala Ala Ser Tyr Gly Met Asp Lieu. Trp Gly Pro Gly 
1. 5 1O 15 
Thr Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 28 
&211s LENGTH: 25 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 28 
Met Asp Ser His Ser Asp Gly Phe Asp Pro Trp Gly Pro Gly Thr Lieu. 
1. 5 1O 15 
Val Ser Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 29 
&211s LENGTH: 21 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 29 
Val Cys Gly Met Asp Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser 
1. 5 1O 15 
Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 3 O 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 30 
Asn Val Ala Gly Tyr Lieu. Cys Ala Pro Ala Phe Asn. Phe Arg 
1. 5 1O 
<210s, SEQ ID NO 31 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 31 
Asn Phe Llys Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 32 
&211s LENGTH: 11 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
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- Continued 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 32 
Glu Lieu. Thr Gly Asn Gly Ile Tyr Ala Lieu Lys 
1. 5 1O 
<210s, SEQ ID NO 33 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 33 
Ala Phe Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 34 
&211s LENGTH: 24 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 34 
Ser Pro Ser Ser Gly Ser Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val 
1. 5 1O 15 
Thr Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 35 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 35 
Gly Met Asp Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 36 
&211s LENGTH: 24 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 36 
Gly Ala Gly Trp Val Asp Tyr Ser Leu Trp Gly Pro Gly Thr Lieu Val 
1. 5 1O 15 
Thr Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 37 
&211s LENGTH: 12 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 37 
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- Continued 
Gly Tyr Gly Ser Ser Ser Asp Gly Trp Lieu. Thir Arg 
1. 5 1O 
<210s, SEQ ID NO 38 
&211s LENGTH: 23 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 38 
Asn Pro Gly Gly Thr Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr 
1. 5 1O 15 
Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 39 
&211s LENGTH: 27 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 39 
Ala Pro Ala Ala Ser Thr Asn Tyr Gly Tyr Asp Lieu. Trp Gly Pro Gly 
1. 5 1O 15 
Thr Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210 SEQ ID NO 40 
&211s LENGTH: 23 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 4 O 
Asn Ser Gly Ser Ala Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr 
1. 5 1O 15 
Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 41 
&211s LENGTH: 18 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 41 
Phe Asp Phe Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly Glin 
1. 5 1O 15 
Pro Llys 
<210s, SEQ ID NO 42 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 42 
Llys Phe Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
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- Continued 
Gln Pro Llys 
<210s, SEQ ID NO 43 
&211s LENGTH: 24 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 43 
Ser Asp Glu Ile Asn Asp Tyr Asn Lieu. Trp Gly Pro Gly. Thir Lieu Val 
1. 5 1O 15 
Thr Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 44 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 44 
Ala Phe Thr Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 45 
&211s LENGTH: 19 
212. TYPE PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 45 
Asn Phe Gly Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
<210s, SEQ ID NO 46 
&211s LENGTH: 23 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 46 
Asn Ala Gly Thr Ala Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val Thr 
1. 5 1O 15 
Val Ser Ser Gly Glin Pro Llys 
2O 
<210s, SEQ ID NO 47 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 47 
Asn Trp Gly Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 1O 15 
Gln Pro Llys 
82 
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<210s, SEQ ID NO 48 
&211s LENGTH: 26 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 48 
Asp Ala Gly Asp Ala Gly Tyr His Lieu. Thir Lieu. Trp Gly Pro Gly Thr 
1. 5 1O 15 
Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 49 
&211s LENGTH: 26 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 49 
Thr Asp Ser Ser Asp His Thr Tyr Phe Ile Leu Trp Gly Pro Gly Thr 
1. 5 1O 15 
Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 50 
&211s LENGTH: 28 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 50 
Ala Ala Gly Tyr Gly Ala Asp Ala Tyr Ala Trp Asn Lieu. Trp Gly Pro 
1. 5 1O 15 
Gly Thr Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
2O 25 
<210s, SEQ ID NO 51 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 51 
Asn Val Ala Gly Tyr Lieu. Cys Ala Pro Ala Phe Asn. Phe Arg 
1. 5 1O 
<210s, SEQ ID NO 52 
&211s LENGTH: 414 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<4 OOs, SEQUENCE: 52 
atggcc.ca.gc cqgc.catggc gcaggaacag Ctggaagaat Ctggtgacct ggittaalacc.g 
ggtgcttct c tdaccctgac ctdcaccgct tctggitttct ctittct citt c ttct tactac 
atggcttggg ttcgtcaggc ticcgggtaaa ggtctggaat ggat.cggttg catgaactict 
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tctaccacca tdaccctgca gct gacct ct ctdaccoctd citgacaccgc tacct acttic 
tgcgct cqta acgttgctgg ttacctgtgc gct Coggctt toaactt.ccg ttctic.cgggt 
accctggitta cc.gttt Cttic tigtggtggc ggtagcggtg gtggtgg tag cqgt 
<210s, SEQ ID NO 53 
&211s LENGTH: 25 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 53 
Synthetic peptide 
Met Asp Ser His Ser Asp Gly Phe Asp Pro Trp Gly Pro Gly Thr Lieu. 
1. 5 
Val Ser Val Ser Ser Gly Glin Pro Llys 
<210s, SEQ ID NO 54 
&211s LENGTH: 411 
&212s. TYPE: DNA 
25 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 54 
atggcc.ca.gc cqgc.catggc 
ccggaaggitt Ctctgacc ct 
tggatctggt giggttcgt.ca 
accogttctg gtaccaccita 
acct cittcta ccaccgttac 
tact tctg.cg citcg tatgga 
ctggitttctg titt cittctgg 
<210s, SEQ ID NO 55 
&211s LENGTH: 19 










gctitctggitt tot ctittctic 
alaaggtctgg aatggat.cgc 
tgggctaaag gtcgttt cac 
acct citctga cc.gctgctga 
gacggitttcg accc.gtgggg 
agcggtggtg gtgg tag.cgg 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 










Asn Phe Llys Lieu. Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 
Gln Pro Llys 
<210s, SEQ ID NO 56 
&211s LENGTH: 387 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 56 
ggtggit accc taccctgac 
aactgggttc gtcaggct Co 







tctggitttcg acttct citt c 
ccggaatgga t cqgttacat 
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tottctacca ccgttaccct gcagatgacc tict ctdaccq ctgctgacac cqctacctac 
ttctgcgctic gta acccggg togg tacct ct aacctgtggg gtc.cggg tac Cctggitt acc 
gttt cittctg gtggtggcgg tag.cggtggit ggtgg tagcg gt 
<210s, SEQ ID NO 61 
&211s LENGTH: 24 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 61 
Synthetic peptide 
Ser Pro Ser Ser Gly Ser Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val 
1. 5 
Thr Val Ser Ser Gly Glin Pro Llys 
<210s, SEQ ID NO 62 
&211s LENGTH: 4 O2 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 62 
ggtaccctga ccctgtc.ttg 
tgctgggttc gtcaggct Co 
tctggttcta ccaactacgc 
tctaccaccg ttaccctgca 
tgcgct cqtt citcc.gt ctitc 
gttt Cttctg gtggtggcgg 
<210s, SEQ ID NO 63 
&211s LENGTH: 19 
















<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 




t ct cittcttic titact acatg 
tcqcttgcat ctacaccggit 
to accat Ct c talaat Cttct 
ctgacac cqc tacct acttic 
gtc.cggg tac Cctggitt acc 
gt 
Gly Met Asp Leu Trp Gly Pro Gly Thr Lieu Val Thr Val Ser Ser Gly 
1. 5 
Gln Pro Llys 
<210s, SEQ ID NO 64 
&211s LENGTH: 429 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 64 
gaaggttctic taccctgac 
atgtgctggg ttcgtcaggc 












ctitt caccogt tdgttacgac 
ggat.cggttg catc.ccgt.ct 
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tctacctctg ttaccctgca gatgaccc.gt ctdac cottg citgacaccgc tacct acttic 3OO 
tgcgct cqtg aagacaccita C9gtgacgct aac accgact acctgtaccg tdgtatggac 360 
Ctgtggggtc. c.gggtaccct ggttaccgtt t cttctggtg gtggcgg tag cqgtggtggit 42O 
ggtagcggit 429 
SEO ID NO 65 
LENGTH: 46 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic primer 
SEQUENCE: 65 
gatgacgatg cggc.ccc.cga ggccttgatt toyacmittgg teccag 46 
SEQ ID NO 66 
LENGTH: 46 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic primer 
SEQUENCE: 66 
gatgacgatg cggc.ccc.cga ggc citygacs accacct cqg tcc ct c 46 
SEO ID NO 67 
LENGTH: 52 
TYPE DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic primer 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (33) . . (34) 
OTHER INFORMATION: n is a, c, g, or t 
SEQUENCE: 67 
ggtggtggtg gtagcggtgg ttggcago gmnnhhgWom tacccagac ts 52 
SEQ ID NO 68 
LENGTH: 32 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic primer 
SEQUENCE: 68 
ggcc.ca.gc.cg gcc atggctic agcagctgga ag 32 
SEO ID NO 69 
LENGTH: 31 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic primer 
SEQUENCE: 69 
ggcc.ca.gc.cg gcc atggctic aggaacagct g 31 
SEO ID NO 7 O 
LENGTH: 32 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
92 
223 OTHER INFORMATION: 
93 
<4 OO > SEQUENCE: 7 O 
ggcc.ca.gc.cg gcc atggctic agt ct ctgga ag 
<210s, SEQ ID NO 71 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<4 OOs, SEQUENCE: 71 
gatgacgatg cggc.ccc.cga g 
<210s, SEQ ID NO 72 
&211s LENGTH: 239 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 



















Glu Gln Lieu. Glu Glu Ser Gly Asp 
Thr Lieu. Thr Cys Thr Ala Ser Gly 
2O 25 
Met Ala Trp Val Arg Glin Ala Pro 
35 4 O 
Cys Met Asn Ser Gly Gly Asp Thr 
SO 55 
Arg Phe Ser Ile Ser Lys Thir Ser 
70 
Thir Ser Lieu. Thir Ala Ala Asp Thr 
Val Ala Gly Tyr Lieu. Cys Ala Pro 
1OO 105 
Thr Lieu Val Thr Val Ser Ser Gly 
115 12 O 
Asp Val Met Thr Glin Thr Pro Ser 
13 O 135 
Thr Val Ser Ile Ser Cys Arg Ser 
150 
Trp Leu Ser Trp Tyr Glin Gln Lys 
65 
Ile Tyr Glu Thir Ser Lys Lieu Pro 
18O 185 
Gly Ser Gly Ser Gly Thr Glin Phe 
195 2OO 
Cys Asp Asp Ala Ala Thr Tyr Tyr 
21 O 215 
Ser Asp Asn Gly Phe Gly Gly Gly 
23 O 
<210s, SEQ ID NO 73 
&211s LENGTH: 239 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
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<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 73 
Glin Glu Gln Lieu. Glu Glu Ser Gly Gly Asp Lieu Val Llys Pro Glu Gly 
1. 5 1O 15 
Ser Lieu. Thir Lieu. Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser 
2O 25 3O 
Tyr Trp Ile Trp Trp Val Arg Glin Ala Pro Gly Lys Gly Lieu. Glu Trp 
35 4 O 45 
Ile Ala Cys Ile Tyr Thr Gly Ser Gly. Thir Thr Tyr Tyr Ala Asn Trp 
SO 55 6 O 
Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr 
65 70 7s 8O 
Lieu Gln Met Thr Ser Lieu. Thir Ala Ala Asp Thr Ala Thr Tyr Phe Cys 
85 90 95 
Ala Arg Met Asp Ser His Ser Asp Gly Phe Asp Pro Trp Gly Pro Gly 
1OO 105 11 O 
Thr Lieu Val Ser Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 
115 12 O 125 
Ser Gly Val Glu Lieu. Thr Glin Thr Pro Ala Ser Val Ser Glu Pro Val 
13 O 135 14 O 
Gly Gly Thr Val Thr Ile Lys Cys Glin Ala Ser Glin Asn Ile Tyr Ser 
145 150 155 160 
Asp Lieu Ala Trp Tyr Glin Glin Llys Pro Gly Glin Pro Pro Lys Arg Lieu 
1.65 17O 17s 
Ile Tyr Asp Ala Ser Llys Lieu Pro Ser Gly Val Pro Ser Arg Phe Lys 
18O 185 19 O 
Gly Ser Gly Ser Gly Thr Glu Tyr Thr Lieu. Thir Ile Ser Asp Leu Glu 
195 2OO 2O5 
Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Glin Thr Tyr His Asp Phe Asp 
21 O 215 22O 
Val Tyr Gly Val Ala Phe Gly Gly Gly Thr Glu Val Val Val Glu 
225 23 O 235 
<210s, SEQ ID NO 74 
&211s LENGTH: 241 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 74 
Glin Ser Lieu. Glu Glu Ser Gly Asp Lieu Val Llys Pro Gly Ser Ser Lieu. 
1. 5 1O 15 
Thr Lieu. Thr Cys Thr Gly Ser Gly Phe Ser Phe Ser Asn Llys Tyr Trp 
2O 25 3O 
Ile Cys Trp Val Arg Glin Ala Pro Gly Lys Gly Lieu. Glu Trp Ile Gly 
35 4 O 45 
Cys Ile Tyr Ile Gly Asn. Ile Asp Asn. Thir Asp Tyr Ala Ser Trp Ala 
SO 55 6 O 
Lys Gly Arg Phe Thr Ile Ser Ser Thr Ser Ser Thr Thr Val Thr Lieu. 
65 70 7s 8O 
Gln Met Thr Ser Lieu. Thir Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala 
85 90 95 
Arg Asn Pro Gly Gly Thr Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val 
1OO 105 11 O 
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Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ala 
115 12 O 125 
Ile Val Lieu. Thr Glin Thr Pro Ser Ser Val Glu Ala Ala Val Gly Gly 
13 O 135 14 O 
Thr Val Thir Ile Lys Cys Glin Ala Ser Glin Ser Ile Gly Ser Ile Leu 
145 150 155 160 
Ala Trp Tyr Glin Gln Llys Pro Gly Glin Arg Pro Llys Lieu. Lieu. Ile Tyr 
1.65 17O 17s 
Tyr Ala Ser Thr Lieu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser 
18O 185 19 O 
Gly Ser Gly Thr Glin Phe Ile Lieu. Thir Ile Ser Asp Lieu. Glu. Cys Ala 
195 2OO 2O5 
Asp Ala Ala Thr Tyr Tyr Cys Glin Ser Tyr Gly Tyr Ser Ser Ser Gly 
21 O 215 22O 
Ser Tyr Gly Tyr Arg Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val 
225 23 O 235 24 O 
Glu 
<210s, SEQ ID NO 75 
&211s LENGTH: 241 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 75 
Glin Ser Lieu. Glu Glu Ser Gly Asp Lieu Val Llys Pro Gly Ser Ser Lieu. 
1. 5 1O 15 
Thr Lieu. Thr Cys Thr Gly Ser Gly Phe Ser Phe Ser Asn Llys Tyr Trp 
2O 25 3O 
Ile Cys Trp Val Arg Glin Ala Pro Gly Lys Gly Lieu. Glu Trp Ile Gly 
35 4 O 45 
Cys Ile Tyr Ile Gly Asn. Ile Asp Asn. Thir Asp Tyr Ala Ser Trp Ala 
SO 55 6 O 
Lys Gly Arg Phe Thr Ile Ser Ser Thr Ser Ser Thr Thr Val Thr Lieu. 
65 70 7s 8O 
Gln Met Thr Ser Lieu. Thir Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala 
85 90 95 
Arg Asn Pro Gly Gly Thr Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val 
1OO 105 11 O 
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Asp 
115 12 O 125 
Val Val Met Thr Glin Thr Pro Ser Ser Val Glu Ala Ala Val Gly Gly 
13 O 135 14 O 
Thr Val Thir Ile Lys Cys Glin Ala Ser Glin Ser Ile Gly Asn Val Lieu. 
145 150 155 160 
Ala Trp Tyr Glin Gln Llys Pro Gly Glin Arg Pro Llys Lieu. Lieu. Ile Tyr 
1.65 17O 17s 
Lieu Ala Ser Thir Lieu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser 
18O 185 19 O 
Gly Ser Gly Thr Glin Phe Ile Lieu. Thir Ile Ser Asp Lieu. Glu. Cys Ala 
195 2OO 2O5 
Asp Ala Ala Thr Tyr Tyr Cys Glin Ser Tyr Gly Tyr Ser Ser Ser Ser 
21 O 215 22O 
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Ser Tyr Gly Tyr Arg Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val 
225 23 O 235 24 O 
Lys 
<210s, SEQ ID NO 76 
&211s LENGTH: 237 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 76 
Glin Glin Lieu. Glu Glu Ser Gly Asp Lieu Val Llys Pro Gly Gly. Thir Lieu. 
1. 5 1O 15 
Thr Lieu Ser Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr Tyr 
2O 25 3O 
Met Cys Trp Val Arg Glin Ala Pro Gly Lys Gly Lieu. Glu Trp Ile Ala 
35 4 O 45 
Cys Ile Tyr Thr Gly Ser Gly Ser Thr Asn Tyr Ala Ser Trp Ala Lys 
SO 55 6 O 
Gly Arg Phe Thr Ile Ser Lys Ser Ser Ser Thr Thr Val Thr Lieu. Glin 
65 70 7s 8O 
Met Thr Ser Lieu. Thir Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg 
85 90 95 
Ser Pro Ser Ser Gly Ser Ser Asn Lieu. Trp Gly Pro Gly Thr Lieu Val 
1OO 105 11 O 
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Asp 
115 12 O 125 
Val Met Thr Glin Thr Pro Ala Ser Val Ser Ala Ala Val Gly Gly Thr 
13 O 135 14 O 
Val Thir Ile Lys Cys Glin Ala Ser Glin Ser Ile Ser Asn Tyr Lieu. Ser 
145 150 155 160 
Trp Tyr Glin Glin Llys Pro Gly Glin Arg Pro Llys Lieu. Lieu. Ile Asp Ala 
1.65 17O 17s 
Ala Ser Thr Lieu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly 
18O 185 19 O 
Ser Gly Thr Glu Ser Thr Lieu. Thir Ile Ser Asp Lieu. Glu. Cys Ala Asp 
195 2OO 2O5 
Ala Ala Thr Tyr Tyr Cys Lieu. Tyr Gly Tyr Tyr Gly Val Ser Ser Thr 
21 O 215 22O 
Ser Val Ala Phe Gly Gly Gly Thr Glu Val Val Val Glu 
225 23 O 235 
<210s, SEQ ID NO 77 
&211s LENGTH: 8 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 77 
Gly Thr Lieu Val Thr Val Ser Ser 
1. 5 
<210s, SEQ ID NO 78 
&211s LENGTH: 8 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
101 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 78 
Gly Thr Met Val Thr Val Ser Ser 
1. 5 
<210s, SEQ ID NO 79 
&211s LENGTH: 8 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 79 
Gly. Thir Thr Val Thr Val Ser Ser 
1. 5 
<210s, SEQ ID NO 8O 
&211s LENGTH: 8 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 80 
Gly Thr Lieu Val Thr Ile Ser Ser 
1. 5 
<210s, SEQ ID NO 81 
&211s LENGTH: 8 
212. TYPE PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 81 
Gly. Thir Thr Lieu. Thr Val Ser Ser 
1. 5 
<210s, SEQ ID NO 82 
&211s LENGTH: 8 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 82 
Gly Thr Lieu Val Thr Val Ser Ala 
1. 5 
<210s, SEQ ID NO 83 
&211s LENGTH: 8 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 83 
Gly. Thir Ser Val Thr Val Ser Ser 
1. 5 
<210s, SEQ ID NO 84 
&211s LENGTH: 8 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
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<4 OOs, SEQUENCE: 84 
Gly Thr Glu Val Ile Val Ser Ser 
1. 5 
<210s, SEQ ID NO 85 
&211s LENGTH: 4 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 85 
Ala Ser Thir Lys 
1. 
<210s, SEQ ID NO 86 
&211s LENGTH: 4 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 86 
Gly Glin Pro Llys 
1. 
<210s, SEQ ID NO 87 
&211s LENGTH: 4 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 87 
Ala Gly Pro Thr 
1. 
<210s, SEQ ID NO 88 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 88 
Cys Gly Gly Thr Lieu Val Thr Val Ser Ser Gly Glin Pro Llys 
1. 5 1O 
<210s, SEQ ID NO 89 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (3) ... (3) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<4 OOs, SEQUENCE: 89 
Trp Gly Xaa Gly Thr Lieu Val Thr Ser Ser Gly Glin Pro Llys 
1. 5 1O 
<210s, SEQ ID NO 90 
&211s LENGTH: 23 
&212s. TYPE: DNA 
105 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 90 
Cagg to cagc tkgtrc agtic tig 
<210s, SEQ ID NO 91 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 91 
Caggtgcagc tiggtgs artic tig 
<210s, SEQ ID NO 92 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 92 
Cagrtc acct talaggagtic td 
<210s, SEQ ID NO 93 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM; Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 93 
gaggtgcagc tigktggagWC y 
<210s, SEQ ID NO 94 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 94 
Caggtgcagc tigcaggagtic Sg 
<210s, SEQ ID NO 95 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OO > SEQUENCE: 95 
Caggtgcagc tacagcagtggg 
<210s, SEQ ID NO 96 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 96 
Cagg tacagc tigcagcagtic a 











<210s, SEQ ID NO 97 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OO > SEQUENCE: 97 
t caacacaac gigttcc cagt ta 
<210s, SEQ ID NO 98 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 98 
ggttgggg.cg gatgcact Co 
<210s, SEQ ID NO 99 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 99 
Sgatgggc cc ttggtggarg C 
<210s, SEQ ID NO 100 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 1.OO 
ggctCctggg gigaagaa.gc.c 
<210s, SEQ ID NO 101 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 101 
gacatccrgd tdacccagtic ticc 
<210s, SEQ ID NO 102 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 102 
gatattgttgm tdacbcagwc toc 
<210s, SEQ ID NO 103 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 








<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 103 
gaaattgtrW tdacrcagtic ticc 
<210s, SEQ ID NO 104 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 104 
gaaacgacac toacgcagtic tic 
<210s, SEQ ID NO 105 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 105 
tittgatttico accttggtco 
<210s, SEQ ID NO 106 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 106 
tittgat citco ascittggtco 
<210s, SEQ ID NO 107 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 107 
tittgat atco actittggtco 
<210s, SEQ ID NO 108 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 108 
tittaatct co agt cqtgtc.c 
<210s, SEQ ID NO 109 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 109 
Cagt ctgtsb tacgcagcc gcc 







<210s, SEQ ID NO 110 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 110 
cagoctdtgc tigacitcairyc 
<210s, SEQ ID NO 111 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 111 
cago cwgkgc tigacticagoc mcc 
<210s, SEQ ID NO 112 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 112 
cagtctgyyc tdayticagoc t 
<210 SEQ ID NO 113 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 113 
t cctatgwgc tigacwo agcc aa 
<210s, SEQ ID NO 114 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 114 
t cct ctdagc tigastcagga scc 
<210s, SEQ ID NO 115 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 115 
t cctatgagc tigayrcagcy acc 
<210s, SEQ ID NO 116 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 








US 9,146,241 B2 
113 114 
- Continued 
<4 OOs, SEQUENCE: 116 
aattittatgc tigacticagoc cc 22 
<210s, SEQ ID NO 117 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 117 
Cagdictgtgg tacycagga gcc 23 
<210s, SEQ ID NO 118 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 118 
taggacggts as Cttggit Co 2O 
<210s, SEQ ID NO 119 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
< 4 OO SEQUENCE: 119 
gaggacggtc agctgggtgc 2O 
<210s, SEQ ID NO 120 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 120 
Glin Val Glin Lieu Val Glu Ser Gly Gly Gly Lieu Val Glin Pro Gly Arg 
1. 5 1O 15 
Ser Lieu. Arg Lieu Ser Cys Val Gly Ser Gly Phe Ser Phe Glu Ser Tyr 
2O 25 3O 
Ala Met His Trp Val Arg Lieu Ala Pro Gly Lys Gly Lieu. Glu Trp Val 
35 4 O 45 
Ala Gly Ile Ser Trp Asp Ser Gly Ala Lys Gly Asn Ala Asp Ser Val 
SO 55 6 O 
Glu Gly Arg Phe Thir Ile Ser Arg Asp Asn Ala Lys Llys Ser Val Tyr 
65 70 7s 8O 
Lieu. Glu Met Arg Ser Lieu. Arg Pro Glu Asp Thr Ala Phe Tyr Tyr Cys 
85 90 95 
Ala Lys Ala Pro Ile Ile Gly Pro Llys Tyr Tyr Phe Tyr Met Asp Val 
1OO 105 11 O 
Trp Gly Lys Gly Thr Ser Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 121 
&211s LENGTH: 120 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
115 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 121 
Glin Wall Glin Lieu Val Glin 
1. 5 
Ser Lieu. Arg Lieu. Ser Cys 
2O 
Asn Met His Trp Val Arg 
35 
Ser Tyr Ile Ser Gly Asp 
SO 
Arg Gly Arg Phe Thr Ile 
65 70 
Leul Glin Met Thir Ser Lieu. 
85 
Gly Lys Ser Tyr Asp Tyr 
1OO 
Gly Thr Lieu Val Thr Val 
115 
<210s, SEQ ID NO 122 
&211s LENGTH: 123 











<213> ORGANISM: Artificial 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 122 
Glin Wall Glin Lieu Val Glin 
1. 5 
Ser Val Arg Val Ser Cys 
2O 
Ala Met His Trp Val Arg 
35 
Gly Trp Ile Asin Val Asp 
SO 
Glin Gly Arg Lieu. Thir Ile 
65 70 
Met Glu Lieu. Ser Ser Lieu. 
85 
Ala Lys Asp Arg Val Arg 
1OO 
Trp Gly Glin Gly Thr Lieu. 
115 
<210s, SEQ ID NO 123 
&211s LENGTH: 121 












































<213> ORGANISM: Artificial 
22 Os. FEATURE: 
223 OTHER INFORMATION: 



















































































































Glin Val Thr Lieu Lys Glu Ser Gly Pro Ala Leu Val Llys Pro Thr Glin 
1. 5 15 










Met Cys Val Ser Trp Ile Arg Gln Pro Pro 
35 4 O 
Lieu Ala Arg Ile Asp Trp Asp Glu Lys Llys 
SO 55 
Llys Thr Arg Lieu. Thir Ile Ser Lys Asp Thr 
70 7s 
Lieu. Thir Met Thr Asn Met Asp Pro Leu Asp 
85 90 
Ala Arg Gly Val Val Pro Ala Gly Ile Pro 
1OO 105 
Gly Ile Met Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 124 
&211s LENGTH: 126 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Val Glin Lieu. Glin Glu Ser Gly Pro Gly Lieu. 
5 1O 
Leu Ser Lieu. Thr Cys Thr Val Ser Gly Gly 
2O 25 
Trp Ser Trp Ile Arg Glin Ser Pro Gly Lys 
35 4 O 
Tyr Ile Tyr Tyr Thr Gly Ile Asn Llys Tyr 
SO 55 
Arg Val Thir Ile Ser Met Asp Thr Ser Lys 
70 7s 
Val Thr Ser Lieu. Thr Pro Ala Asp Thr Ala 
85 90 
Lieu. His Pro Thr Cys Ala Ser Thr Arg Cys 
1OO 105 
Asp Val Trp Gly Glin Gly. Thir Thr Val Ala 
115 12 O 
<210s, SEQ ID NO 125 
&211s LENGTH: 127 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Val Glin Lieu. Glin Glu Ser Gly Gly Lys Lieu. 
5 1O 
Lieu. Arg Lieu. Ser Cys Val Val Ser Gly Phe 
2O 25 
Met Ser Trp Val Arg Glin Ala Pro Gly Lys 
35 4 O 
Ala Val Ser Gly Ser Gly Asp Glu Thr Phe 
SO 55 
Gly Arg Phe Thir Ile Ser Arg Asp Asn. Ser 
70 7s 
Gln Met Thr Ser Lieu. Gly Val Glu Asp Thr 
85 90 
US 9,146,241 B2 
- Continued 
Gly Lys Ala Lieu. Glu 
45 
Tyr Tyr Ser Pro Ser 
6 O 
Ser Lys Asp Glin Val 
8O 
Thr Ala Met Tyr Ser 
95 
Phe Asp Phe Trp Gly 
11 O 
Val Lys Pro Ser Glu 
15 
Ser Ile Asin Ser Tyr 
3O 
Gly Lieu. Glu Trp Ile 
45 
Asn Pro Ser Lieu Lys 
6 O 
Arg Glin Val Ser Lieu. 
8O 
Val Tyr Phe Cys Ala 
95 
Pro Glu Asn Tyr Gly 
11 O 
Wall Ser Ser 
125 
Val Arg Pro Gly Gly 
15 
Thr Phe Ser Asp Phe 
3O 
Gly Pro Leu Trp Val 
45 
Tyr Ala Asp Ser Val 
6 O 
Lys Asn. Thir Ile Phe 
8O 




US 9,146,241 B2 
- Continued 
Val Arg Asp Pro Arg His Tyr His Asn Met Gly Arg Tyr Tyr Ala Gly 
105 11 O 
Trp Phe Asp Ala Trp Gly Glin Gly Thr Arg Val Ile Val Ser Ser 
115 
PRT 













































































































<210s, SEQ ID NO 128 
&211s LENGTH: 





























































































































































































US 9,146,241 B2 
121 122 
- Continued 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 128 
Glin Val Glin Lieu Val Glu Ser Gly Gly Gly Lieu Val Llys Pro Gly Gly 
1. 5 1O 15 
Ser Lieu. Arg Lieu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser His Tyr 
2O 25 3O 
Ser Met Asn Trp Ile Arg Glin Ala Pro Gly Lys Gly Lieu. Glu Trp Val 
35 4 O 45 
Ala Ser Ile Thr Ser Gly Ser Thr Asn Met Val Tyr Ala Asp Ser Leu 
SO 55 6 O 
Arg Ala Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn. Ser Lieu. Tyr 
65 70 7s 8O 
Lieu. Glin Met Asp Ser Lieu. Ser Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Lys Gly Met Gly His Tyr Phe Asp Phe Trp Gly Glin Gly Thr 
1OO 105 11 O 
Pro Wall. Thir Wal Ser Ser 
115 
<210s, SEQ ID NO 129 
&211s LENGTH: 122 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 129 
Glin Val Glin Leu Gln Glu Ser Gly Pro Gly Lieu Val Llys Pro Ser Gly 
1. 5 1O 15 
Thr Lieu Ser Lieu. Thr Cys Ala Val Ser Gly Val Pro Val Tyr Thr Gly 
2O 25 3O 
His Trp Trp Thir Trp Val Arg Glin Ala Pro Gly Lys Gly Lieu. Glu Trp 
35 4 O 45 
Ile Gly Glu Ile His His Thr Val Thir Thr Asn Tyr Asn Pro Ser Lieu. 
SO 55 6 O 
Arg Ser Arg Val Thir Ile Ser Glu Asp Arg Ser Lys Asn. Glin Ile Ser 
65 70 7s 8O 
Lieu. Thir Lieu. Glin Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys 
85 90 95 
Ala Arg Gly Glu Asp Cys Val Gly Gly Ser Cys Tyr Ser Ala Asp Trip 
1OO 105 11 O 
Gly Glin Gly Ile Leu Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 130 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 130 
Glin Val Glin Lieu. Glin Glu Ser Gly Gly Gly Lieu Val Glin Pro Gly Arg 
1. 5 1O 15 
Ser Lieu. Arg Lieu Ser Cys Val Gly Ser Gly Phe Ser Phe Glu Ser Tyr 









Met His Trp Val Arg Glin Ala Pro Gly Lys 
35 4 O 
Gly Ile Ser Trp Asp Ser Gly Ala Lys Gly 
SO 55 
Gly Arg Phe Thir Ile Ser Arg Asp Asn Ala 
70 7s 
Glu Met Arg Ser Lieu. Arg Pro Glu Asp Thr 
85 90 
Lys Ala Pro Ile Ile Gly Pro Llys His Tyr 
1OO 105 
Gly Lys Gly Thr Ser Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 131 
&211s LENGTH: 120 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 











Phe Llys Lieu Val Glu Ser Gly Ser Trp Gly 
5 1O 
Val Llys Val Ser Cys Lys Ala Ser Gly Asp 
2O 25 
Ile Thir Trp Lieu. Arg Glin Ala Pro Gly Glin 
35 4 O 
Glu Ile Ile Thr Met Phe Gly Thr Thr Lys 
SO 55 
Gly Arg Met Thr Ile Thr Val Asp Glu Lieu. 
70 7s 
Glu Lieu. Thir Ser Lieu. Arg Ser Glu Asp Thr 
85 90 
Arg Glin Arg Pro Ser Pro Arg Trp Ala Phe 
1OO 105 
Thir Met Wall. Thir Wal Ser Ser 
115 12 O 
<210s, SEQ ID NO 132 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Val Glin Lieu Val Glu Ser Gly Ala Glu Val 
5 1O 
Val Arg Val Ser Cys Lys Ala Ser Gly Tyr 
2O 25 
Lieu Ala Trp Val Arg Glin Ala Pro Gly Glin 
35 4 O 
Trp Ile Thr Val Tyr Asn Gly His Thr Ser 
SO 55 
Asp Arg Val Thr Met Thr Thr Asp Thr Ser 
70 7s 
Glu Val Arg Asn Lieu. Gly Ser Asp Asp Thr 
US 9,146,241 B2 
- Continued 
Gly Lieu. Glu Trp Val 
45 
Asn Ala Asp Ser Val 
6 O 
Llys Llys Ser Lieu. Tyr 
8O 
Ala Phe Tyr Tyr Cys 
95 
Phe Tyr Met Asp Val 
11 O 
Llys Llys Pro Gly Ser 
15 
Thr Lieu. Thir Ser Tyr 
3O 
Gly Pro Glu Trp Met 
45 
Phe Ala Asn. Asn. Phe 
6 O 
Lys. Thir Thr Ala Tyr 
8O 
Ala Val Tyr Tyr Cys 
95 
Asp Ile Trp Gly Glin 
11 O 
Llys Llys Pro Gly Ala 
15 
Thr Phe Thr Asn Tyr 
3O 
Gly Lieu. Glu Trp Met 
45 
Tyr Ala Glin Llys Phe 
6 O 
Thr Arg Thr Ala Tyr 
8O 





US 9,146,241 B2 
- Continued 
95 
Ala Arg Llys Pro Arg Phe Tyr Tyr Asp Thr Ser Ala Trp Phe Glu Phe 
105 
Trp Gly Glin Gly Thr Lieu Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 133 
&211s LENGTH: 108 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 133 
Glu Ile Val Lieu. Thr Glin Ser Pro Gly Thr Lieu. 
1. 5 1O 
Glu Arg Ala Thr Lieu. Ser Cys Arg Ala Ser Glin 
2O 25 
Tyr Lieu Ala Trp Tyr Glin Gln Llys Pro Gly Glin 
35 4 O 
Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile 
SO 55 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Lieu. Thr 
65 70 7s 
Pro Glu Asp Val Ala Val Tyr Tyr Cys Glin Gln 
85 90 
Gly Thr Phe Gly Glin Gly Thr Arg Lieu. Glu Ile 
1OO 105 
<210s, SEQ ID NO 134 
&211s LENGTH: 108 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 134 
Gln Pro Gly Lieu. Thr Glin Pro Pro Ser Val Ser 
1. 5 1O 
Thir Ala Arg Ile Thr Cys Gly Gly Asn. Asn. Ile 
2O 25 
His Trp Tyr Glin Glin Arg Pro Gly Glin Ala Pro 
35 4 O 
Asp Asp Asp Ala Arg Pro Ser Gly Ile Ser Gly 
SO 55 
Asn Ser Gly Asn Thr Ala Thr Lieu. Thir Ile Ser 
65 70 7s 
Asp Glu Ala Asp Tyr Tyr Cys Glin Val Ser Asp 
85 90 
Gly Val Phe Gly Ser Gly Thr Llys Val Thr Val 
1OO 105 
<210s, SEQ ID NO 135 
&211s LENGTH: 109 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
















































































Ile Val Lieu. Thr Glin Ser Pro Gly Thr Lieu. 
Arg Ala Thir Lieu. Ser Cys Arg Ala Ser Glin 
2O 25 
Lieu. Gly Trp Tyr Glin Glin Llys Lieu. Gly Glin 
35 4 O 
Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 
SO 55 
Ser Gly Ser Gly Thr Asp Phe Thr Lieu. Thr 
70 7s 
Glu Asp Phe Ala Val Tyr Tyr Cys Glin Glin 
85 90 
Ile Thr Phe Gly Glin Gly Thr Arg Lieu. Glu 
1OO 105 
<210s, SEQ ID NO 136 
&211s LENGTH: 108 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Thir Thir Lieu. Thir Glin Ser Pro Ser Thir Lieu. 
5 1O 
Arg Val Thir Ile Thr Cys Arg Ala Ser Glu 
2O 25 
Ala Trp Tyr Glin Gln Llys Pro Gly Lys Ala 
35 4 O 
Arg Ala Ser Asn Lieu. Glu Ser Gly Val Pro 
SO 55 
Gly Ser Gly Thr Glu Phe Thr Lieu. Thir Ile 
70 7s 
Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe 
85 90 
Thr Phe Gly His Gly Thr Llys Val Glu Ile 
1OO 105 
<210s, SEQ ID NO 137 
&211s LENGTH: 107 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 








Ile Arg Lieu. Thr Glin Ser Pro Ser Ser Leu 
5 1O 
Arg Val Thir Ile Thr Cys Arg Ser Ser Glin 
2O 25 
Asn Trp Tyr Glin Gln Llys Pro Gly Glu Ala 
35 4 O 
Ala Ala Ser Ser Lieu. His Thr Gly Val Pro 
SO 55 
Gly Ser Gly Thr Asp Phe Thr Lieu. Thir Ile 
70 7s 
Asp Phe Ala Ile Tyr His Cys Glin Glin Ser 
US 9,146,241 B2 
- Continued 
Ser Leu Ser Pro Gly 
15 
Thir Ile Pro Ser Lys 
3O 
Ala Pro Arg Lieu. Lieu. 
45 
Pro Asp Arg Phe Ser 
6 O 
Ile Ser Arg Lieu. Glu 
8O 
Tyr Gly Ser Leu Ser 
95 
Ile Llys 
Pro Ala Ser Val Gly 
15 
Asn. Ile Asin Ser Trp 
30 
Pro Llys Ile Lieu. Ile 
45 
Ser Arg Phe Ser Gly 
6 O 
Ser Ser Lieu. Glin Pro 
8O 
Asp Llys Tyr Phe Ser 
95 
Ser Ala Ser Val Gly 
15 
Thir Ile Ser Thr Tyr 
3O 
Pro Llys Ile Lieu. Ile 
45 
Ser Arg Phe Ser Gly 
6 O 
Thir Ser Lieu. Glin Pro 
8O 





Thr Phe Gly Glin Gly Thr Lys Val Glu Ile Llys 











































SEQ ID NO 139 





















































































































































































































Asp Ile Gln Met Thr Glin Ser Pro Ser Thr Lieu Ser Ala Ser Val Gly 









Ser Val Thir Ile Thr Cys Arg Ala Ser Glin 
2O 25 
Ala Trp Tyr Glin Gln Llys Pro Gly Lys Ala 
35 4 O 
Lys Ala Ser Lieu. Lieu. Glu Ser Gly Val Pro 
SO 55 
Gly Ser Gly Thr Glu Phe Thr Lieu. Thir Ile 
70 7s 
Asp Phe Ala Thr Tyr Tyr Cys Glin Glin Tyr 
85 90 
Thr Phe Gly Pro Gly Thr Lys Lieu. Glu Ile 
1OO 105 
<210s, SEQ ID NO 141 
&211s LENGTH: 110 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Thir Wal Wall. Thir Glin Glu Pro Ser Ser Ser 
5 1O 
Val Thr Lieu. Thr Cys Gly Lieu. Thir Ser Gly 
2O 25 
Tyr Pro Ser Trp His Glin Gln Thr Pro Gly 
35 4 O 
Ile Tyr Asn Thr Tyr Ser Leu Ser Ser Gly 
SO 55 
Gly Ser Ile Lieu. Gly Asn Lys Ala Ala Lieu. 
70 7s 
Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val 
85 90 
Ile Trp Met Phe Gly Gly Gly Thr Lys Lieu. 
1OO 105 
<210s, SEQ ID NO 142 
&211s LENGTH: 107 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Ile Wall Lieu. Thir Glin Ser Pro Ser Ser Lieu. 
5 1O 
Arg Val Thir Ile Thr Cys Arg Ala Ser Glin 
2O 25 
Asn Trp Tyr Glin Glin Arg Pro Gly Arg Val 
35 4 O 
Ala Thr Ser Thr Lieu. Glin Ser Gly Val Pro 
SO 55 
Gly Ser Gly Thr Asp Phe Thr Lieu. Thir Ile 
70 7s 
Asp Phe Ala Thr Tyr Tyr Cys Glin Glin Ser 
85 90 
Phe Gly Pro Gly Thr Lys Val Glu Ile Llys 
US 9,146,241 B2 
- Continued 
Ser Ile Thr Arg Trp 
3O 
Pro Llys Lieu. Lieu. Ile 
45 
Ser Arg Phe Ser Gly 
6 O 
Ser Ser Lieu. Glin Pro 
8O 
Asn Ser Tyr Ser Pro 
95 
Val Ser Lieu. Gly Gly 
15 
Pro Val Thr Gly Ala 
3O 
Glin Ala Pro Arg Thr 
45 
Val Ser Asp Arg Phe 
6 O 
Thir Ile Ser Gly Ala 
8O 
Lieu. Tyr Met Gly Ser 
95 
Thir Wall Lieu. 
11 O 
Ser Ala Ser Val Gly 
15 
ASn Ile His Lieu. Phe 
3O 
Pro Llys Val Lieu. Ile 
45 
Ser Arg Phe Ser Gly 
6 O 
Ser Ser Wall Glin Pro 
8O 
Phe Ser Thr Pro Arg 
95 
132 




<210s, SEQ ID NO 143 
&211s LENGTH: 108 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Ile Val Lieu. Thr Glin Ser Pro Gly Thr Lieu Ser Leu Ser Pro Gly 
5 1O 15 
Arg Ala Thir Lieu. Ser Cys Arg Ala Ser Glin Arg Val Lys Ser Ser 
2O 25 3O 
Lieu Ala Trp Tyr Glin Glin Llys Pro Gly Glin Ala Pro Arg Lieu. Lieu. 
35 4 O 45 
Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
SO 55 6 O 
Ser Gly Ser Gly Thr Asp Phe Thr Lieu. Thir Ile Ser Arg Lieu. Glu 
70 7s 8O 
Glu Asp Val Ala Val Tyr Tyr Cys Glin Glin Tyr Gly Thr Ser Arg 
85 90 95 
Thr Phe Gly Glin Gly Thr Arg Lieu. Glu Ile Lys 
1OO 105 
<210s, SEQ ID NO 144 
&211s LENGTH: 108 
212. TYPE PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 









Ile Gln Met Thr Glin Ser Pro Ser Thr Lieu Ser Ala Ser Val Gly 
5 1O 15 
Arg Val Ser Ile Thr Cys Arg Ala Ser Glin Ser Ile Ser Gly Trp 
2O 25 3O 
Ala Trp Tyr Glin Gln Llys Pro Gly Lys Ala Pro Llys Lieu. Lieu. Ile 
35 4 O 45 
Lys Ala Ser Ser Lieu. Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
SO 55 6 O 
Gly Ser Gly Thr Glu Phe Thr Lieu. Thir Ile Ser Ser Leu Gln Pro 
70 7s 8O 
Asp Phe Ala Thr Tyr Tyr Cys Glin Glin Tyr Asn Ser Tyr Ser Pro 
85 90 95 
Thr Phe Gly Glin Gly Thr Llys Val Glu Ile Lys 
1OO 105 
<210s, SEQ ID NO 145 
&211s LENGTH: 106 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 




Ile Val Lieu. Thr Glin Ser Pro Glu Thir Lieu Ser Val Ser Pro Gly 
5 1O 15 
Ser Ala Thr Lieu. Ser Cys Arg Ala Ser Glin Ser Val Ser Thr Asp 
2O 25 3O 
134 
US 9,146,241 B2 
135 
- Continued 
Lieu Ala Trp Tyr Glin His Llys Pro Gly Glin Ala Pro Arg Lieu. Lieu. Ile 
35 4 O 45 
Trp Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
SO 55 6 O 
Ser Gly Ser Gly Thr Glu Phe Thr Lieu. Thir Ile Ser Ser Leu Glin Ser 
65 70 7s 8O 
Glu Asp Phe Ala Ile Cys Phe Cys His Glin Tyr Asn Asn Trp Pro Thr 
85 90 95 
Phe Gly Glin Gly Thr Lys Val Glu Ile Llys 
1OO 105 
<210s, SEQ ID NO 146 
&211s LENGTH: 16 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 146 
Ala Lys Ala Pro Ile Ile Gly Pro Llys Tyr Tyr Phe Tyr Met Asp Val 
1. 5 1O 15 
<210s, SEQ ID NO 147 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 147 
Cys Gly Lys Ser Tyr Asp Tyr Ile Arg Glu Asn Lieu. Asp Ser 
1. 5 1O 
<210s, SEQ ID NO 148 
&211s LENGTH: 16 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 148 
Ala Lys Asp Arg Val Arg Val Val Glin Ala Ala Thir Thr Lieu. Asp Phe 
1. 5 1O 15 
<210s, SEQ ID NO 149 
&211s LENGTH: 12 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 149 
Ala Arg Gly Val Val Pro Ala Gly Ile Pro Phe Asp 
1. 5 1O 
<210s, SEQ ID NO 150 
&211s LENGTH: 18 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 150 
Ala Arg Lieu. His Pro Thr Cys Ala Ser Thr Arg Cys Pro Glu Asn Tyr 
136 
US 9,146,241 B2 
137 
- Continued 
1. 5 1O 15 
Gly Met 
<210s, SEQ ID NO 151 
&211s LENGTH: 19 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 151 
Val Arg Asp Pro Arg His Tyr His Asn Met Gly Arg Tyr Tyr Ala Gly 
1. 5 1O 15 
Trp Phe Asp 
<210s, SEQ ID NO 152 
&211s LENGTH: 15 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 152 
Ala Arg Asp Tyr Phe His Ser Gly Ser Glin Tyr Phe Phe Asp Tyr 
1. 5 1O 15 
<210s, SEQ ID NO 153 
&211s LENGTH: 14 
212. TYPE: PRT 
<213> ORGANISM; Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 153 
Ala Arg Ala Arg Asn Tyr Gly Phe Pro His Phe Phe Asp Phe 
1. 5 1O 
<210s, SEQ ID NO 154 
&211s LENGTH: 11 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 154 
Ala Arg Lys Gly Met Gly His Tyr Phe Asp Phe 
1. 5 1O 
<210s, SEQ ID NO 155 
&211s LENGTH: 15 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OO > SEQUENCE: 155 
Ala Arg Gly Glu Asp Cys Val Gly Gly Ser Cys Tyr Ser Ala Asp 
1. 5 1O 15 
<210s, SEQ ID NO 156 
&211s LENGTH: 17 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
138 
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<4 OOs, SEQUENCE: 156 
Ala Lys Ala Pro Ile Ile Gly Pro Llys His Tyr Phe Tyr Met Asp Val 
1. 5 1O 15 
Trp 
<210s, SEQ ID NO 157 
&211s LENGTH: 17 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OO > SEQUENCE: 157 
Ala Arg Glin Arg Pro Ser Pro Arg Trp Ala Phe Asp Ile Trp Gly Glin 
1. 5 1O 15 
Gly 
<210s, SEQ ID NO 158 
&211s LENGTH: 16 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: antibody fragment 
<4 OOs, SEQUENCE: 158 
Ala Arg Llys Pro Arg Phe Tyr Tyr Asp Thr Ser Ala Trp Phe Glu Phe 
1. 5 1O 15 
<210 SEQ ID NO 159 
&211s LENGTH: 19 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 159 
cgcagtagcg gtaaacggc 19 
<210s, SEQ ID NO 160 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 160 
gcggataiaca attt cacaca gg 22 
<210s, SEQ ID NO 161 
&211s LENGTH: 38 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 161 
cgcagtagcg gtaaacggca giggygcCagg gigaagac 38 
<210s, SEQ ID NO 162 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
140 
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<4 OOs, SEQUENCE: 162 
cgcagtagcg gtaaacggcc gggaagacct toggctgg 
<210s, SEQ ID NO 163 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 163 
cgcagtagcg gtaaacggcc acaggagacg agggggaaa 
<210s, SEQ ID NO 164 
&211s LENGTH: 42 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 164 
gcggataiaca attt cacaca gggatgaaga Cagatggtgc ag 
<210s, SEQ ID NO 165 
&211s LENGTH: 42 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
< 4 OO SEQUENCE: 165 
gcggataiaca attt cacaca ggit cotcaga ggagggyggg aa 
<210s, SEQ ID NO 166 
&211s LENGTH: 4 O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 166 
tatt cocatg gcgc.gc.ccag gtc.ca.gctkg tric agtctgg 
<210s, SEQ ID NO 167 
&211s LENGTH: 4 O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 167 
tatt cocatg gcgc.gc.ccag gtgcagotgg tsartctgg 
<210s, SEQ ID NO 168 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 168 
tatt cocatg gcgc.gc.ccag rtc accttga aggagtctg 
<210s, SEQ ID NO 169 
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&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 169 
tatt cocatg gcgc.gc.cgag gtgcagotgk tagWCy 
<210s, SEQ ID NO 170 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 170 
tatt cocatg gcgc.gc.ccag gtgcagotgc aggagtic Sg 
<210s, SEQ ID NO 171 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 171 
tatt cocatg gcgc.gc.ccag gtgcagdtac agcagtggg 
<210s, SEQ ID NO 172 
&211s LENGTH: 38 
& 212 TYPE DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 172 
tatt cocatg gcgc.gc.ccag gtacagotgc agcagtica 
<210s, SEQ ID NO 173 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 173 
tatt cocatg gcgc.gc.ctica acacaacggit toccagtta 
<210s, SEQ ID NO 174 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 174 
ggcgc.gc.cat gggaatagcc gaCat CCrgd tacc cagtic ticc 
<210s, SEQ ID NO 175 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
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ggcgc.gc.cat gggaatagcc gat attgttgm tacbcagWC to c 





OTHER INFORMATION: synthetic primer 
SEQUENCE: 176 
ggcgc.gc.cat gggaatagcc galaattgtrW tacrcagtic ticc 





OTHER INFORMATION: synthetic primer 
SEQUENCE: 177 
ggcgc.gc.cat gggaatagcc gaaacgacac toacgcagtic tic 





OTHER INFORMATION: synthetic primer 
SEQUENCE: 178 
ggcgc.gc.cat giggaat agcc Cagtctgtsb tacgcagcc gCC 
SEO ID NO 179 




OTHER INFORMATION: synthetic primer 
SEQUENCE: 179 
ggcgc.gc.cat gggaatagcc cagcctgtgc tigact caryc 





OTHER INFORMATION: synthetic primer 
SEQUENCE: 18O 
ggcgc.gc.cat gggaatagcc cagccWgkgc tigact cagcc moc 





OTHER INFORMATION: synthetic primer 
SEQUENCE: 181 
ggcgc.gc.cat gggaatagcc cagtctgyyc tayt cagcc t 












US 9,146,241 B2 
147 
- Continued 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 182 
ggcgc.gc.cat gggaatagcc ticcitatgWgc tigacWCagcc aa 
<210s, SEQ ID NO 183 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 183 
ggcgc.gc.cat gggaatagcc ticcitctgagc tigast Cagga Sco 
<210s, SEQ ID NO 184 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 184 
ggcgc.gc.cat gggaatagcc ticcitatgagc tigayrcagcy acc 
<210s, SEQ ID NO 185 
&211s LENGTH: 42 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
& 22 O FEATURE; 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 185 
ggcgc.gc.cat gggaatagcc aattt tatgc tigact cagcc cc 
<210s, SEQ ID NO 186 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 186 
ggcgc.gc.cat gggaatagcc cagoctgtgg tacycagga gcc 
<210s, SEQ ID NO 187 
&211s LENGTH: 31 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 187 
atgggc cctg. Sgatgggc cc ttggtggarg C 
<210s, SEQ ID NO 188 
&211s LENGTH: 30 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 188 
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OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 189 
atgggc cctg. g.gttggggcg gatgcact Co 





OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 190 
gtgcggcc.gc agatggtgca gcc acagttc 





OTHER INFORMATION: synthetic primer 
<4 OOs, SEQUENCE: 191 
gtgcggcc.gc gagggyggga acagagtgac 
SEQ ID NO 192 
LENGTH: 15 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 192 
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1. 5 1O 15 
What is claimed is: 
1. A method of identifying a repertoire of different anti- 4s 
bodies specific to an antigen in a biological fluid of a subject 
comprising: 
a) obtaining a biological fluid sample from the Subject; 





the peptide fragments using chromatography, and gen 
erating mass spectra of the separated CDR3-containing 
peptide fragments; 
e) using the sequence information and the mass spectra to 
determine the amino acid sequence of the V and V of 
antibodies in multiple single B cells; and 
fluid of the subject; 
c) co-isolating nucleic acids encoding VH and VL genes 
from the single B-cells, thereby obtaining the natively 
paired VH and VL coding sequences that are expressed 
in the same B-cell, and sequencing the co-isolated 
nucleic acids using a high-throughput sequencing 
method, wherein the high-throughput sequencing 
method is selected from the group consisting of 
sequencing-by-synthesis, sequencing-by-ligation, 
sequencing-by-hybridization, single molecule DNA 
sequencing, multiplex polony sequencing and nanopore 
sequencing, and determining the nucleic acid sequence 
and the corresponding amino acid sequence information 
of the VH and natively paired VL gene repertoire 
encoded by the single B cells; 
d) isolating antibodies from the biological fluid of the 
Subject and preparing CDR3-containing peptide frag 





f) expressing one or more antibodies or antigen-binding 
fragments determined in step e). 
2. The method of claim 1, wherein a repertoire of at least 20 
V chains or antibodies is identified. 
3. The method of claim 2, wherein a repertoire of 20 to 250 
V chains or antibodies is identified. 
4. The method of claim 1, wherein the biological fluid is 
S. 
5. The method of claim 1, wherein the biological fluid is 
intestinal lavage or bronchoalveolar lavage. 
6. The method of claim 1, wherein the nucleic acid 
sequences are determined from a cDNA library. 
7. The method of claim 1, wherein the nucleic acid 
sequences are determined from genomic DNA. 
8. The method of claim 1, wherein the subject has or has 
been exposed to an antigen that is an infectious agent, a tumor 
antigen, a tumor cell, or a self-antigen. 
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9. The method of claim 1, wherein the method further 
comprises determining the relative abundancy level or rela 
tive frequency of the amino acid sequences of the antibodies 
in the sample. 
10. The method of claim 1, wherein each of the antibodies 
or antigen-binding fragments so generated comprises simi 
larly abundantamino acid sequences of V, and V, or is part 
of a cluster of highly homologous amino acid sequence that 
are similarly abundant. 
k k k k k 
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